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Current chemotherapies for oesophageal cancer display poor efficacy and tolerability, 
highlighting an unmet need for novel chemotherapeutic agents. Artemisinin derivatives, 
currently used to treat malaria, were recently shown to possess potent anticancer activity. 
This study investigated the potential of two first generation artemisinin derivatives 
(artesunate and dihydroartemisinin), together with novel artemisinin hybrid compounds, as 
cancer chemotherapeutic agents and explored the mechanism of action in oesophageal cancer. 
 
Artesunate and dihydroartemisinin including seventeen other artemisinin derivatives were 
screened against oesophageal cancer cells using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay and GraphPad Prism Software to calculate IC50 
(50% inhibitory concentration) values. Novel halogenated artemisinin-isatin hybrid 
compounds displayed the best activity against oesophageal cancer cells, and were more 
potent than artesunate and dihydroartemisinin in a small panel of oesophageal, breast and 
cervical cancer cell lines tested. The novel derivatives induced a G0/G1 cell cycle arrest 
whilst the parental compounds induced a G2/M block of the cell cycle, using flow cytometry. 
This suggested a different mechanism of action for the novel compounds. Dihydroartemisinin 
and the most active novel hybrid, EXP57EA, were investigated to understand their molecular 




The results indicated that dihydroartemisinin induced apoptosis (based on poly (ADP-ribose) 
polymerase cleavage analysis and caspase-3/7 activation) while EXP57EA induced 
autophagy (based on LC3-II and Beclin 1 expression and transmission electron microscopy 
analysis). Both compounds significantly increased reactive oxygen species (ROS) production 
in oesophageal cancer cells, shown using a fluorescent probe (2’,7’-dichloro-fluorescein 
diacetate) to measure intracellular ROS production. However, different types of ROS were 
implicated in the activation of downstream signalling pathways. Dihydroartemisinin-induced 
ROS resulted in deoxyribonucleic acid (DNA) damage, G2/M cell cycle arrest and apoptosis, 
which could all be blocked with the ROS scavenger, N-acetyl-L-cysteine. However, 
EXP57EA induced the production of superoxide, based on the observation that the 
superoxide-specific ROS scavenger, 4-hydroxy-2,2,6,6- tetra-ethylpiperidine 1-oxyl 
(TEMPOL), blocked ROS production, autophagy and cell death.  
 
Taken together, the results of this study indicate that EXP57EA may have potential as an 
effective cancer chemotherapeutic agent that is more active than, and employs a mechanism 














1.1 Oesophageal Cancer  
 
1.1.1 Introduction 
South Africa is heavily burdened with a wide range of communicable diseases particularly 
HIV/AIDS (Human immunodeficiency virus/acquired immunodeficiency syndrome) and TB 
(Tuberculosis), extracting a heavy mortality toll on the country. According to a recent report 
by the World Health Organisation (WHO), HIV/AIDS and TB prevalence in South Africa is 
11 087 per 100 000 and 768 per 100 000, respectively (WHO, 2013). Understandably, major 
efforts are dedicated to research for treatment and prevention of these communicable 
diseases. With this attention focussed on the devastating effects of HIV/AIDS and TB in 
South Africa, it has recently become apparent that non-communicable diseases, such as 
cancer, also present a significant burden on the health complex of the country. In addition, 
once the delivery of highly effective antiretroviral treatment becomes commonplace in the 
public health sector, it is predicted that deaths from HIV/AIDS should decrease resulting in a 
rise in life expectancy of South Africans, together with a rise in cancer (Mayosi et al., 2009; 




The IARC (International Agency for Research on Cancer) reported 542 000 deaths from 
cancer and 715 000 new cancer cases in Africa for 2008, and estimations dictate that these 
alarming figures will double by 2030 (Ferlay et al., 2010; McCormack and Schüz, 2012). 
This represents a significant health challenge considering that Africa is a high risk area for a 
variety of cancers, including oesophageal cancer (OC) in South Africa. OC is characterised 
by malignant tumours that develop in the epithelium of the oesophagus, and this type of 
cancer poses a formidable threat as it is usually asymptomatic and therefore diagnosed at a 
very late stage. The prognosis for patients with OC is very poor, and South Africa currently 
ranks as one on the top five countries with the highest age-standardised death rate (18.2 per 
100 000) due to OC (Chai and Jamal, 2012). Therefore there is a significant demand to 
unravel the molecular circuitry maintaining the biologic properties of OC cells and to 
thoroughly investigate better and highly effective treatment options in order to combat this 
disease.  
 
1.1.2 Description of OC 
The aetiology of OC differs by cell type, and can be categorised into two main forms: 
adenocarcinoma (AD) and oesophageal squamous cell carcinoma (OSCC). Despite both 
types displaying characteristic male predominance and being included jointly in therapeutic 
and prognostic clinical studies (Pennathur et al., 2008), AD and OSCC are by no means 
similar. They have clear differences including causes, epidemiology and originating cells 
(Bandla et al., 2012). Of the two types of epithelial tumours, adenocarcinoma (AD) arises 
from columnar epithelial cells and occurs mostly within the distal third of the oesophagus 
(Figure 1.1). Factors influencing this disease include chronic reflux, obesity and Barrett’s 
oesophagus (Stein et al., 2005). There has been a remarkable increase in AD in first world 
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countries over the past fifty years, with the greatest upsurge observed in the United States of 
America (Demeester, 2009; Simard et al., 2012). In contrast, oesophageal squamous cell 
carcinoma (OSCC), which develops from squamous epithelium in the proximal oesophagus, 
predominates in developing countries and is of particular relevance to South Africa where an 
unusually high occurrence is observed in certain areas. Hence, this study is directed toward 
squamous cell carcinoma and is explored in further detail below.  
Figure 1.1: Diagram showing the location of the two main types of oesophageal cancer. Oesophageal 
squamous cell carcinoma near the proximal third of the oesophagus; and adenocarcinoma near the distal third of 
the oesophagus. 
 
1.1.3 Epidemiology of OSCC 
OC has displayed one of the most remarkable epidemiological shifts that has been 
documented, where AD was a disease that was not widely known in the 1950’s and has 
become one of the greatest rising cancers in the Western world (Demeester, 2009). Yet, 
despite this profound change, OSCC still accounts for the majority of oesophageal cancer 
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diagnoses worldwide. This is mostly due to the high prevalence of this disease in Asian and 
African countries (Mawhinney and Glasgow, 2012). As illustrated in Figure 1.2, the 
incidence of OSCC varies widely geographically; where Southern and Eastern Africa as well 
as Eastern Asia have the highest incidence rates in the world, and Western and Middle Africa 
have the lowest rates in the world (Chai and Jamal, 2012). The disease is frequently two to 
four times more common among males than females, and in South Africa OSCC affects 
mostly the black population, especially in the high risk former Transkei region of the Eastern 
Cape Province (Hendricks and Parker, 2002; Jemal et al., 2011; Pacella-Norman et al., 2002; 
Somdyala et al., 2003).  
 
A variety of risk factors have been implicated in the aetiology of OSCC. Smoking and 
alcohol consumption are important contributors to the disease in most parts of the world, but 
in developing countries nutritional deficiencies, drinking beverages at high temperatures, 
chewing tobacco and betel nut, consuming food contaminated with fungal mycotoxins and 
diets rich in nitrosamines have also been identified as important risk factors for the disease 
(Griffin and Wahed, 2011; Jemal et al., 2011; Sewram et al., 2003; Stoner and Gupta, 2001). 
In addition, a number of studies have implicated Human papillomavirus (HPV) in the 
pathogenesis of OSCC (Eslick, 2010; Löfdahl et al., 2012; Matsha et al., 2002, 2007; Togawa 
et al., 1994). Furthermore, agents that irritate the oesophagus such as lye, high-starch foods 
and radiation have been associated with the development of OSCC (Layke and Lopez, 2006). 
Other risk factors include disorders characterised by chronic inflammation and stasis, such as 
achalasia, previous head and neck cancer, Plummer-Vinson syndrome (oesophageal webs 
associated with iron deficiency anaemia), Tylosis (an autosomal-dominant genetic disorder 
characterised by hyperkeratosis of the palms and soles) and HDGC (Hereditary Diffuse 
Gastric Cancer) (Elton, 2005; Lao-Sirieix et al., 2010; Layke and Lopez, 2006). Interestingly, 
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inflammation has recently been described as one of the newly recognised hallmarks of cancer 
as it is thought to contribute to the genesis of cancer by supplying bioactive molecules, such 
as growth factors, survival factors and proangiogenic factors, to the tumour 
microenvironment, and this adds to the complexity of the disease (Hanahan and Weinberg, 
2011). 
Figure 1.2: Global distribution of oesophageal squamous cell carcinoma. Red indicates the regions with the 
highest incidence rates in the world, including Southern and Eastern Africa as well as Eastern Asia. The regions 
coloured in grey, such as Western and Middle Africa, indicate the lowest incidence rates in the world (Image 
reproduced from Chai and Jamal, 2012). 
 
1.1.4 Treatment 
The multiple modes of oesophageal cancer treatment involves surgery, chemotherapy and 
radiotherapy (Kranzfelder et al., 2010). Surgical removal of the oesophagus is the standard 
treatment for patients with excisable OC (if detected at an early stage), but most patients 
present with an advanced stage of disease. Therefore surgery alone as a treatment option is 
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limited because metastasis would have already occurred at the first diagnosis (Ilson, 2008; 
Lv, 2009). As a result, radiotherapy and chemotherapy are frequently used in combination, 
either as neoadjuvant (preoperative) therapy or adjuvant (postoperative) therapy, to try to 
improve patient survival outcomes. However, these approaches have had little effect on 
improving prognosis and survival of OC patients, and the 5-year overall survival rate remains 
between 5 and 15% (Scarpa et al., 2011). 
 
A number of cytotoxic drugs and drug combinations have been tested in various clinical trials 
for efficacy against OC and are currently being used to treat OC. The drugs most commonly 
used in the chemotherapeutic regimens to treat OC patients include cisplatin and 5-
fluorouracil. Cisplatin is an alkylating-like platinum compound whereas 5-fluorouracil is a 
pyrimidine analogue of the antimetabolite class of anticancer drugs. Cisplatin forms adducts 
(in the cis configuration, hence the name cisplatin) with DNA (deoxyribonucleic acid) 
resulting in the inhibition of DNA synthesis and repair. This is a result of the disruption of the 
three-dimensional structure of DNA caused by the platinum adducts. Cisplatin ultimately 
induces apoptosis via the intrinsic apoptotic pathway (to be discussed in more detail later) 
(Desoize and Madoulet, 2002). Ototoxicity (damage to ears associated with hearing loss) and 
anosmia (inability to smell) are some of the side effects associated with cisplatin treatment. 
However, the major side effect patients experience is nephrotoxicity. Other side effects 
include sensory peripheral neuropathy, optic neuritis, cortical blindness and seizures (SAMF, 
2010). 
 
The antimetabolite 5-fluorouracil (a uracil analogue with a fluorine atom at the 5’ carbon of 
the pyrimidine ring) inhibits thymidilate synthase which leads to the inhibition of DNA 
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synthesis and repair. When 5-fluorouracil is metabolized in the cell it forms 
fluorodeoxyuridine monophosphate (FdUMP) which tightly binds thymidilate synthase and 
prevents the formation of thymidilate, an important precursor for deoxythymidine 
monophosphate (dTMP). Therefore dTMP and dTTP (deoxythymidine triphosphate) become 
depleted and DNA synthesis and repair is inhibited (Kunz et al., 2009). Furthermore, 5-
fluorouracil can be incorporated into RNA as a false nucleotide and in so doing disrupt many 
cellular processes (Longley et al., 2003). Patients treated with 5-fluorouracil experience side 
effects such as cardiotoxicity, diarrhoea, stomatitis (infection around mouth), hand-foot 
syndrome and skin rashes (SAMF, 2010). Mucositis and myelosuppression have also been 
reported in cisplatin/5-fluorouracil combination treatments (Ilson, 2008). These significant 
adverse effects associated with the cisplatin/5-fluorouracil chemotherapy limit the tolerability 
in patients suffering from OC. 
 
Recent interest in cancer treatment has focussed on targeted agents. Several molecular 
pathways have been investigated to identify potential targets in oesophageal cancer and these 
include cyclin-dependent kinases, NFĸB (nuclear factor kappa-light-chain-enhancer of 
activated B cells), matrix metalloproteinases, COX-2 (cyclooxygenase-2), c-MET (a proto-
oncogene), mTOR (mammalian Target of Rapamycin), EGFR (epidermal growth factor 
receptor) and VEGF (vascular endothelial growth factor). The latter two currently appear to 
be the most promising targets (Boone et al., 2008; Campbell, 2010; Tew et al., 2005; Villaflor 
et al., 2012). 
 
EGFR, a member of the human epidermal growth factor receptor family, plays an important 
role in cell differentiation, proliferation and survival. Overexpression of EGFR proteins may 
8 
 
occur in 30 - 90% of OSCC tissue and is associated with increased aggressiveness of the 
disease as well as poor prognosis (Lin and Papadopoulos, 2007). EGFR tyrosine kinase 
inhibitors (erlotinib, gefitinib and lapatinib) and anti-EGFR monoclonal antibodies 
(cetuximab, panitumumab and matuzumab) are the two most developed EGFR-targeting 
strategies (Lin and Papadopoulos, 2007; Syrigos et al., 2008; Villaflor et al., 2012).  
 
The small molecule tyrosine kinase inhibitors targeting EGFR have limited monotherapy 
efficacy with low response rates thus triggering the investigation into the typical OC 
multimodal therapy. Combination of tyrosine kinase inhibitors with other drugs displayed 
limited further benefit with a response rate of 51.5%, 5.5 months progression free survival 
and only 11 months overall survival (Wainberg et al., 2011). As a result, this approach has 
mostly been abandoned (Boland and Burtness, 2013). Radiation and erlotinib combination 
treatment yielded a clinical complete response rate of 46% and phase III study of 
chemoradiation with or without erlotinib is ongoing (Boland and Burtness, 2013). Cetuximab, 
a monoclonal antibody targeting EGFR, used in monotherapy also displayed limited activity 
with response rates ranging from 3 - 6% but when used in combination with other drugs 
response rates of 51 - 62% were observed (Boland and Burtness, 2013). However, it was 
reported that the median progression free survival (5.7 months) and overall survival (10 
months) were not significantly different to historical controls (Boland and Burtness, 2013). In 
addition, grade III/IV nonhaematologic toxicity occurred in 70% of patients (Boland and 
Burtness, 2013).  
 
Metastasis of oesophageal cancer is associated with angiogenesis, which is one of the 
hallmarks of cancer (Hanahan and Weinberg, 2000, 2011). During this process a complex 
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interplay between several angiogenic growth factors, receptors and signalling molecules is 
deployed for the development of new blood vessels that allow cancer cells to thrive and 
opportunistically metastasize (Hanahan and Weinberg, 2000, 2011). The VEGF family of 
proteins are the main players in the process, and VEGF-A and VEGF-C were reported to be 
frequently overexpressed in OC (Syrigos et al., 2008). Therefore strategies targeting this 
family of proteins are highly attractive, and similar to the situation in EGFR targeted therapy, 
the anti-VEGF monoclonal antibodies (bevacizumab) and the VEGF (multi-target) tyrosine 
kinase inhibitors (vandetatanib, sorafenib and sunitinib) are the most developed (Syrigos et 
al., 2008). Despite various ongoing phase-II and phase-III clinical trials employing these 
targeted therapies with and without the conventional multimodal OC therapy, the reported 
results reflect poor response rates (2.6 - 46%) coupled with serious side-effects (oesophageal 
fistula formation and fatal gastrointestinal haemorrhage), especially in patients who present 
with multiple comorbidities (Bang et al., 2011; Boland and Burtness, 2013; Campbell, 2010; 
Schmitt et al., 2012; Villaflor et al., 2012). 
 
As mentioned before, despite recent advances and the use of the above-mentioned therapies 
for oesophageal cancer, the 5-year mortality rate remains unacceptably high at 80 - 90% 
(Ilson, 2008). Therefore it is important to develop more effective chemotherapeutic agents 
with fewer side-effects for the treatment of this disease. One of the goals of developing 
effective chemotherapeutic agents is the production of agents capable of targeting and killing 
cancer cells without affecting normal cells. Research in developing novel agents capable of 
triggering cell death pathways in cancer cells may provide improved alternatives to current 




1.2 Cell Death Pathways 
 
1.2.1 Introduction 
Programmed cell death (PCD) plays a significant role in normal development as well as in 
disease. Extensive research underpinned the in-depth characterisation of necrosis and 
apoptosis, originally the main two cell death mechanisms identified, which have fundamental 
differences in morphology and biochemistry. There are, however, other recently characterised 
cell death pathways that are coming to the fore that include autophagy, necroptosis, 
paraptosis, pyroptosis, pyronecrosis, lysosomal mediated-programmed cell death (LM-PCD), 
mitotic catastrophe and entosis (Kreuzaler and Watson, 2012; Kroemer et al., 2009).  
 
Evasion of cell death is one of the hallmarks of cancer, as described by Hanahan and 
Weinberg, since cancer cells have developed mechanisms to avoid cell death (Hanahan and 
Weinberg, 2000, 2011). Apoptosis has been the main PCD pathway implicated since it is 
known that some of the mechanisms employed by cancer cells to avoid cell death include 
upregulating the expression of antiapoptotic members and downregulating the expression of 
proapoptotic members (Hanahan and Weinberg, 2011), and many chemotherapeutic agents 
have been directed at inducing this type of cell death (Lockshin and Zakeri, 2004). However, 
it is clear that more evidence is required to elucidate the role of other cell death pathways, 







1.2.2.1 Description and Function 
Since its official description by Kerr et al. in 1972, apoptosis has received a great deal of 
attention from molecular and cell biologists the world over. The word ‘apoptosis’ is of Greek 
origin and is used to describe “falling off” of leaves from trees or petals from flowers and 
aptly portrays the type of cell death that is characterised by cells breaking away from or 
losing contact with surrounding cells (Kerr et al., 1972). Other morphological features of 
apoptosis include cell shrinkage, chromatin condensation (pyknosis) and nuclear 
fragmentation (karyorrhexis), blebbing of the plasma membrane and ultimately disintegration 
into apoptotic bodies (Hockenbery, 1995; Kaufmann and Hengartner, 2001; Saikumar et al., 
1999).  
 
Apoptosis is a tightly regulated, energy-dependent process that occurs during adult tissue 
homeostasis, development and disease (Hockenbery, 1995; Kerr et al., 1972). It performs a 
significant function that complements (but has an opposite role to) mitosis to maintain 
homeostasis. In adult humans, approximately ten billion cells are synthesised every day to 
account for those undergoing apoptosis (Elmore, 2007). A. Glucksman was one of the earliest 
researchers to implicate cell death in development and since then many studies have 
confirmed the importance of programmed cell death in development (Glucksman, 1951). 
Studies performed in different cell types and species indicated that RNA and protein 
synthesis were essential for this type of cell death to occur, and that inhibiting any of these 
two processes blocked apoptosis, and consequently some developmental processes like 
metamorphosis in model systems (Lockshin and Williams, 1964; Tata, 1966). These 
pioneering studies proved that cell death required the expression of endogenous genes and 
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that apoptosis had important physiological roles in development. Indeed, apoptosis must be 
tightly regulated as insufficient or excessive cell death may result in pathology such as 
developmental faults, neurodegenerative diseases (including Parkinson’s disease, 
Alzheimer’s disease and Huntington’s disease), autoimmune diseases and cancer (Elmore, 
2007; Hotchkiss et al., 2009; Nicholson, 2000). 
 
The management of over-produced cells, a frequent occurrence in many tissues and organs, 
by programmed cell death is critical for maintaining optimal cell numbers (Jacobson et al., 
1997). Examples include the excess of neurons and oligodendrocytes produced in the 
vertebrate nervous system and oocytes produced in human females which are removed by 
apoptosis (Fuchs and Steller, 2011; Jacobson et al., 1997). Apoptosis plays an important role 
in the elimination of cells in response to viral infection, cells containing damaged DNA that 
is not sufficiently repaired or that display cell-cycle irregularities (Fuchs and Steller, 2011). 
Apoptosis is critically important for the death of mutated cells and thus plays a vital role in 
the prevention of cancer. When mutated cells destined to die develop mechanisms to evade 
programmed cell death pathways a window to tumourigenesis is opened (Green and Evan, 
2002; Hanahan and Weinberg, 2000, 2011). 
 
1.2.2.2 The Apoptosis Pathway 
Apoptosis is a highly complex cellular pathway (made up of various sub-pathways) that can 
be induced by either extracellular or intracellular signals. Groundbreaking discoveries in 
apoptosis research that contributed the elucidation of this pathway include the identification 
of the anti-apoptotic bcl-2 gene by Vaux and colleagues (Vaux et al., 1988) followed by the 
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characterisation of the Bcl-2 family (consisting of pro-apoptotic and anti-apoptotic members) 
of proteins, as well as the identification of the key destructive enzymes called the caspases 
(cysteinyl-aspartate-cleaving proteases) (Lockshin and Zakeri, 2001; Yuan et al., 1993).  
 
In humans, fourteen caspases have been identified and characterised (Duprez et al., 2009; 
Shi, 2002), and they exist as zymogens or procaspases within the cell that once activated, 
result in the cleavage of proteins at aspartic acid residues. The caspases are the main 
mediators of apoptosis and are grouped into the initiator caspases (caspase-2, -8, -9, -10 and -
12) and executioner or effector caspases (caspase-3, -6 and -7) (Hengartner, 2000; 
Thornberry et al., 1997). The initiator procaspases are present as monomers in the cell and 
when an apoptotic signal is triggered, dimers are formed which are activated by 
oligomerisation with adaptor molecules (Boatright and Salvesen, 2003). The activated 
initiator caspases cleave the executioner procaspases (dimers) into activated executioner 
caspases (monomers), which are in turn responsible for the cleavage of a large variety of 
substrates ultimately responsible for the demise of the cell (Boatright and Salvesen, 2003; 
Elmore, 2007; Green, 2000).  
 
The key pathways identified according to the type of initiator caspase activated are the 
intrinsic or mitochondrial apoptotic pathway (caspase-9), the extrinsic or death receptor 
apoptotic pathway (caspase-8), the ER stress pathway (caspase-12) and the 
perforin/granzyme B pathway (caspase-10) (Assunção Guimarães and Linden, 2004; Elmore, 




1.2.2.2.1 Intrinsic pathway 
The intrinsic apoptotic pathway is mainly activated by stimuli that could reflect exposure of 
cells to a noxious environment that could lead to irreparable cellular damage. These stimuli 
include increased intracellular reactive oxygen species (ROS), DNA damage, decrease in 
growth factors, ionising radiation, chemotherapeutic drugs and mitochondrial damage 
(Boatright and Salvesen, 2003; Hotchkiss et al., 2009). The death signal is accompanied by 
the selective permeabilisation of the mitochondria orchestrated by the Bcl-2 (B-cell 
lymphoma-2) family of pro- and anti-apoptotic members.  
 
The family members are grouped according to structure and function into anti-apoptotic and 
pro-apoptotic members. The anti-apoptotic members (Table 1.1) contain four Bcl-2 
homology (BH) domains (BH1-4). The pro-apoptotic members (Table 1.1) are further 
divided into effectors, with multiple BH domains (BH1-4), and BH3-only members with only 
one BH domain (BH3) (Chipuk et al., 2010). The effectors, Bax, Bak, and Bok (refer to Table 
1.1 for full names), are the main positive regulators of apoptosis and are usually present on 
the mitochondrial outer membrane or in the cytoplasm (Green, 2000; Hengartner, 2000). The 
BH3-only family members are further characterised into “sensitisers and/or derepressors” 
(Bad, Noxa, Bik, Hrk, PUMA) and “direct activators” (Bid and Bim) (Table 1.1) (Chipuk et 
al., 2010). The former group is able to bind and inhibit anti-apoptotic Bcl-2 family members 
only whereas the latter group interacts with both the anti-apoptotic and pro-apoptotic 
(effectors), and can directly stimulate Bax and Bak homo-oligomerisation and activation thus 




Table 1.1: The Bcl-2 family of anti-apoptotic and pro-apoptotic members, including their 
abbreviations and full names.  
Anti-apoptotic Pro-apoptotic 
Bcl-2 B-cell lymphoma-2 Bax Bcl-2 associated x protein 
A1 Bcl-2-related gene A1 Bak Bcl-2 agonist killer 1 
Bcl-w Bcl-2 like 2 protein Bok Bcl-2 ovarian killer 
Bcl-xL Bcl-2-related gene, long isoform Bad Bcl-2 agonist of cell death 
Mcl-1 Myeloid cell leukemia 1 Bid BH3 interacting domain death agonist 
  Bim Bcl-2 interacting mediator of cell death 
Bik Bcl-2-interacting killer 
Hrk Harakiri 
Noxa Phorbol-12-myristate-13-acetate-induced protein 1 
 
 
PUMA P53 up-regulated modulator of apoptosis 
 
MOMP induces the release of the mitochondrial protein cytochrome c, one of the key 
regulators of the intrinsic apoptotic pathway, into the cytoplasm where it binds Apaf-1 
(Apoptotic protease activating factor 1), the cytoplasmic adaptor protein. Apaf-1 then forms a 
complex with cytochrome c, attracting procaspase-9 and ATP molecules, resulting in the 
formation of the apoptosome (Figure 1.3). The initiator caspase, procaspase-9, contains a N-
terminal CARD (caspase activation and recruitment domain) domain that facilitates binding 
and association with Apaf-1 (Hengartner, 2000). Procaspase-9, a monomer, is activated by 
dimerisation and conformational changes once in contact with Apaf-1 in the apoptosome 
(Boatright and Salvesen, 2003; Zimmermann and Green, 2001). Caspase-9 is responsible for 
the cleavage and activation of procaspase-3 into mature caspase-3, which is the ultimate 




During homeostasis the anti-apoptotic Bcl-2 family members (such as Bcl-2 and Bcl-xL) 
prevent unwanted cell death by antagonising the pro-apoptotic effector proteins (Bax and 
Bad) and preventing the release of cytochrome c from the mitochondria. In the presence of a 
death signal, the BH-3 only pro-apoptotic proteins (such as Bim and PUMA) are responsible 
for binding and inhibiting the anti-apoptotic proteins resulting in the liberation of Bax and 
Bak, which are able to facilitate the release of cytochrome c upon activation and induction of 
MOMP (Figure 1.3).  
 
Other proteins released from the mitochondria include Smac/DIABLO (Second 
mitochondria-derived activator of caspases/Direct IAP-binding protein with low pI), 
HtrA2/Omi (High temperature requirement/Omi stress regulated endoprotease) and AIF 
(Apoptosis inducing factor) (involved in early DNA fragmentation and chromatin 
condensation after translocation to the nucleus) (Elmore, 2007). Smac/DIABLO and 
HtrA2/Omi function by inhibiting the IAPs (Inhibitor of apoptosis proteins), such as XIAP 
(X-linked mammalian inhibitor of apoptosis protein), cIAP1, cIAP2 and survivin, which are 
deployed in the cell to prevent the activation of caspase-3 (Figure 1.3) (Green, 2000; 






Figure 1.3: The extrinsic and intrinsic pathways of apoptosis. The intrinsic (mitochondria mediated) and the 
extrinsic (death-receptor mediated) pathways are the two main pathways of apoptosis. The intrinsic pathway is 
mediated by the Bcl-2 family of anti-apoptotic (Bcl-2 and Bcl-xL) and pro-apoptotic proteins (Bax and Bak). 
Stimuli such as γ radiation and ROS cause pro-apoptotic BH3 only proteins (such as Bim and PUMA) to inhibit 
anti-apoptotic Bcl-2 and Bcl-xL, allowing Bax and Bak to promote MOMP resulting in the release of 
cytochrome c. This leads to the activation of caspase-9, which then activates caspase-3 The extrinsic pathway is 
mediated by the activation of death receptors by binding of extracellular ligands (such as FAS, TNF and 
TRAIL), allowing recruitment of adaptor proteins (such as FADD). FADD recruits caspase-8, ultimately 




1.2.2.2.2 Extrinsic pathway 
The extrinsic or death receptor pathway of apoptosis mainly functions to eliminate unwanted 
cells during development, immune system function and immune-surveillance (including 
immune-system-mediated tumour elimination) (Boatright and Salvesen, 2003). This apoptotic 
pathway relies on the binding of extracellular ligands to the death receptors of the TNFR 
(Tumour necrosis factor receptor) family including FAS (Fatty acid synthetase) or CD95, 
TNFR1 (Tumour necrosis factor receptor 1), DR3 (Death receptor 3), DR4 (Death receptor 4) 
or TRAIL-R1 (TNF-related apoptosis inducing ligand-Receptor 1) and DR5 (Death receptor 
5) or TRAIL-R2 (TNF-related apoptosis inducing ligand-Receptor 2) (Elmore, 2007; 
Zimmermann and Green, 2001).  
 
The extrinsic pathway is best described by the FAS/FASL (FAS ligand) model where upon 
ligand binding, the receptors aggregate in a trimeric manner facilitating the recruitment of 
adaptor proteins such as FADD (FAS-associated death domain). FADD recruits procaspase-8 
molecules (initiator caspase), forming a death-inducing signalling complex (DISC), via 
interaction with the zymogen’s N-terminal death effector domain (DED). This allows 
activation of caspase-8. Depending on its concentration, c-FLIP (FLICE inhibitory protein) 
can inhibit or support binding of FADD to caspase-8 (Hotchkiss et al., 2009). Activated 
caspase-8 cleaves and activates caspase-3 in addition to Bid, the connector of the intrinsic 
and extrinsic apoptotic pathways. Truncated Bid (tBid) translocates to the mitochondria in 
order to activate Bax and Bax which promotes MOMP and cytochrome c release ultimately 
resulting in caspase-3 activation (Figure 1.3) (Boatright and Salvesen, 2003). As this 
description illustrates, activation of apoptosis by the extrinsic pathway is frequently 
associated with activation of the intrinsic pathway as a result of Bid cleavage by caspase-8. 
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As mentioned earlier, caspase-3 has a large number of substrates, and their cleavage 
ultimately results in the execution of cell death. For example, caspase-3 activates CAD 
(Caspase-activated DNAse), a DNAse that is normally attached to an inhibitory subunit, 
ICAD (Inhibitor of Caspase-activated DNAse), that is present in cells. Cleavage of the 
inhibitory subunit, ICAD, allows the release of the catalytic subunit, CAD, that in turn 
cleaves genomic DNA between nucleosomes generating DNA fragments with lengths of 
approximately 180 base pairs (bp) (Hengartner, 2000; Wyllie, 1980). This feature has been 
used as a generally accepted method to detect apoptosis by analysing DNA ladders using 
electrophoresis or to demonstrate TUNEL (Terminal deoxynucleotidyl transferase-mediated 
2’-deoxyuridine 5’-triphosphate nick end-labelling) staining of nuclei using histochemical 
approaches.  
 
DNA fragmentation assays were among the first biochemical assays used to characterise 
apoptosis (Wyllie, 1980) and over the years numerous methods to detect apoptosis have been 
established. These include Caspase-3/7 activity, Annexin V staining (based on the binding of 
labelled Annexin V to phosphatidylserine, which translocates from the inner leaflet of the 
plasma membrane to the outer part during apoptosis) and PARP (poly (ADP-ribose) 
polymerase cleavage. PARP is a 116 kilo Dalton (kDa) nuclear enzyme responsible for DNA 
repair, and is cleaved into 89 kDa and 24 kDa fragments by caspase-3 (and caspase-7) during 
apoptotic cell death (Boulares et al., 1999; Germain et al., 1999). Western blot analysis to 
determine the expression of the 89 kDa cleaved fragment of PARP is a widely employed 
biochemical assay for apoptosis. These methods used to detect apoptosis not only added to 
the further understanding of the apoptotic pathway but also facilitated the elucidation of 




1.2.3.1 Description and Function 
Autophagy is an important cellular pathway, and it has seen a substantial surge in 
publications in the past two decades despite being discovered in the 1960’s by Christian de 
Duve (De Duve and Wattiaux, 1966; Klionsky, 2008). The term “autophagy” comes from the 
Greek words “auto” (self) and “phagy” (to eat) and literally means “to eat oneself”. Indeed 
autophagy works hand-in-hand with lysosomes as the cell’s main pathway responsible for 
turnover of long-lived proteins and damaged or old cytoplasmic organelles. This is especially 
true for those too large for degradation by the proteosome, another important protein 
degradation system employed by the cell for the degradation of short-lived proteins. 
Autophagy occurs constitutively in the cell at a basal level to maintain homeostasis by 
ensuring “quality control” of important proteins and organelles (Yang and Klionsky, 2010a). 
This pathway is activated in response to stress including starvation, oxidative stress, 
accumulation of misfolded proteins, hormonal signalling, irradiation and treatment with 
chemical compounds (Meijer and Codogno, 2004). 
 
Three distinct types of autophagy have been classified according to the different methods of 
cargo to lysosome delivery: macroautophagy, micro-autophagy and chaperone-mediated 
autophagy (CMA). CMA involves the specific degradation of proteins containing a specific 
KFERQ-like motif. Tagged proteins are directly translocated through the lysosomal 
membrane facilitated by LAMP (lysosome-associated membrane protein) type 2A (Dice, 
2007; Kaushik et al., 2008). Interestingly, CMA has not been characterised in yeast, yet this 
type of autophagy has been characterised in all higher eukaryotes (Chen and Klionsky, 2011). 
The lysosomal membrane directly engulfs parts of the cytosol in cells undergoing 
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microautophagy (Mortimore et al., 1988; Müller et al., 2000), a process which is not well 
understood in mammalian cells. Macroautophagy is evolutionarily well conserved and is the 
main pathway involved in the turnover of cytoplasmic constituents (Klionsky and Emr, 
2000). For the sake of simplicity, macroautophagy will be referred to as autophagy hereafter. 
 
Autophagy plays a role in normal development, senescence, microbial invasion, immunity 
and defence as well as in disease states that include cancer, myopathies, neurodegeneration, 
gastrointestinal disorders and heart and liver diseases (Baehrecke, 2003; Chen and Klionsky, 
2011; Klionsky and Emr, 2000). One of its main functions is to facilitate cell survival during 
times of stress, particularly starvation. Nutrient deprivation can activate autophagy to break 
down cytoplasmic constituents that can be sacrificed in order to produce new proteins or ATP 
essential for cell survival. Uncontrolled or excessive autophagy can result in autophagic cell 
death, previously known as Type II programmed cell death (Clarke, 1990; Galluzzi et al., 
2012; Klionsky and Emr, 2000; Kroemer et al., 2009; Maiuri et al., 2007), a pathway that was 
subjected to intense debate and scrutiny (Clarke and Puyal, 2012; Edinger and Thompson, 
2004; Gozuacik and Kimchi, 2004, 2007; Kroemer and Levine, 2008; Kroemer et al., 2009; 
Levine and Yuan, 2005; Li et al., 2009b; Shen et al., 2012; Tsujimoto and Shimizu, 2005). 
This is mostly due to the paradoxical roles of autophagy in cell survival and in cell death, as 
well as in cancer (discussed further in Section 1.2.3.4). 
 
Autophagic cell death is thought to occur by excessive autophagic activity that results in a 
cell “eating” itself (Gozuacik and Kimchi, 2004), however it was proposed that this type of 
cell death mostly occurs in cells where apoptosis is compromised since apoptosis is perceived 
as the preferred cell death pathway (Levine and Yuan, 2005; Lockshin and Zakeri, 2004). 
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There are a number of reports that demonstrated that autophagy directly caused cell death 
when apoptosis was blocked (Shimizu et al., 2004; Xavier et al., 2013; Yu et al., 2004), 
suggesting that autophagy has a causative role in cell death in cells exposed to harsh stimuli. 
Shimizu and colleagues demonstrated this by treating Bax-/-Bak-/- mouse embryonic 
fibroblasts with etoposide or staurosporine, which resulted in cell death together with a 
significant increase in autophagic vacuoles (Shimizu et al., 2004). Furthermore, they showed 
a reduction in autophagy and cell death by treating cells with a pharmacological autophagy 
inhibitor as well as using siRNA (small interfering RNA) directed at essential autophagy 
genes (Shimizu et al., 2004).  
 
Interestingly, autophagy can occur in the absence of apoptosis and it can also occur at the 
same time as apoptosis (Codogno and Meijer, 2005). This has been evidenced by studies that 
demonstrated the ability of promising anticancer agents (such as histone deacetylase 
inhibitors (sodium butyrate and suberoylanilide hydroxamic acid) and 2-methoxyestradiol) to 
activate both autophagy and apoptosis resulting in cell death (Kim et al., 2012; Lorin et al., 
2009; Shao et al., 2004; Wong et al., 2010; Zhang et al., 2013). Numerous reports have 
shown that anticancer compounds (including temozolomide and soybean B-group 
triperpenoid saponins) can induce autophagic cell death independently of apoptosis in cancer 
cells (Ellington et al., 2006; Huang et al., 2011b; Kanzawa et al., 2004; Li and Johnson, 2012; 
Li et al., 2009a; Shinojima et al., 2007; Wang et al., 2012). In addition, studies have 
demonstrated that compounds that cause oxidative stress stimulate ROS-mediated signalling 
pathways that activate the autophagic cell death pathway in cancer cells (Chen et al., 2008; 
Duan et al., 2011; Eom et al., 2010; Gong et al., 2012; Son et al., 2011; Xie et al., 2011), also 
to be discussed further in Section 1.2.3.4.  
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Considering the substantial body of evidence demonstrating the ability of a variety of 
anticancer compounds to induce autophagy as the main cell death pathway employed by 
cancer cells, it is difficult to dispute that autophagy causes cell death. However, conflicting 
views have been put forward questioning the existence of autophagic cell death, and there has 
been uncertainty regarding the precise function of autophagy in cell death, and whether cell 
death occurred “by” autophagy or “with” autophagy (Kroemer and Levine, 2008; Levine and 
Yuan, 2005; Shen et al., 2012). According to specific guidelines set out by the Nomenclature 
Committee on Cell Death (NCCD), the term “autophagic cell death” can only be used once 
the following criteria have been met: firstly, cell death must be inhibited when cells are 
treated with pharmacological agents known to block autophagy; secondly, inhibition of 
autophagy by genetically targeting two or more essential autophagy mediators must suppress 
cell death (Galluzzi et al., 2012). An additional criterion has been put forward, 
recommending that the term autophagic cell death should only be used when the above two 
criteria are met independently of other cell death pathways such as apoptosis or necrosis 
(Clarke and Puyal, 2012; Shen et al., 2012). In light of the controversy surrounding 
autophagic cell death, these recommendations were clearly put forward to assist cell death 
researchers in making meaningful conclusions regarding autophagic cell death.  
 
The morphology of a cell undergoing autophagic cell death differs substantially from that of a 
cell undergoing apoptosis. While apoptosis results in nuclear degradation, the nucleus of an 
autophagic cell remains intact until the late stages of the process. In addition, autophagy is 
characterised by the presence of many vesicles within the cell that range from tiny 
autophagosomes (double-membrane) to relatively large autophagolysosomes (single-
membrane) that are not observed in apoptosis. However, similarities do exist in the molecular 
regulation of apoptosis and autophagy where key players in the apoptotic program such as 
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Bcl-2 and Bax are involved in cross-talk with important autophagy regulatory proteins 
(Maiuri et al., 2007). Moreover, the lysosomes play a key role in the removal of cells 
undergoing cell death via both pathways. During apoptosis the lysosomes of the phagocytes 
and neighbouring cells take responsibility for disposal of the dead cell whereas cells 
undergoing death by autophagy employ their own lysosomes that fuse with the 
autophagosomes (to generate autophagolysosomes) to self-digest (Gozuacik and Kimchi, 
2004).  
 
Autophagy has made an explosive impact on the literature in the recent years. One of the 
main reasons for this was the discovery of the autophagy-related (ATG) genes that were first 
characterised in yeast (Matsuura et al., 1997). Presently, a total of thirty five ATG genes have 
been characterised in the yeast model with at least seventeen orthologues identified in 
eukaryotes (Chen and Klionsky, 2011). These genes have made a significant contribution to 
the understanding of the molecular regulation of autophagy and formation of the double 
membraned autophagosomes central to the process. The yeast model system was ideal to 
study autophagy because it contains a single phagophore assembly site (PAS), the only site 
where the autophagosome is produced, situated close to the vacuole (mammalian lysosome) 
for degradation (He and Klionsky, 2009). The nomenclature and pathway differs slightly 
compared to higher eukaryotes and for the purposes of this study the mammalian molecular 






1.2.3.2 The Autophagy Pathway 
The autophagic process involves very distinct stages where specific regulatory proteins 
interact and allow progression to the next stage. The main stages include: initiation of 
preautophagosomal structure, elongation of autophagosomal membrane, maturation of 
autophagosome and autophagosome-lysosome fusion. Unlike in yeast, the initiation of the 
preautophagosomal isolation membrane (phagophore) can occur at several sites within the 
mammalian cell and structures such as the ER, Golgi apparatus and mitochondrial outer 
membrane have been implicated in this process, although no conclusive evidence is available 
(He and Klionsky, 2009; Juhasz and Neufeld, 2006; Yang and Klionsky, 2010b).  
 
The formation of the autophagosome involve very intricate interactions between various 
proteins (often referred to as the ‘core machinery’) resulting in a completed double-
membrane vesicle that fuses with lysosomes forming autophagolysosomes or autolysosomes 
for degradation of the organelles and cytoplasmic constituents contained within the 
autophagosome (Xie and Klionsky, 2007). Four important core complexes involved in this 
process are: (1) ULK1/2 (Uncoordinated-51-like kinase-1 or -2)-Atg13-Atg101-FIP200 (the 
focal adhesion kinase family-interacting protein of 200kDa) complex, (2) the class III PI3K 
(phosphatidylinositol 3-kinase ) complexes, (3) the Atg12 complex and the Atg8 complex, 
representing two ubiquitin-like conjugation systems and (4) Atg9, which cycles between the 
phagophore and other structures and is essential for formation of the autophagosome (Yang 




The mammalian Target of Rapamycin (mTOR) has a key function in the regulation of 
autophagy (Jung et al., 2010). In the presence of sufficient nutrients, mTOR inhibits 
autophagy by associating with and inhibiting (by phosphorylation) ULK-1 or ULK-2 
(mammalian homologs of Atg1 and collectively referred to ULK1/2) and Atg13 (inactivated 
by hyperphosphorylation) (Figure 1.4). ULK1/2-Atg13-FIP200 forms a stable complex in 
cells irrespective of nutrient conditions (He and Klionsky, 2009). Starvation or chemical 
inhibition of mTOR results in its disassociation from ULK1/2 (Figure 1.4). ULK1/2 is then 
activated by a conformational change, and in turn phosphorylates and activates Atg13 and 
FIP200 (Atg17) (activated by hyperphosphorylation), forming an active complex (Figure 
1.4). In addition, a recently identified Atg-13 binding protein, Atg101, was also found to be 
part of this complex necessary for the assembly of the preautophagosome during the 
induction of autophagy (Chen and Klionsky, 2011; Hosokawa et al., 2009; Jung et al., 2009; 
Mercer et al., 2009).  
 
Mammalian cells have three types of PI3K, Class I, II and III PI3K, with Class I and Class III 
implicated in the control of autophagy. Class I members negatively regulate autophagy of 
which AKT (AK (refers to a mouse strain) Thymoma) is an example (Chen and Klionsky, 
2011; Ellington et al., 2006). The Class III PI3K, hVps34 (human Vacuolar protein sorting 
34), positively regulates autophagy (Chen and Klionsky, 2011) and forms part of three 
important complexes together with Beclin 1 (Atg6 or Vps 30, a coiled-coil, myosin-like Bcl-
2-interacting protein) and p150 (Vps 15 or phosphoinositide-3-kinase regulatory subunit 4, a 
myristoylated kinase) that are essential for the formation of the preautophagosomal structure 
(Figure 1.5) (Chen and Klionsky, 2011). The Atg14L complex consisting of the core 
components (hVps34, Beclin 1 and p150) associated with Atg14L (yeast Atg14-like or 
Barkor) and AMBRA 1 (activating molecule in Beclin 1-regulated autophagy), and the 
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UVRAG (ultraviolet irradiation resistant-associated gene) complex made up of the core 
components associated with Bif 1 (Bax-interacting factor 1) and UVRAG positively regulate 
autophagy (Figure 1.5). 
Figure 1.4: mTOR regulation of autophagy during nutrient-rich and starvation conditions. During 
nutrient-rich conditions mTOR associates with and phosphorylates ULK1/2 resulting in the 
hyperphosphorylation and inactivation of Atg13, thus inhibiting autophagy. During starvation or chemical 
inhibition, mTOR dissociates from ULK1/2 which undergoes a conformational change and is activated by 
autophosphorylation resulting in hypophosphorylation of Atg13 and hyperphosphorylation of FIP200 thus 
activating autophagy. (Image reproduced from Chen and Klionsky, 2011). 
 
In contrast, the Rubicon (RUN domain and cysteine-rich domain containing Beclin 1-
interacting protein) complex (Figure 1.5) - where Rubicon interacts with the Class III PI3K 
core components and UVRAG - has an inhibitory role on autophagy (Chen and Klionsky, 
2011; He and Klionsky, 2009; Kuppusamy et al., 2011; Matsunaga et al., 2009; Yang and 
Klionsky, 2010a). Another inhibitor of this process is Bcl-2 (from the ER) that binds to 
Beclin 1 at the BH3 domain (Beclin 1 is a BH3-only family member) preventing Beclin 1 
from forming the PI3K complexes necessary for autophagy induction (He and Levine, 2010). 
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Figure 1.5: Class III PI3K complexes essential for the formation of the preautophagosomal structure.  
PI3K Class III, hVps34, together with Beclin 1 and p150 can exist as multiple complexes that associate with 
different partners: Ambra 1, Atg14L, Bif 1, UVRAG and Rubicon. The Ambra 1-Atg14L and Bif 1-UVRAG 
complexes activate autophagy whereas the Rubicon-UVRAG complex inhibits autophagy (Image reproduced 
from Yang and Klionsky, 2010b). 
 
The Class III PI3K complexes play an important role in the formation of the 
preautophagosomal structure or phagophore, to which two strongly interdependent ubiquitin-
like systems are recruited (Ohsumi, 2001). The first is the Atg12-Atg5-Atg16 system where 
Atg12 represents an ubiquitin-like (Ubl) protein. Atg12 is activated by Atg7 (which acts as an 
E1 activating enzyme) and then transferred to Atg10 (playing the role of the E2 conjugating 
enzyme) that facilitates the binding of Atg12 to Atg5 via covalent linkage of an internal 
lysine on Atg5. The Atg12-Atg5 conjugates interact with Atg16, allowing self-
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oligomerisation (of Atg16) to form a tetramic complex with Atg12-Atg5. The Atg16-Atg12-
Atg5 complex attaches to the phagophore (via Atg16) enabling the elongation process (Yang 
and Klionsky, 2010a) (Figure 1.6).  
 
The second essential Ubl system employed for the expansion of the preautophagosome is 
Atg8-PE (phosphatidylethanolamine). Atg8 or LC3 (Microtubule-associated protein 1 light 
chain 3), the second Ubl protein, is cleaved by the cysteine-protease Atg4, exposing a C-
terminal glycine residue thus generating LC3-I. This is recognised by Atg7 (E1 activating 
enzyme) which activates and transfers LC3-I to Atg3 (E2 conjugating enzyme) (Figure 1.6). 
The first Ubl system (Atg16-Atg12-Atg5) facilitates the second system by conjugating LC3-I 
to PE, via an amide bond, producing a lipidated form of LC3 called LC3-II (Yang and 
Klionsky, 2010a). In this way, LC3 is responsible for controlling the expansion of the 
autophagosome by recruiting lipid molecules (Knævelsrud and Simonsen, 2012; Xie et al., 
2008). LC3-II is extensively used in biochemical assays for autophagy as it is found on both 
the inner and outer autophagosome membrane and is directly associated with the 
autophagosome, which form randomly throughout the cytoplasm (Jahreiss et al., 2008; 
Kabeya et al., 2000).  
 
An adaptor protein called sequestosome-1 (SQSTM 1) or p62, also bound by LC3-II, 
functions to aid the degradation of ubiquitinated protein aggregates via autophagy. During the 
autophagic process p62/SQSTM 1 is degraded, but accumulates during autophagy inhibition 
(Mathew et al., 2009; Moscat and Diaz-Meco, 2009). Thus levels of p62/SQSTM 1 is also 
used in biochemical assays monitoring autophagy (Klionsky et al., 2009). Once the 
completed autophagosome fuses with the lysosome the LC3-II on the outer membrane is 
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cleaved and delipidated by Atg4 and returned to the cytoplasm to be recycled while the LC3-
II on the inner autophagosomal membrane is degraded with the rest of the cargo (He and 
Klionsky, 2009).  
Figure 1.6: The pathways regulating autophagy. During the initiation phase of autophagy the Class III PI3K 
complexes, including Beclin 1, play a pivotal role in the recruitment of two ubiquitin-like conjugation systems: 
the Atg12-Atg5-Atg16 system and LC3-PE system. Both systems function together to elongate the 
autophagosome resulting in a mature autophagosome. The maturation of autophagosomes and fusion with 
lysosomes is facilitated by UVRAG, RAB7A and LAMP-2. Autophagosomes fused with lysosomes are called 
autolysosomes, and contain acidic hydrolases from the lysosomes that are responsible for the degradation of the 
contents of the autophagosome (Image reproduced from Liu and Ryan, 2012). 
 
The fusion of the autophagosome to the lysosome is made possible by LAMP-2 (lysosome-
associated membrane protein-2), a lysosomal membrane protein and the small GTP 
(guanosine-5’-triphosphate) binding protein RAB7A (Jäger et al., 2004; Liu and Ryan, 2012; 
Tanaka et al., 2000). UVRAG, apart from its function in autophagosome initiation, activates 
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RAB7A thereby controlling autophagosome maturation (Liu and Ryan, 2012). Fusion of the 
autophagosome to the lysosome results in a single-membrane autolysosome, where the inner 
membrane of the autophagosome attaches to the lysosome releasing its contents (Figure 1.6). 
The lysosome contains acidic hydrolases (cathepsin B, D and L) responsible for breakdown 
of the material contained within the autophagosome (Tanida et al., 2005). The amino acids, 
fatty acids and nucleosides produced can be reused by the cell to maintain energy production 
and protein synthesis required for cell survival, especially during stressful conditions such as 
starvation (Wirawan et al., 2012). If the autophagic process is excessive, cell death occurs 
(Kroemer et al., 2009).  
 
1.2.3.3 Autophagy in Cancer 
Autophagy has been frequently referred to as a “double-edged sword” because of its 
paradoxical roles in both cell survival and cell death of cancer cells (Apel et al., 2009; 
Shintani and Klionsky, 2004). Many studies have implicated autophagy as a tumour 
suppressor mechanism whereas others have demonstrated its tumourigenic role in cancer. The 
diverse roles of autophagy in tumour suppression and as a promoter of tumourigenesis will be 
explored further below. 
 
Beclin 1 provided the first evidence that autophagy had tumour suppressive functions. Initial 
studies demonstrated that allelic BECN1 (gene encoding Beclin 1) deletion was repeatedly 
detected in ovarian, breast and prostate human cancers (Eccles et al., 1990; Futreal et al., 
1992; Gao et al., 1995; Russell et al., 1990; Saito et al., 1993). Liang and colleagues reported 
that overexpression of Beclin 1 induced autophagy and inhibited tumourigenesis in human 
breast carcinoma cell lines (Liang et al., 1999). In addition, later studies demonstrated a high 
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incidence of spontaneously occurring tumours as well as promotion of tumourigenesis in 
mice with Beclin 1 mutations confirming the tumour suppressing function of Beclin 1 (Qu et 
al., 2003; Yue et al., 2003). Furthermore, decreased expression or alterations of several other 
essential autophagy regulatory proteins (including LC3-II, Atg5, Atg12 UVRAG, Bif-1) have 
been observed in a wide variety of human tumours (such as brain, colon, gastric and prostate) 
thus supporting the notion that tumour suppression is achieved by various components of the 
autophagic pathway (Huang et al., 2010; Liang et al., 2006; Liu and Ryan, 2012; Takahashi et 
al., 2007). In addition, autophagy is responsible for degrading p62/SQSTM 1, which is 
implicated in the promotion of tumourigenesis and is often upregulated in cancer cells 
(Mathew et al., 2009; Moscat and Diaz-Meco, 2009). 
 
In order to understand the role of autophagy in cancer cell survival and cancer cell death, 
various hypotheses have been suggested, mainly that the stages of tumour development are 
important factors in determining whether autophagy is pro-death or pro-survival. Some 
authors hold that autophagy is important for the survival of cancer cells during the initial 
stages of tumour formation, since the mutated cells trying to proliferate in a distressed 
environment with limited nutrients enter a state of dormancy, thus depending on autophagy as 
a survival mechanism (Liu and Ryan, 2012). Yet, others propose that autophagy limits the 
growth of tumours in the early stages of tumourigenesis by removing damaged proteins and 
organelles that contribute to tumourigenesis (Karantza-Wadsworth et al., 2007). This includes 
mitochondria that produce high levels of reactive oxygen species contributing to increased 
DNA damage that could result in cancer development (Jin, 2006; Karantza-Wadsworth et al., 
2007). Furthermore, other studies demonstrate that autophagy promotes cancer cell survival 
at the late stages of cancer (Fung et al., 2008; Kenific et al., 2010). Cancer cells are under 
increased metabolic stress due to increased cell proliferation, and the cells at the core of 
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tumours are prone to starvation and/or hypoxia due to poor blood perfusion. Thus, in this 
scenario, autophagy represents an attractive survival mechanism (Chen and Karantza, 2011; 
Mathew et al., 2007).  
 
Studies have also implicated autophagy as a survival mechanism employed by various cancer 
cells during treatment with a number of anticancer agents (including cisplatin, trastuzumab 
and camptothecin) (Chen and Karantza, 2011; Eskelinen, 2011; Liu et al., 2011). 
Paradoxically, other anticancer agents (including arsenic trioxide and temozolomide) have 
been shown to induce autophagic cell death (Kanzawa et al., 2004; Li and Johnson, 2012). 
Interestingly certain anticancer agents such as bortezomib and tamoxifen have been shown to 
induce autophagic cell death in some cancer cell model systems (Bursch et al., 1996; Li and 
Johnson, 2012), yet in other model systems inhibition of autophagy sensitized cultured cancer 
cells to treatment with the same agents (in this case bortezomib and tamoxifen) (Fels et al., 
2008; Schoenlein et al., 2009).  
 
Taken together, it is evident that cancer chemotherapeutic agents can either increase 
autophagy or decrease autophagy in cancer cells. Furthermore, increased autophagy by 
cancer therapeutics can have a pro-survival or a pro-death effect on cancer cells. 
Understandably, the role of autophagy in cancer is a complex one. It would appear that the 
cell death and cell survival functions of autophagy in cancer are context-, tissue-, and cell-
specific. Moreover, several cancer-associated signalling pathways, both divergent and 
convergent, have been characterised to regulate autophagy. Some of the main signalling 
networks will be discussed below. 
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As mentioned earlier, mTOR plays a key regulatory role in autophagy. Mammalian cells have 
two mTOR complexes: mTORC1 (mTOR complex 1) and mTORC2 (mTORC2). mTORC1 
consists of mTOR, mLST8 (mammalian lethal with sec-thirteen protein 8), PRAS40 (Proline 
rich AKT substrate of 40kDa) and RAPTOR (regulatory associated protein of mTOR), and it 
is the main complex involved in autophagy regulation (Guertin and Sabatini, 2007; Jung et 
al., 2010). An important inhibitory pathway of autophagy regulated by Class I PI3K members 
and mTOR is referred to as the PI3K-AKT-mTOR pathway (Chen and Karantza-Wadsworth, 
2009). This pathway, activated by nutrients, growth factors and insulin, involves the 
phosphorylation of phosphatidylinositol-phosphate (PIP) forming phosphatidylinositol-3,4-
biphosphate, and phosphatidylinositol-4,5-biphosphate (PIP2) and also forming 
phosphatidylinositol-3,4,5-triphosphate (PIP3) by Class I PI3K enzymes. This allows the 
activation of AKT, which inhibits the TSC1/2 (Tuberous sclerosis factor 1 and 2, harmartin 
and tuberin, respectively) stable complex by phosphorylation of TSC2 (Manning et al., 2002). 
The inhibition of TSC1/2 results in the activation of Rheb (Ras Homolog Enriched in Brain) 
that is able to activate mTOR, which inhibits autophagy (Figure 1.7). The tumour suppressor, 
PTEN (Phosphatase and tensin homolog deleted on chromosome 10), functions in this 
pathway by hydrolysing and dephosphorylating PIP3 therefore resulting in the inhibition of 
AKT and ultimately the inhibition of mTOR resulting in activation of autophagy (Figure 1.7) 
(Esclatine et al., 2009).  
 
Abnormal activation of the PI3K-AKT-mTOR axis is frequently observed in cancer and may 
be caused by loss of PTEN function, loss of TSC1/2 function, increased activity or mutation 
of Class I PI3K proteins, overexpression of AKT, constitutive activation of tyrosine kinase 
growth factor receptors and carcinogen exposure (Chen and Karantza-Wadsworth, 2009). The 
deregulation and increased activation of the PI3K-AKT-mTOR pathway inhibits autophagy 
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and is therefore believed to play a role in increased tumourigenesis (Chen and Karantza, 
2011). In addition, this pathway induces cell growth and proliferation, both critical for 
tumourigenesis. Given this content, inhibitors of the Class I PI3K members, AKT and mTOR 
are thought to represent good potential anticancer agents as has been demonstrated by a 
number of reports (Chen and Karantza-Wadsworth, 2009; Crazzolara et al., 2009; Tanemura 
et al., 2009). 
 
In contrast to the PI3K-AKT-mTOR pathway, the AMPK-mTOR signalling pathway is 
involved in the induction of autophagy (Meley et al., 2006). AMPK (Adenosine 
monophosphate-activated protein) is mainly activated by the tumour suppressor LKB1 (a 
serine/threonine kinase gene defective in Peutz–Jeghers syndrome) in response to a decrease 
in energy levels, starvation and oxygen deprivation (Woods et al., 2003). These metabolic 
stress conditions result in a reduction of ATP with a concomitant increase in the AMP/ATP 
ratio thus activating LKB1 (Shaw et al., 2004). LKB1 activates AMPK by phosphorylation 
on threonine 172, triggering a cascade that ultimately induces autophagy (Figure 1.7). AMPK 
activates the TSC1/2 complex resulting in mTOR inhibition via inactivation of Rheb. AMPK 
can employ a TSC-independent mechanism of autophagy induction by directly inhibiting 
mTORC1 by means of RAPTOR phosphorylation.  
 
A recent study demonstrated that the LKB1-AMPK pathway can induce autophagy 
independently of mTOR via phosphorylation of p27KIP and cell cycle arrest (Liang et al., 
2007). Furthermore, LKB1 independent mechanisms of AMPK activation have been 
identified that are involved in the regulation of autophagy. Recently, a study showed that 
epithelial cells treated with the cytokine TRAIL was shown to activate TAK1 (transforming 
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growth factor-β-activating kinase 1), a protein that is capable of directly activating AMPK 
(Herrero-Martín et al., 2009). Most recently, studies demonstrated the ability of AMPK to 
directly activate autophagy via direct phosphorylation of ULK1, a process independent of 
both LKB1 and mTOR signalling (Lee et al., 2010).  
Figure 1.7: The molecular regulation of autophagy illustrating the upstream control of AMPK and 
mTOR. The PI3K-AKT-mTOR axis inhibits autophagy whereas the Class III PI3K complexed with Beclin 1 
activates autophagy. Bcl-2 complexed with Beclin 1 inhibits Beclin 1 functions in the induction of autophagy. 
AMPK upregulates autophagy via TSC1/2 inhibition of the mTORC1 complex and can be activated by LKB1, 
nuclear p53, TAK1 and calcium. Calcium release is linked to ER stress, which plays a role in the activation of 




Calcium is another important regulator of AMPK that is independent of LKB1. Various stress 
conditions result in calcium release into the cytoplasm allowing the phosphorylation and 
activation of CaMKKβ (calcium-activated calmodulin-dependent kinase kinase-β), an 
activator of AMPK and autophagy (Figure 1.7) (Høyer-Hansen and Jäättelä, 2007; Høyer-
Hansen et al., 2007). The ER is the main intracellular storage facility for calcium, and the ER 
stress pathway is one of the main pathways involved in calcium-mediated AMPK-induced 
autophagy.  
 
Apart from being the main storage site of calcium, the ER is important for protein folding and 
posttranslational modifications, biosynthesis of steroids, cholesterol and lipids, cell signalling 
pathways mediated by calcium and drug detoxification in mammalian cells (Rutkowski and 
Kaufman, 2007; Verfaillie et al., 2009). ER stress can be induced by a variety of factors 
including an accumulation of unfolded proteins, severe decrease in glucose, hypoxia, 
oxidative stress and loss of calcium homeostasis (Rutkowski and Kaufman, 2004, 2007). The 
UPR (Unfolded Protein Response) is induced by ER stress to ease the stress on the ER by 
upregulation of protein folding and degradation pathways and inhibition of protein synthesis. 
Severe ER stress can result in cell death mostly by apoptosis, however autophagy has also 
been implicated in this process (Høyer-Hansen and Jäättelä, 2007).  
 
The UPR is facilitated by three ER stress sensors: PERK (Protein kinase R-like ER kinase), 
IRE1 (inositol requiring enzyme 1) and ATF6 (activating transcription factor 6) (Verfaillie et 
al., 2009). PERK is involved in the autophagic pathway by phosphorylation of eIF2α 
(eukaryotic initiation factor 2 alpha) which increases the transcription of ATG12 and plays a 
role in LC3 conversion (Kouroku et al., 2007). Additionally, IRE1 induces autophagy by 
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activating JNK (c-Jun N-terminal kinase), an important regulator in autophagy (Ogata et al., 
2006). Activation of JNK plays an important role in Beclin 1 activity as it phosphorylates 
Bcl-2 releasing Beclin 1 from its inhibitory complex (He and Levine, 2010). Similarly, DAPk 
(death-associated protein kinase) can be activated by increased levels of calcium resulting in 
the phosphorylation of Beclin 1, hindering the Beclin 1-Bcl-2 complex and allowing Beclin 1 
to activate autophagy (He and Klionsky, 2009; Zalckvar et al., 2009). 
 
JNK activation plays a further role in autophagy regulation as it is involved in the 
transcriptional regulation of Beclin 1 via c-Jun, its target transcriptional factor (Li et al., 
2009a; Park et al., 2009). In addition, JNK-induced autophagy can be controlled by ROS, 
important signalling molecules involved in cancer and in the autophagic process (Huang et 
al., 2011a).The ERK1/2 (extracellular-signal-related kinase 1 or 2) pathway, another MAPK 
pathway, can also be activated by ROS to stimulate autophagy (Cagnol and Chambard, 
2010). ROS regulation of autophagy encompasses a number of signalling pathways in 
addition to the JNK and ERK pathways such as the AMPK and p53 (a key tumour suppressor 
that is mutated in many types of cancer) signalling pathways (Huang et al., 2011a; Li et al., 
2012; Scherz-Shouval and Elazar, 2011). 
 
Initial studies implicating ROS in the autophagic pathway were performed by Schval and 
colleagues who demonstrated that ROS inhibited Atg4 thus preventing LC3 inhibition and 
promoting autophagy (Scherz-Shouval and Elazar, 2007). High levels of ROS can also 
activate AMPK via LKB1 directly or indirectly via ER stress and calcium signalling (Høyer-
Hansen et al., 2007; Li et al., 2012; Son et al., 2011). ROS activation of p53 is important for 
cell cycle arrest and apoptosis, and interestingly for autophagy as well. Nuclear activation of 
39 
 
p53 by ROS stimulates the transcription of important autophagy regulatory proteins including 
AMPK, sestrin, TSC2, PTEN and DRAM (damage-regulated autophagy modulator) (Chen 
and Debnath, 2010; Chen and Karantza, 2011; Li et al., 2012). DRAM, a new p53 target, was 
recently identified as a specific positive regulator of autophagy (Crighton et al., 2007). In 
contrast, cytoplasmic activation of p53 is involved in the inhibition of autophagy thus 
demonstrating the opposing roles of p53 in autophagy (Chen and Debnath, 2010).  
 
Given the information discussed above, it is clear that numerous links between autophagy and 
signalling pathways involved in cancer have emerged. Furthermore, the role of autophagy in 
tumourigenesis, tumour suppression and cancer treatment is complex as autophagy can 
function in cancer cell survival, cancer cell death and resistance of cancer cells to 
chemotherapeutic agents. Moreover, a large number of anticancer compounds have been 
shown to induce autophagic cell death in a variety of cancer cell lines, demonstrating that 
autophagy has potential as a promising target for chemotherapeutic agents. However, it is 
evident that the cell death and cell survival functions of autophagy in cancer are context-, 
tissue-, and cell-specific. Ongoing research should provide valuable information on how 
autophagy can be manipulated to offer the best possible outcomes in the treatment of cancer.  
 
1.2.4 Necrosis 
1.2.4.1 A Brief Introduction to Necrosis 
Necrosis is synonymous with ‘accidental cell death’, just as apoptosis is synonymous with 
‘programmed cell death’ (a concept that is undergoing a profound transformation as more 
programmed cell death pathways are being elucidated) (Kroemer et al., 2009). The word 
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‘necrosis’ is derived from the Greek word ‘nekros’ meaning corpse but this cell death 
mechanism goes by other names including oncosis (from the Greek ‘oncos’ for swelling) and 
oncotic necrosis (Hotchkiss et al., 2009; Proskuryakov et al., 2003). Recently, it has been 
reported that necrosis can also be ‘programmed’ and more names have been added to the 
lexicon such as necroptosis, programmed necrosis, necrotic cell death and Type III cell death 
(Galluzzi and Kroemer, 2008; McCall, 2010).  
 
Classical (accidental) necrosis is a process that does not rely on strict genetic control and 
requires minimal energy, which cells undergo upon a wide variety of stimuli. Necrosis has 
been shown to occur in response to severe physiological changes such as hypoxia, abrupt 
anoxia, ischemia, hypoglycaemia, toxin exposure, reactive oxygen species, extreme changes 
in temperature/pH and nutrient withdrawal (Kroemer et al., 1998; Syntichaki and 
Tavernarakis, 2002). In contrast to apoptosis, there is little evidence implicating classical 
necrosis in development but plenty of evidence implicating its involvement in disease. It has 
a significant role in Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, 
Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, muscular dystrophy, diabetes and 
epilepsy (McCall, 2010; Proskuryakov et al., 2003; Syntichaki and Tavernarakis, 2002).  
 
Necrosis can occur as primary necrosis (necrosis in the absence of apoptosis) or secondary 
necrosis (necrosis after the onset of apoptosis) (Kroemer et al., 1998). The main 
characteristics of necrosis include widespread swelling of the cell (hence the name oncosis), 
swelling of several cellular organelles (including the mitochondria), clumping and random 
degradation of nuclear DNA and loss of plasma membrane integrity (Assunção Guimarães 
and Linden, 2004; Syntichaki and Tavernarakis, 2002). The breakdown of the plasma 
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membrane results in the release of intracellular contents and pro-inflammatory molecules into 
the local environment around the dying cell that induces an immune response and attracts 
immune cells ultimately causing inflammation, a key characteristic of necrosis (Edinger and 
Thompson, 2004). 
 
1.2.4.2 The Programmed Necrosis Pathway 
Necroptosis is the name given to programmed necrosis (Degterev et al., 2005; Galluzzi and 
Kroemer, 2008; Golstein and Kroemer, 2007). This type of cell death demonstrates necrotic 
morphology and, interestingly, relies on the stimulation of the same ligands involved in 
death-receptor mediated apoptosis such as TNF-α, FASL and TRAIL (Holler et al., 2000; 
Vercammen et al., 1998). In addition, caspase-8 was shown to play an important regulatory 
role in this cell death pathway and demonstrated a link between apoptosis and necroptosis 
(Holler et al., 2000; Varfolomeev et al., 1998). Other key regulatory proteins involved in 
necroptosis include RIP1 (Receptor-interacting protein 1), RIP3 (Receptor-interacting protein 
3) and CYLD (cylindromatosis 1) (Figure 1.8) (Degterev et al., 2005, 2008; Hitomi et al., 
2008; Zhang et al., 2009) . 
 
The induction of necroptosis can be mediated by a wide variety of molecules including 
reactive oxygen species and calcium, and is thought to have functions in mediating neuronal 
excitotoxicity and stimulating the immune system in response to viral infections 
(Christofferson and Yuan, 2010; Duprez et al., 2009). The molecular regulation of 
necroptosis is best described using the TNF-α/TNFR model (Figure 1.8). The binding of the 
ligand, TNF-α, to its receptor, TNFR, in the absence of apoptosis inhibitors or apoptosis-
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defective conditions, results in the intracellular assembly of complex I. This complex consists 
of TRADD (TNFR type-1-associated DEATH domain protein), TRAF (TNF receptor 
associated factors), RIP1 and cIAPI. cIAPI is responsible for the ubiquitination of RIP1, 
which then allows NEMO (NFĸB essential modulator) to be recruited to form part of the IKK 
(inhibitor of NFĸB kinase) complex that activates NFĸB, and a pro-survival pathway. 
However, it is not completely understood how the transition from complex I to complex IIa 
occurs (Yuan and Kroemer, 2010). RIP1 dissociates from complex 1 and joins complex IIa 
together with caspase-8 and FADD. Caspase-8 is then able to proteolytically cleave and 
inactivate RIP1 resulting in the initiation of the caspase-dependent death receptor apoptotic 
pathway (Figure 1.8) (Christofferson and Yuan, 2010; Yuan and Kroemer, 2010).  
Figure 1.8: An illustration of the molecular regulation of necroptosis showing the role of RIP1 in NF-kB 
activation, apoptosis and programmed necrosis. TNFα stimulates TNFR resulting in an intracellular complex 
including TRADD, TRAF2, RIP1 and cIAP1. cIAP1 ubiquitinates RIP1 allowing NEMO to be recruited for NF-
ĸβ activation. When apoptosis is not compromised, RIP1 forms a stable complex with FADD and caspase-8 
(Complex IIa) that can activate apoptosis. When apoptosis is compromised, RIP1 forms a stable complex with 
RIP3 (Complex IIb) that activates necroptosis. Nec-1 can inhibit the kinase activity of RIP1 and necroptosis. 
(Image reproduced from Christofferson and Yuan, 2010). 
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In contrast, in the presence of apoptosis inhibitors or when apoptosis is compromised 
complex IIb is formed, facilitated by CYLD deubiquitination of RIP1, which is thought to be 
a key process involved in the regulation of necroptosis (Christofferson and Yuan, 2010). Nec-
1 (necrostatin-1) can inhibit RIP1, which is required for the formation of complex IIb with 
RIP3 (Degterev et al., 2005; Hitomi et al., 2008). The interaction between RIP1 and RIP3 is 
important for the induction of necroptosis (Duprez et al., 2009). Many studies involved in the 
characterisation of necroptosis were performed in models where apoptosis was inhibited, 
suggesting that this mechanism of cell death could represent a compensatory pathway when 
cell death is necessary. Interestingly, it is also suggested that necroptosis and autophagy may 
function in concert, since autophagic vacuoles are often observed in cells undergoing 
necroptosis proposing that autophagy may precede necroptosis in some cell types 
(Christofferson and Yuan, 2010). However, more research is needed in order to fully 
understand the role of necroptosis in the armamentarium of the cell’s death pathways.  
 
Section 1.2 described some of the programmed cell death pathways employed by cells to 
execute homeostasis, development and survival. When these pathways are deregulated, 
cancer ensues. Of note, cells have a variety of tightly coordinated death pathways at their 
disposal, and an in-depth understanding of these pathways in cancer cells as well as clever 
manipulation of these pathways by anticancer compounds may lead to an increase in 






1.3 Cancer Drug Development 
 
1.3.1 Introduction 
Many drugs currently used for the treatment of cancer are known to offer a minimal increase 
in overall survival, are coupled with serious side effects and are expensive (Gupta et al., 
2013). Therefore, there is a significant need for the development of novel anticancer 
compounds. Novel chemotherapeutic agents targeted at cancer cells frequently elicit their 
effect by inducing cell death by modulating the highly regulated cell death pathways 
described previously (Section 1.2). Generally, most drug development programmes choose to 
target apoptosis although this probably reflected a poor understanding of the role of other 
programmed cell death pathways such as autophagy and programmed necrosis, and their 
potential as cancer therapeutic targets. Cancer cells often develop resistance to 
chemotherapeutic agents; therefore developing agents that exploit more than one cell death 
pathway may prove beneficial in the pursuit of eradicating cancer cells. 
 
The development of cytotoxic compounds represents a significant thrust of cancer drug 
discovery and remains an important focus area in many research institutions. Natural 
products have made a significant contribution to our current arsenal of therapeutic agents and 
research continues in the search for more promising anticancer agents from nature’s sources. 
Considering the advancement of technologies in all fields of research and development, it is 
not surprising that novel drug development strategies have surfaced. Small molecule targeted 
therapies and nanotechnology are presently exciting fields in cancer drug development. In 
addition, medicinal chemistry approaches have been forthcoming in the crusade against 
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cancer by not only introducing novel hybrid compounds but by also going back to old drugs 
used to treat non-cancer related diseases with the aim of repurposing them to treat cancer. 
 
1.3.2 Approaches to Improve Anticancer Drug Development 
1.3.2.1 Drug repurposing 
Repurposing, repositioning, reprofiling or redirecting are some of the terms used to describe 
the process that searches for new uses for drugs already in the market (Ashburn and Thor, 
2004). This is an ingenious venture considering that the drug discovery process is long and 
arduous involving many steps from the discovery process (screening and identification) to the 
preclinical phase (in vitro and in vivo testing) and finally, the clinical development stage 
(clinical trials in human beings). This entire process can take close to twenty years (Padhy 
and Gupta, 2011). In addition, the cost of bringing a new drug into the market is another 
major factor that contributes to the interest in repurposing old drugs. It has been estimated 
that in developed countries the average cost of producing one new drug is 1.24 billion USD 
(United States Dollars) (Padhy and Gupta, 2011). Time and cost factors are significantly 
reduced in repurposed drugs since a large amount of data is available at the onset with regard 
to safety and pharmokinetics (Tobinick, 2009). Moreover, many different diseases share 
common molecular pathways resulting in the observation of secondary indications in a large 
percentage of currently approved drugs (Boguski et al., 2009). It is therefore not surprising 
that a number of successful drugs have already been repurposed to treat different ailments, 
and a recent estimate indicates that 65% of repurposed compounds reach the market from 




The serendipitous discovery of the angina drug, sildenafil, as a treatment for erectile 
dysfunction led to the production of the extremely popular drug Viagra® by Pfizer, 
representing a successful example of drug repurposing that has stimulated interest in the 
pharmaceutical industry (Novac, 2013). Other examples of repurposed drugs include 
amantadine (influenza), colchicine (gout) and propranolol (hypertension) now used to for 
Parkinson’s disease, recurrent pericarditis and migraine prophylaxis, respectively (Bidabadi 
and Mashouf, 2010; Padhy and Gupta, 2011). In addition, zidovudine, paclitaxel, 
methotrexate and miltefosine, part of the arsenal against cancer, are now used in the treatment 
of HIV/AIDS, restenosis, rheumatoid arthritis and visceral leishmaniasis, respectively 
(Ashburn and Thor, 2004; Novac, 2013; Padhy and Gupta, 2011).  
 
Not surprisingly, numerous drugs used for a variety of non-cancerous diseases are now being 
used for or investigated as anticancer agents (Gupta et al., 2013). Thalidomide was initially 
used to treat nausea during pregnancy but was withdrawn due to its teratogenic effects 
(Mcbride, 1961). Further investigation demonstrated its valuable anticancer characteristics 
and it is now used to treat multiple myeloma (Boguski et al., 2009). Aspirin, valproic acid, 
statins, metformin and celecoxib are additional examples of drugs originally indicated for a 
variety of diseases that are now repurposed as anticancer agents (Gupta et al., 2013). The 
antimalarial, chloroquine, has also been repurposed as a potential treatment for cancer and 
was shown to induce cell death in a variety of cancer cell lines, including breast, lung and 
colon cancer (Jiang et al., 2008; Solomon and Lee, 2009; Zheng et al., 2009). Interestingly, 
another antimalarial compound, artemisinin, has recently also displayed promising anticancer 




1.3.2.2 Artemisinins: from antimalarial to anticancer agents  
Artemisinin is a compound isolated from a Chinese herbal plant (Artemisia annua, also 
known as sweet wormwood) that has been used for many years in Traditional Chinese 
Medicine (TCM). The first recorded use of the plant dates as far back as the third century BC 
(Before Christ) to treat fever and chills. Much later in the late 1960’s, the Chinese 
government embarked on a search for new antimalarial drugs from TCM and this led to the 
discovery of artemisinin or qinghaosu (Klayman, 1985). Artemisinin displayed low solubility 
in oil and water, poor bioavailability and a short half life in vivo (Crespo-Ortiz and Wei, 
2012), therefore many derivatives such as dihydroartemisinin, artemether, arteether and 
artesunate (collectively called the artemisinins) were developed (Figure 1.9). The 
artemisinins are commonly used to treat malaria and the World Health Organisation 
recommends artemisinin combination therapies as the first-line treatment of uncomplicated 
malaria to prevent to development of resistance (Kokwaro et al., 2007). In Africa, 
artemether/lumefantrine and amodiaquine/artesunate are the two main artemisinin 
combination therapies in use (Kokwaro et al., 2007; SAMF, 2010). Recently the artemisinins 
were found to be effective against cancer cells (Lai and Singh, 1995), and therefore 
represents an example of good candidates for repurposing. 
 
Artemisinin is a sesquiterpene lactone that contains an endoperoxide bridge (C-O-O-C) and is 
the parent compound to several first generation derivatives: the reduced lactol 
dihydroartemisinin (DHA) (in vivo metabolite of some artemisinin derivatives) and the 
semisynthetic derivatives (artemether, arteether, artesunate and artelinate) are the ethers or 
esters of the lactol (Figure 1.9). The water-soluble artesunate (ART) was shown to have 
significant pharmacokinetic advantages over the lipid-soluble derivatives (artemether and 
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arteether) in addition to being less toxic (Haynes and Krishna, 2004). Many second-
generation derivatives of artemisinin have also been synthesized, all of which contain the 
endoperoxide bridge. This bridge is located in the trioxane pharmacophore (a six-membered 
ring containing three oxygen atoms) (Figure1.9), and is essential for artemisinin activity as an 
antimalarial agent (Olliaro et al., 2001). An artemisinin derivative designed without the 
endoperoxide bridge, deoxyartemisinin, had no antimalarial activity demonstrating that the 
peroxide structure is crucial for the pharmacological activity of the artemisinins (Klayman, 
1985; Neill and Posner, 2004). One of the proposed antimalarial mechanisms of action of the 
artemisinins is the iron-mediated cleavage of the endoperoxide bridge generating ROS and 
carbon-centred radical molecules that causes extensive protein damage and ultimately death 
of the malaria parasites (Meshnick, 2002; Olliaro et al., 2001). 
Figure 1.9: Chemical structures of artemisinin (a) and the first generation derivatives (b-e).  
 
As previously mentioned, artemisinin derivatives have displayed potent anticancer activity, 
both in vitro and in vivo (Crespo-Ortiz and Wei, 2012; Dell’Eva et al., 2004; Hou et al., 
2008; Ji et al., 2011; Morrissey et al., 2010; Singh and Lai, 2004). ART showed strong 
anticancer activity against 55 human cancer cell lines, including leukaemia, colon cancer, 
melanomas, breast, ovarian, prostate, central nervous system and renal cancer cell lines, in 
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the Developmental Therapeutics Program of the National Cancer Institute (NCI), United 
States of America (USA) (Efferth et al., 2001). The mechanism of action of artemisinins as 
anticancer agents is proposed to be similar to the action as antimalarial agents. Most cancer 
cells have high rates of iron intake (via transferrin receptors) and this facilitates the cleavage 
of the artemisinin endoperoxide bridge generating ROS which are toxic to cells at high 
concentrations (Lai and Singh, 2006). Furthermore, the different rates of iron metabolism 
between cancerous and normal cells can be associated with the high selectivity of 
artemisinins to cancer cells relative to normal cells (Oh et al., 2009). This observation holds 
promise for the future of the artemisinins in cancer chemotherapy. 
 
The endoperoxide bridge of the artemisinins represent the active moiety of the compound, 
and it leads to an increase of ROS within cancer cells. In a study where leukaemia cells were 
treated with ART, a rapid increase in ROS was observed, which was completely blocked by 
the antioxidant, N-acetyl-L-cysteine (NAC) (Efferth et al., 2007). It was further demonstrated 
that treatment with NAC not only completely blocked ROS production but also inhibited 
ART-induced apoptosis (via the intrinsic mitochondrial pathway) which was initially shown 
in the same cell line. It was therefore suggested that ART induced the accumulation of ROS 
resulting in the initiation of apoptosis in the cancer cells (Efferth et al., 2007). 
Anthracyclines, well-known cancer drugs, also produce ROS but are also associated with 
cardiotoxicity (Rajagopalan et al., 1988). Interestingly, artemisinins are currently used to treat 
malaria and have not revealed cardiotoxicity or any other significant side effects (Crespo-




Studies performed to examine the effects of artemisinins on DNA damage showed that cancer 
cells treated with ART caused both single and double-strand breaks in DNA, and the authors 
proposed that the DNA damage observed after ART-treatment may be a result of oxidative 
stress induced by the compound (Li et al., 2008). Other studies have revealed that artemisinin 
derivatives induced growth arrest involving changes in the expression and activity of 
different components of the cell cycle. Leukaemia, lung carcinoma, pancreatic cancer and 
liver cancer cell lines treated with ART or DHA were shown to induce G1-phase cell cycle 
arrest (Chen et al., 2010a; Hou et al., 2008; Li et al., 2001). However, DHA has been reported 
to induce a G2/M cell cycle arrest in various cancer cells including osteosarcoma and ovarian 
cancer cells (Ji et al., 2011; Jiao et al., 2007). It can be speculated that the artemisinins-
induced increase in ROS production is linked to the DNA damage observed, leading to cell 
cycle arrest and ultimately apoptosis of cancer cells.  
 
Efferth and colleagues used leukaemic T cells as a model system and showed that artesunate 
induced the cells to undergo apoptosis via the intrinsic mitochondrial pathway. This was 
demonstrated by the release of cytochrome c from the mitochondria after cells were treated 
with artesunate followed by the activation of caspase-9, a key component of the intrinsic 
pathway (Efferth et al., 2007). Ovarian cancer cells treated with DHA led to decreased levels 
of anti-apoptotic proteins, Bcl-2 and Bcl-xL, and increased levels of pro-apoptotic proteins, 
Bax and Bad (Jiao et al., 2007). Additionally, human lung adenocarcinoma ASTC-a-I cells 
treated with DHA showed an induction of caspase-3, the key effector caspase which mediates 




A panel of chemoresistant neuroblastoma cell lines treated with artesunate exhibited 
increased levels of caspase-3 as well as an enhanced number of cells in the sub-G1 phase of 
the cell cycle, indicative of apoptosis (Michaelis et al., 2010). HepG2 cells (liver cancer cells) 
exposed to ART or DHA displayed a dose-dependent reduction in the level of Bcl-2 protein 
with a corresponding increase in the level of Bax (Hou et al., 2008). A study performed by 
Singh and Lai showed that apoptosis was the primary mode of cell death in Molt-4 human 
lymphoblastoid leukaemia cells treated with the artemisinin derivatives (Singh and Lai, 
2004). Taken together, it is evident that apoptosis is the predominant form of cell death 
employed by these compounds in a wide variety of cancer cell lines. 
 
Many studies were performed to further elucidate the mechanism of action of artemisinin 
derivatives in cancer cells, and have gone on to show that artemisinin derivatives not only 
induce apoptosis and increase ROS production, but also inhibit angiogenesis and alter various 
signalling pathways involved in the proliferative, metastatic and invasive properties of cancer 
cells (Chen et al., 2010a; Crespo-Ortiz and Wei, 2012; Efferth et al., 2004; Konkimalla et al., 
2009; Zhou et al., 2007). Some of these findings will be explored briefly. 
 
Pancreatic cancer cells, BxPC-3 and AsPC-1 cells, treated with DHA and subjected to cell 
cycle analysis also demonstrated a G1-phase cell cycle arrest as well as NFκB inactivation 
(Chen et al., 2010a). NFκB has been associated with cell proliferation, invasion, 
angiogenesis, metastasis as well as suppression of apoptosis in cancer cells. The transcription 
factor is known to promote the growth of pancreatic cancer cells and Chen and colleagues 
found that DHA inhibited Bcl-2 and cyclin D1 in these cells in addition to NFκB inactivation 
(Chen et al., 2010a). Therefore, it was suggested that DHA induced cell cycle arrest and 
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apoptosis in pancreatic cancer cells as a result of inhibition of NFκB signalling (Chen et al., 
2010a).  
 
Other signalling pathways implicated in the anticancer activity of artemisinins include the 
Wnt/β-catenin pathway. Colorectal cancer cells treated with artesunate displayed a strong 
inhibition of the hyperactive Wnt/ß-catenin pathway, which is an important pathway for 
survival, proliferation and migration in many tissues (Li et al., 2007). Furthermore, studies 
have demonstrated the ability of ART and DHA to inhibit angiogenesis by downregulation of 
VEGF (Chen et al., 2003; Zhou et al., 2007), and inhibition of proliferation, movement and 
tube formation in human umbilical vein endothelial cell (Chen et al., 2003). Moreover, ART 
reduced angiogenesis in an in vivo experiment involving vascularisation of Matrigel plugs 
injected subcutaneously into mice (Dell’Eva et al., 2004). These studies, along with the 
numerous others, point to the artemisinins as attractive cancer chemotherapeutic drug 
candidates.  
 
In addition to its antimalarial and anticancer properties, artemisinins also displayed evidence 
of antifungal and antiviral activity (Efferth et al., 2008; Galal et al., 2005; Romero et al., 
2005). Therefore it represents a promising family of compounds that has great potential for 
repurposing. Although artemisinin derivatives have been shown to have anticancer effects 
and have been studied extensively in a wide variety of cancer cell lines such as breast cancer 
(Lai and Singh, 1995; Lai et al., 2005; Nakase et al., 2008; Singh and Lai, 2001; Tin et al., 
2012), ovarian cancer (Chen et al., 2009a; Jiao et al., 2007), pancreatic cancer (Chen et al., 
2010a; Du et al., 2010; Wang et al., 2010), prostate cancer (Huang et al., 2008; Morrissey et 
al., 2010; Nakase et al., 2009; Willoughby et al., 2009) and lung cancer (Lu et al., 2009; Mu 
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et al., 2008; Sadava et al., 2002; Zhao et al., 2011), the role of artemisinin derivatives in 
oesophageal cancer cells and the molecular mechanisms involved are not well known. It is 
therefore imperative that studies are performed to fully understand the effects of the 
artemisinins in oesophageal cancer, considering that it is one of the top ten most common 
types of cancer in the world with a poor overall response to current chemotherapeutic agents.  
 
1.3.2.3 Rationale for design of novel compounds used in this study 
Combination drug therapy is used in a wide variety of diseases, an approach that partners two 
or more drugs to increase the therapeutic effect and prevent resistance. In addition, this 
strategy reduces adverse side effects by allowing lower doses of each agent to be used. The 
treatment of OC frequently involves the use of cisplatin and 5-fluorouracil in combination, 
two drugs with differing structures and mechanisms of action. Another well known example, 
as mentioned above, is artesunate and amodiaquine that is used together to treat malaria in 
most African countries. An alternative approach based on this strategy of combination drug 
therapy is hybridization, a medicinal chemistry ‘tool’ that fuses two active drugs to produce a 
molecule with more potent activity than the parent compounds (Decker, 2011).  
 
The development of hybrid molecules is a very useful drug discovery technique that aims to 
produce novel compounds with improved biological functions. Using one drug that contains 
the active moiety of a combination of drugs is a highly beneficial treatment option as this 
approach may involve lower drug doses and fewer side effects. The use of drug hybridization 
has been investigated quite broadly in the search for antimalarial, antibacterial and anticancer 
agents, as well agents that treat neurodegenerative disorders (Decker, 2011). Natural products 
54 
 
have been the main source of anticancer drugs in the past and hybrid drug design 
incorporating natural products has been a major focus area for many medicinal chemists 
(reviewed by Tietze et al., 2003; Decker, 2011). Of note, hybridizing compounds with 
artemisinin has produced several interesting new compounds that show good activity as 
antimalarial and anticancer agents (Lai et al., 2013).  
 
One example is the DHA-quinine hybrids that have been reported that have more potent in 
vitro activity against the malaria parasite, Plasmodium falciparum, than the parent 
compounds alone (Walsh et al., 2007). Quinine, a natural product from the bark of the 
Cinchona tree, has been used for many years in the treatment of malaria and it is the 
structural basis from which chloroquine and mefloquine were designed. Chalcones are also 
natural products found abundantly in plants and are part of the flavanoid family. These 
compounds too have been hybridized with artemisinins by two different research groups who 
demonstrated that the hybrids displayed greater toxicity to cancer cells than the parent 
compounds alone (Ixe et al., 2011; Yang et al., 2009), thus achieving the objectives of hybrid 
compounds. The artemisinins are compounds with promising anticancer activity, largely due 
to the endoperoxide bridge, and therefore serve as excellent candidates for the synthesis of 
hybrid compounds with improved biological functions, as demonstrated above.  
 
On the basis of these considerations and promising results achieved with artemisinins as both 
antimalarial and anticancer agents, this study undertook to investigate a series of novel 
artemisinin hybrid compounds designed and synthesized by the Department of Chemistry at 
the University of Cape Town. These compounds, to the best of our knowledge, have not been 
investigated for their biological effects against oesophageal cancer. Current oesophageal 
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cancer chemotherapy is limited by the development of resistance and adverse side effects, as 
described in Section 1.1.4. Therefore the investigation of more effective anticancer agents is 
required to circumvent these limitations. Considering that a large number of 
chemotherapeutic agents in current use were sought from natural sources, this study aimed to 
investigate the potential of compounds obtained from natural products that exploited 

















1.4 Aim and Objectives 
 
1.4.1 Aim: 
Investigate the potential of artemisinin derivatives as chemotherapeutic agents and determine 
the mechanism of action in cultured oesophageal cancer cells.  
 
1.4.2 Objectives: 
 To determine the effect of artemisinin derivatives in an oesophageal cancer cell 
culture model. 
 To investigate the cell death pathways activated by the artemisinin derivatives in 
oesophageal cancer cells. 




















Currently, some of the key drivers associated with the extensive, worldwide search for novel 
chemotherapeutic agents are the serious side effects often accompanying cancer 
chemotherapy and the observation that cancer cells frequently develop resistance in response 
to therapy. Natural product drug discovery has in the past, and continues to be a significant 
source of new drugs, and this together with various medicinal chemistry approaches, such as 
the synthesis of hybrid compounds and repurposing “old” drugs, may increase the 
development of new lead anticancer agents with lower costs and in shorter time periods.  
 
Artemisinin has been cited as one of the best examples of natural product drug discovery and 
development for its role as an antimalarial, according to a recent review by Cragg and 
Newman (Cragg and Newman, 2013). In addition, it is also a spectacular example of drug 
repurposing as many studies have demonstrated its anticancer properties, as discussed in 
Section 1.3.2.2. This study took advantage of artemisinin’s repurposing potential by 
employing its reduction product, dihydroartemisinin (DHA), to form hybrid compounds with 
various other compounds in order to enhance anticancer activity. Colleagues from the 
Department of Chemistry at the University of Cape Town designed and synthesized novel 
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hybrid compounds by linking, in this case, artemisinin to other compounds to produce novel 
hybrid compounds. The work presented in this chapter explores the anticancer potential of 
these compounds in an oesophageal cancer cell culture model.  
 
The MTT assay and GraphPad Prism software were (50% inhibitory concentration) employed 
to perform dose response curves and calculate IC50 values. The most active compounds were 
selected for further investigations including testing in a variety of cancer cell lines such as 
cervical, breast and liver cancer. Two non-cancerous cell types were also included to 
determine if the compounds displayed reduced activity against normal cells compared to 
cancer cells. Furthermore, the ability of the compounds to disturb the cell cycle was also 
analysed. The results discussed in this chapter provided initial evidence that the novel hybrid 

















2.2.1 The effect of a library of artemisinin derivatives on the proliferation of 
oesophageal squamous carcinoma cell lines 
A total of twenty compounds were screened to determine their effect on cell proliferation. 
This panel of compounds included three first generation artemisinin derivatives, ART, DHA 
and artemether. The remaining sixteen compounds, with the exception of isatin (1H-indole-
2,3-dione), were novel artemisinin hybrid compounds designed and synthesized by the 
Department of Chemistry at the University of Cape Town. The effects of the compounds 
were tested in an oesophageal cancer cell line (WHCO1) that has routinely been used as a 
model oesophageal cancer cell line in our laboratory (Stringer et al., 2013; Sunassee et al., 
2013; Whibley et al., 2005, 2007). To determine the effect of the compounds on cell viability 
and proliferation, the MTT assay was performed. The IC50 values and 95% confidence 
intervals (CI) were calculated using GraphPad Prism version 5.00 for Windows, GraphPad 
Software, which generated IC50 curves, and each experiment was performed at least twice 
(Figure 2.1). IC50 is the minimum compound concentration required for 50% inhibition of cell 
growth. Table 2.1 shows the IC50 values obtained for the panel of 20 compounds tested in the 
WHCO1 cell lines and Figure 2.1 shows the dose-response curves obtained for ART and 
DHA. 
 
ART was the most active first generation derivative yielding an IC50 value of 13.4 µM and 
artemether was completely inactive. DHA, the in vivo metabolite of some artemisinin 
derivatives (including ART), displayed a slightly higher IC50 value (20.0 µM) than ART in 
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WHCO1 cells (Figure 2.1). The novel compounds tested included three compounds that were 
completely inactive (Dihyate, EXP62A, EXP39) and one compound (EXP66B) that was 
insoluble (Table 2.1). The remaining twelve novel compounds yielded IC50 values ranging 
from 3.5 µM (EXP57EA) to 45.3 µM (EXP66A). The most active compounds (EXP57A, 
EXP57EA and EXP57FA), marked with an asterisk in Table 2.1, were chosen for further 
analysis together with the first generation derivatives, ART and DHA (Figure 2.2). Isatin, one 
of the natural product scaffolds used in the synthesis of the artemisinin hybrids that was 
included in this study, was completely inactive.  
Figure 2.1: IC50 curves demonstrating sensitivity of WHCO1 cells to ART and DHA. WHCO1 cells were 
seeded at a density of 3000 cells per well in 96-well plates and were treated with a range of concentrations of 
ART (A) and DHA (B) to determine the IC50 values. Cells were incubated with ART and DHA for 48 h 
followed by the MTT assay. The absorbance was read using a multi-plate reader at 595 nm and data was 
analysed using GraphPad Prism software. Each point was performed in triplicate and error bars represent the 
mean ±SD. The experiments were independently repeated at least three times.  
 
The most active novel compounds yielded IC50 values lower than that observed for the first 
generation derivatives (Table 2.1). The novel compounds chosen for further analysis 
(EXP57A, EXP57EA and EXP57FA) were artemisinin-isatin hybrids that were structurally 




Table 2.1: IC50 values for a panel of compounds tested in WHCO1 cells. 
The MTT assay and GraphPad Prism software were used to calculate IC50 values and 95 % confidence intervals 
(CI) for a panel of 20 compounds consisting of the natural product scaffold isatin, 3 first generation artemisinin 
derivatives (ART, DHA and artemether) and 16 novel artemisinin hybrid compounds against WHCO1 cells. 
Cells were seeded in triplicate and each experiment was performed at least twice.  
 
Compound IC50 [µM] 95% CI 
*ART 13.4 11.9 - 15.2 
*DHA 20.0 18.1 – 22.1 
Artemether Inactive  
Dihyate Inactive  
AJ19 14.7 12.9 - 16.6 
AJ38 31.0 25.0 - 38.3 
AJ2DH1 17.6 12.2 - 25.5 
*EXP57A 6.6 5.3 – 8.1 
EXP57BA 13.0 9.3 - 18.2 
EXP57CC 25.9 14.7 - 45.6 
EXP57D 12.7 9.5 - 17.1 
*EXP57EA 3.5 2.4 – 5.1 
*EXP57FA 10.0 7.8 - 12.9 
EXP61C 39.1 35.5 - 43.1 
EXP62A Inactive  
EXP66A 45.3 31.6 - 64.9 
EXP66B Insoluble Insoluble 
EXP66C 44.1 39.3 - 49.6 
EXP39 Inactive  
Isatin Inactive  




The compound, EXP57EA, with an iodine group occupying the side chain was the most 
active with an IC50 value of 3.5 µM. Interestingly, isatin was completely inactive against 
WHCO1 cells but when fused with artemisinin, the hybrid compounds displayed lower IC50 




Figure 2.2: Structure of artemisinin derivatives selected for further investigation. (A) The structures of the 
first generation derivatives ART (A.1) and DHA (A.2) are illustrated, (B) represents the novel artemisinin 
derivatives chosen for further investigation (B.1) – (B.3). 
 
2.2.2 The effect of selected artemisinin derivatives on a broad panel of cancer cell lines 
The artemisinin-isatin hybrids together with the parent compound, DHA, and another first 
generation artemisinin, ART, were tested against a number of cell lines, following the 
promising results obtained in the initial screens against WHCO1 cells. The cancer cell lines 
tested included six oesophageal cancer, three cervical cancer, three breast cancer cell lines as 
well as one liver cancer and one neuroblastoma cell line. As control cells, we routinely used 
human skin fibroblasts - DMB and FG0 cells.  
(A)  First generation derivatives  (B) Novel artemisinin derivatives 
(A.1) R = CO(CH2)2CO2Na, ART   (B.1) R = Cl, EXP57A 
(A.2) R = H, DHA    (B.2) R = I, EXP57EA 
      (B.3) R = Br, EXP57FA 
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The three artemisinin-isatin hybrid compounds were more active than the first generation 
derivatives in all six oesophageal cancer cell lines tested. The OC cell lines were more 
sensitive to EXP57EA (average IC50 value across OC cell lines = 4.4 µM) than the other 
compounds EXP57A and EXP57FA (average IC50 values = 7.8 µM and 10.7 µM, 
respectively), suggesting that the iodine side chain conferred higher activity than the 
compounds containing the other side chains. As observed in WHCO1 cells, the other five OC 
cell lines treated with isatin were completely unaffected by this compound and continued 
proliferation at all treatment concentrations (Table 2.2).  
 
Testing the selected panel of compounds against cervical cancer and breast cancer cell lines 
as well as a liver cancer and neuroblastoma cell lines, demonstrated that the artemisinin-isatin 
hybrids were more active than ART and DHA, as observed in the panel of OC cell lines 
(Table 2.2 and 2.3). A similar observation was made in the cervical, breast, liver and 
neuroblastoma cell lines regarding their response to isatin, where no IC50 values could be 
calculated due to inactivity (Table 2.3). In general, the cervical, breast, liver and 
neuroblastoma cell lines tested were less sensitive to the artemisinin derivatives than the OC 
cell lines. Furthermore, no IC50 values could be calculated for MDA-MB-231 cells treated 
with ART and DHA since this highly metastatic breast cancer cell line was completely 
insensitive to the first generation artemisinin derivatives. Following suit, the T47D breast 
cancer cell line displayed high IC50 values for ART and DHA (87.9 µM and 78.5 µM, 






Table 2.2: IC50 values of selected compounds in a panel of oesophageal cancer cell lines. 
The IC50 values (and 95 % CI) obtained for the selected artemisinin derivatives and isatin against six 
oesophageal cancer cell lines, three of South African origin (WHCO1, WHCO5 and WHCO6) and three of 
Japanese origin (KYSE30, KYSE150 and KYSE180). The MTT assay and GraphPad software were used to 
calculate IC50 values and 95 % CI. 
IC50 values in µM (95% CI) 















































































*NA = Not active at the highest concentration (200µM) tested 
The cervical cancer cell line, SiHa, also displayed decreased sensitivity to ART (82.2 µM) 
and DHA (77.4 µM) compared to the OC cell lines, where the average IC50 value calculated 
for both compounds was 20.7 µM. In fact, in the small panel of 3 cervical cancer cell lines 
examined, this cell line was most resistant to the first generation artemisinin derivatives. 
Similar activity profiles were observed for the CaSki and HeLa cell lines as well as for the 
HepG2 liver cancer cell line and the SK-N-SH neuroblastoma cell line. In summary, all the 
cell lines tested were more sensitive to the novel artemisinin-isatin hybrid compounds than 
the first generation artemisinin derivatives. Furthermore, isatin was completely inactive 
against all cancer cell lines tested here. 
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Table 2.3: IC50 values of selected compounds in a broad panel of cancer cell lines. 
The IC50 values (and 95 % CI) obtained for the selected artemisinin derivatives and isatin against three cervical 
cancer cell lines (CaSki, HeLa and SiHa), three breast cancer cell lines (MCF7, MDA-MB-231 and T47D), a 
liver cancer cell line (HepG2) and a neuroblastoma cell line (SK-N-SH). The MTT assay and GraphPad Prism 
software were used to calculate IC50 values and 95 % CI. 
IC50 values in µM (95% CI) 






















































































































*NA = Not active at the highest concentration (200µM) tested 
 
We next tested the activity of the artemisinin hybrids against normal cultured fibroblasts 
compared to an oesophageal cancer cell line. In this study, cultured fibroblasts were used as a 
model for normal cultured cells considering that it is difficult to culture normal epithelial 
cells and since the immortalized normal epithelial cells typically used in this context may not 
reflect normal biology (Allen et al., 2005; Fenton and Hord, 2006; Haglund et al., 2012; 
Kroemer et al., 2009; Zang et al., 2012).  
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The first generation derivatives, ART and DHA, were nearly ten-fold and five-fold more 
effective at killing OC cells compared to DMB and FG0 cells, respectively (Figure 2.3 A). 
However the novel compounds, EXP57A, EXP57EA and EXP57FA, were only between five-
fold and two-fold more active in killing OC cells compared to normal fibroblasts (Figure 2.3 
B). These results indicate that the novel artemisinin hybrid compounds were four to five 
times more active than the first generation artemisinin derivatives, and that they still retained 
some selectivity to cancer cells compared to normal cells albeit less so than the first 
generation derivatives.  
 
We continued to explore the activity of the novel artemisinin hybrid compounds because of 
the increased activity displayed by these compounds in a variety of cancer cell lines, and the 
observation that these novel artemisinin hybrids also blocked the proliferation of cells that 






Figure 2.3: The effects artemisinin derivatives on fibroblast cells versus the oesophageal cancer cell line – 
WHCO1. WHCO1, DMB and FG0 cells cultured in 96-well plates were treated with a range of either the first 
generation derivatives, ART and DHA (A), or the novel artemisinin-isatin hybrids, EXP57A, EXP57EA or 
EXP57FA (B) followed by the MTT assay. The IC50 values were calculated using GraphPad Prism software and 
analysed based on 3 experiments. The error bars represent the mean ±SD. * P<0.05 compared with WHCO1-







2.2.3 Investigating the growth inhibitory effects of artemisinin derivatives  
A growth curve of cells treated with and without artemisinin derivatives was carried out over 
a period of 4 days (Figure 2.4). Cells were seeded at 1500 cells per well in quadruplicate in 
96-well plates and allowed to settle overnight. This was followed by treatment with three 
concentrations of the indicated compound close to the IC50 value of each compound, for the 
indicated time, followed by the MTT assay. Cells treated with the vehicle, dimethyl 
sulphoxide (DMSO), only were included as the control and were represented by the dotted 
line in Figure 2.4 (A-E).  
 
The effects of the novel artemisinin hybrid compounds can already be observed at the 24-
hour time point for all concentrations tested. This effect on cell number was maintained up to 
the last time point tested (96 hours) (Figure 2.4 C-E). A similar observation was recorded for 
ART and DHA (Figure 2.4 A and B). The novel compound EXP57EA, at 12 µM, displayed a 
cell number lower than the cell number plated at the 24 hour time point, suggesting a 
cytotoxic effect.  
 
To determine whether the reduced cell number caused by the artemisinin derivatives was 
associated with changes in the cell cycle progression, an analysis was performed comparing 
the cell cycle profiles of control (vehicle-only treatment) and compound-treated WHCO1 
cells (Figures 2.5 and 2.6). WHCO1 cells were seeded in 100 mm dishes in triplicate and 
treated with varying concentrations of each compound for 24 and 48 hours. Cells were 
trypsinised, stained with propidium iodide and analysed by flow cytometry using a 
FACSCalibur machine together with CELLQuest Pro software and Modfit LT Version 3.2 
software for data analysis. 
69 
 
Figure 2.4: Growth curves of WHCO1 cells treated with artemisinin derivatives. Cells were seeded at a 
density of 1500 cells per well in quadruplicate and allowed to settle overnight before treatment with the 
artemisinin derivatives. Once the relevant time points had elapsed the MTT assay was performed. Each point 
represents the mean of 4 wells, with standard deviation, and this is representative of at least two independent 
experiments.  
 
Treatment of WHCO1 cells with the artemisinin hybrid compounds was associated with an 
increase in the G0/G1 population at the 24-hour time point, and this was apparent at the 
lowest concentration of all hybrids tested. However, after 48 hours, EXP57A and EXP57EA 
70 
 
had no obvious effect on the G0/G1 pool size (relative to control), whereas EXP57FA still 
induced an increase in the G0/G1 pool size at 10 µM (Figure 2.5). These results are quite 
different from those observed for ART and DHA, which resulted in an increased G2/M pool 
size after treatment for 24 hours, which was sustained after 48 hours (Figure 2.6).  
 
The results obtained from the cell cycle analysis indicated that first generation artemisinin 
derivatives and the novel artemisinin-isatin hybrid compounds exerted a biological effect on 
WHCO1 OC cells and that this warranted further investigation. Furthermore, ART and DHA 
acted in a similar manner by arresting cells in the G2/M phase of the cell cycle while the 
three hybrid compounds tested arrested cells in the G0/G1 phase of the cell cycle. From these 
observations it is fair to deduce that the mode of action of the novel compounds may be quite  
alike due to their close structural similarity. Bearing this in mind, as well as the limited 
amounts of compounds available it was decided that further investigations would be carried 
out on DHA and EXP57EA, the most active hybrid compound synthesized by the linkage of 







Figure 2.5: Cell cycle profile of WHCO1 cells treated with the artemisinin-isatin hybrids. WHCO1 cells 
were seeded at a density of 5 x 105 cells per 100 mm dish. The next day cells were treated with the indicated 
concentrations (in triplicate) of EXP57A (A, B), EXP57EA (C, D) and EXP57FA (E, F) for 24 h (A, C, E) and 
48 h (B, D, F). Cells were processed for flow cytometry, stained with propidium iodide and analysed on a 
FACSCalibur machine using CELLQuest Pro software and Modfit LT version 3.2 for data analysis. The results 




Figure 2.6: Cell cycle profile of WHCO1 cells treated with the first generation artemisinin derivatives. 
WHCO1 cells were seeded at a density of 5 x 105 cells per 100 mm dish in triplicate and cultured for 24 h. Once 
settled, cells were treated with 0 µM (vehicle-only), 15 µM, 30 µM and 60 µM of ART (A, B) and DHA (C, D) 
for 24 h (A, C) and 48 h (B, D). Cells were processed for flow cytometry, stained with propidium iodide and 
analysed on a FACSCalibur machine using CELLQuest Pro software and Modfit LT version 3.2 for data 





2.2.4 Structure-activity analysis of EXP57EA 
The novel artemisinin-isatin hybrid, EXP57EA, was the most active novel compound tested 
in this study. In addition, we observed that this novel compound displayed activity against 
cells insensitive to ART and DHA, the first generation artemisinin derivatives. EXP57EA, 
distinguished from the other novel artemisinin-isatin hybrid compounds by the iodine side 
chain, was synthesized via covalent linkage of the dihydroartemisinin intermediate compound 
(IM1, Figure 2.7) to the iodo-isatin azide intermediate compound (IM2, Figure 2.7) using 
‘click’ chemistry (Hans, 2009). Each of the intermediates involved in the synthesis of 
EXP57EA was tested for activity against WHCO1 and WHCO6 OC cells (Table 2.4). 
 
 
Figure 2.7: General structure showing design of EXP57EA. The chemical structure of EXP57EA illustrating 




Table 2.4: The effects of the intermediate compounds involved in the synthesis of EXP57EA 
against WHCO1 and WHCO6 OC cells. 
The IC50 values (and 95 % CI) obtained for the panel of intermediate compounds including the parent 
compounds, DHA and EXP57EA, against WHCO1 and WHCO6 oesophageal cancer cells. The MTT assay and 
GraphPad Prism software were used to calculate IC50 values and 95% CI. 
IC50 values in µM 
(95% CI)  WHCO1 WHCO6 
DHA 21.4 
(17.7 – 25.7) 
23.8 
(18.4 – 30.9) Isatin NA NA 
Iodoisatin 19.95 
(13.97 - 28.50) 
17.05 
(13.10 - 22.19) IM1 NA NA 
IM2 20.73 
(15.38 - 27.94) 
20.70 
(14.85 – 28.86) EXP57EA 4.2 
(2.6 – 6.4) 
7.6 
(4.9 – 11.7) DHA 21.4 
(17.7 – 25.7) 
23.8 
(18.4 – 30.9) *NA = Not active at the highest concentration (200µM) tested 
 
The results obtained after WHCO1 and WHCO6 OC cells were treated with the various 
chemical moieties involved in the synthesis of EXP57EA showed that isatin had no effect 
against OC cells (and a variety of other cancer cell lines) and that an IC50 value could not be 
calculated. However, when halogenated with an iodine molecule, forming iodo-isatin, a 
distinct improvement in activity was observed, demonstrated by IC50 values close to those 
obtained for DHA in WHCO1 and WHCO6 cells (Table 2.4). Interestingly, the intermediate 
DHA compound synthesized (IM1) for linkage with the isatin intermediate compound was 
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completely inactive as the cells continued proliferation even at the highest treatment 
concentration tested (200 µM). On the contrary, the isatin intermediate compound (IM2) was 
more potent than IM1 with IC50 values close to those of DHA and iodoisatin (Table 2.4). The 
fusion of IM1 and IM2 produced the artemisinin hybrid compound, EXP57EA, with IC50 
values lower than that of DHA and the intermediate compounds in both OC cell lines tested, 
























In this project the effect of ART and DHA (first generation derivatives of artemisinin) 
together with a panel of novel artemisinin hybrid compounds was assessed on oesophageal 
cancer cell lines. The novel derivatives were designed and synthesized by the Department of 
Chemistry at the University of Cape Town. These compounds include the active moiety of 
DHA (containing the endoperoxide bridge) linked to the active part of other compounds, 
forming novel hybrid molecules. A series of nineteen artemisinin derivatives were screened 
for activity against the WHCO1 oesophageal cancer cell line. Active compounds were chosen 
based on an arbitrary cut off IC50 value of 10 µM, which was also used in studies discussed 
by other authors (Koch et al., 2004; Newman, 2008). Previous reports in our laboratory 
demonstrated that WHCO1 treated with cisplatin generated an IC50 value of 14 µM (Wyk et 
al., 2008), therefore the aim was to identify novel compounds with better activity against 
oesophageal cancer cells.  
 
Of the nineteen compounds tested, three  represented first generation derivatives (ART, DHA 
and artemether). Artemether was inactive against WHCO1 cells but ART and DHA displayed 
IC50 values of 13.4 µM and 20.0 µM, respectively, which compared favourably with the IC50 
value of cisplatin against WHCO1 cells. Hybrid compounds were synthesized by linking the 
artemisinin derivative, DHA, to compounds such as azidothymidine (Dihyate), chloroquine 
(AJ19) and isatin (EXPCC). Dihyate was completely inactive in our system and AJ19 
generated an IC50 value of 14.7 µM, which was similar to that of cisplatin in WHCO1 but did 
not match the chosen criteria of 10 µM or below. When DHA was hybridized with isatin (a 
compound that is completely inactive against all cancer cell lines tested) forming 
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(EXP57CC), an IC50 value of 25.9 µM was achieved. However, when DHA-isatin hybrids 
(referred to as artemisinin-isatin hybrids) were halogenated (EXP57A, EXP57BA, EXP57EA 
and EXP57FA) a distinct improvement in activity was observed. Isatins represent a class of 
heterocyclic compounds that is well known for their synthetic versatility and was also found 
to possess anticancer activity especially when halogenated (Sabet et al., 2010; Vine et al., 
2007). Previous studies demonstrated that bromine attached to isatin conferred potent 
anticancer activity compared to other halogen side chains (Vine et al., 2007). Interestingly, in 
this study we found that the iodine side chain (EXP57EA) displayed more than two-fold 
better activity than the bromine side chain (EXP57FA), generating an IC50 value of 3.5 µM. 
When the various intermediate moieties used in the synthesis of EXP57EA were tested, it 
was shown that none compared to the activity of the whole structure. 
 
In addition to EXP57EA, two other artemisinin-isatin novel hybrid compounds, EXP57A and 
EXP57FA, displayed IC50 values of 10 µM and below, which fell within the pre-specified 
criteria. Further IC50 experiments were carried out against a range of cancer cell lines 
including oesophageal cancer, cervical cancer, breast cancer, liver cancer and neuroblastoma 
cell lines, as well as fibroblasts, DMB and FG0. When tested against the two normal skin 
fibroblast cells, the first generation artemisinin derivatives, ART and DHA, displayed 
significantly higher IC50 values compared to the values obtained for WHCO1 cells. The novel 
hybrid artemisinin derivatives displayed decreased activity in the DMB and FG0 cells 
compared to WHCO1 cells, although not to the same extent as the first generation 
derivatives. However, the three novel hybrid compounds were reproducibly more active than 
the first generation derivatives in all cancer cell lines tested. EXP57A, EXP57EA and 
EXP57FA generated very similar IC50 values in all cell lines with the exception of the two 
breast cancer cell lines MCF7 and MDA-MB-231 and all the OC cell lines, where EXP57EA 
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was more active than EXP57A and EXP57FA. Notably, cell lines that frequently display 
resistance to chemotherapeutic agents, such as SiHa, MDA-MB-231 and T47D (Ciucci et al., 
2006; Saxena et al., 2005), also displayed decreased sensitivity to ART and DHA with IC50 
values well above 50 µM, but these cell lines were quite sensitive to the novel compounds, 
particularly EXP57EA.  
 
Further biological exploration of the effects of the compounds showed that the novel 
compounds had an inhibitory effect on WHCO1 growth and proliferation over time, 
comparable to the first generation derivatives. ART and DHA have been shown by previous 
investigators to be implicated in cell cycle arrest in various types of cancer cells, particularly 
the G0/G1 phase of the cell cycle (Hou et al., 2008; Jiang et al., 2012; Lai et al., 2013; Li et 
al., 2001; Michaelis et al., 2010; Morrissey et al., 2010; Tin et al., 2012; Tran et al., 2013; 
Wang et al., 2010; Willoughby et al., 2009; Wu et al., 2011). However, other studies have 
reported that the first generation derivatives induced a G2/M cell cycle arrest in various 
cancer cells including osteosarcoma, leukaemia, pancreatic, ovarian and non-small cell lung 
cancer (Ji et al., 2011; Jiao et al., 2007; Zhao et al., 2011; Zhou et al., 2007). In this study, 
WHCO1 oesophageal cancer cells treated with ART and DHA arrested cells in the G2/M 
phase of the cell cycle after 24 hours and 48 hours.  
 
In contrast, the novel hybrid compounds (EXP57A, EXP57EA and EXP57FA) arrested cells 
in the G0/G1 phase of the cell cycle after 24 hours and 48 hours. The results obtained here 
provided the first indication that the novel halogenated isatin-artemisinin hybrid compounds 
had a mechanism of action that differs from that of the first generation derivatives ART and 
DHA. In addition, these results clearly showed that the first generation derivatives ART and 
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DHA acted similarly (both induced a G2/M cell cycle arrest) in the model cell culture system 
employed in this study, whereas the hybrid compounds induced a G0/G1 cell cycle arrest. 
Since compound availability was one of the problems experienced during this project, it was 
decided that further investigations would be continued on the first generation derivative DHA 
and the most active novel compound EXP57EA. 
 
The results obtained from this study are consistent with previous reports suggesting the 
anticancer activity of the first generation derivatives, ART and DHA. The novel artemisinin-
isatin hybrid compounds displayed better activity than the first generation derivatives against 
cancer cell lines tested. The aim of synthesizing hybrid compounds is to produce compounds 
that have better activity than the parent compounds (Meunier, 2008). The results presented 
here indicated that this has been achieved where EXP57EA was more active than both DHA 
and isatin against the cancer cells tested in this study. Hybrid compounds are believed to be 
pharmacologically different from the parent compounds displaying properties that may differ 
from parent compounds (Decker, 2011). The initial biological investigation (cell cycle 
analysis) indicates that the first generation derivatives may have a different molecular 
mechanism of action compared to the hybrid compounds. Further mechanistic studies are 
warranted, and due to compound availability, will be continued using DHA and the most 
active artemisinin-isatin hybrid compound, EXP57EA. It would be valuable to elucidate 
EXP57EA’s biological functions in our oesophageal cancer cell culture model system in 








CHARACTERISING THE CYTOTOXIC EFFECTS OF DIHYDROARTEMISININ 
AND EXP57EA 
 
3.1 Introduction  
 
In the previous chapter, we determined that the novel artemisinin-isatin hybrid compounds 
were more active than the first generation artemisinin derivatives against oesophageal cancer. 
Furthermore, the novel compounds were more active than the first generation artemisinin 
derivatives when tested against previously recognised chemoresistant cell lines. An 
investigation into the effects of the compounds on the cell cycle revealed that the novel 
hybrid compounds arrested cells in a different phase of the cell cycle compared to the 
parental compounds, suggesting that these novel compounds required further investigation in 
oesophageal cancer.  
 
Since the small panel of novel artemisinin-isatin hybrid compounds displayed similar results 
and due to compound availability, further studies were performed with the most active 
artemisinin-hybrid compound, EXP57EA. Furthermore, the parental compounds also 
displayed similar results therefore DHA was selected for the mechanistic investigation 
alongside EXP57EA. Previous studies have reported the anticancer effects of DHA, and 
demonstrated the ability of DHA to induce apoptosis in a number of cancer cell lines (Chen et 
al., 2010a; Fujita et al., 2008; Hou et al., 2008; Huang et al., 2007; Ji et al., 2011; Jiao et al., 
2007; Lu et al., 2008, 2009; Mu et al., 2008; Singh and Lai, 2004, 2001). Therefore, in order 
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to understand how DHA and EXP57EA caused cell death in oesophageal cancer cells we 
investigated apoptosis as a possible pathway, using the PARP (poly (ADP-ribose) 
polymerase) cleavage assay and analysis of activated caspase 3/7 to establish the extent of 
apoptosis.  
 
Having determined that DHA induced apoptosis in oesophageal cancer cells and that 
EXP57EA did not, other cell death mechanisms were investigated. Using lactate 
dehydrogenase (LDH) release to measure necrosis, we showed that both compounds did not 
induce this type of cell death. Morphological studies confirmed these results but also revealed 
increased perinuclear vacuoles in EXP57EA-treated cells, indicating that the novel compound 
may activate autophagy. Quantitative real time reverse transcription polymerase chain 
reaction (RT-PCR) and western blot analysis were used to investigate the expression of 
important autophagy regulatory proteins. Furthermore, immunofluorescent analysis and 
transmission electron microscopy (TEM) were also employed to demonstrate the appearance 
of autophagosome-bound LC3-II and the perinuclear localisation of autophagosomes, 
respectively. Furthermore, experiments demonstrating autophagic flux and inhibition of 












3.2.1 Effect of DHA and EXP57EA on morphology of oesophageal squamous 
carcinoma cells 
To determine the effect of DHA and EXP57EA on cell morphology, treated cells were 
observed under light microscopy. Images were captured with an Olympus CKX42 inverted 
phase contrast microscope with an Olympus CMOS Colour Camera for Light Microscopy 
SC30 and analysis® getIT! image software (Centre Valley, USA). After exposure to DHA 
and EXP57EA for 24 and 48 hours, marked morphological changes were observed in 
WHCO1 cells (Figure 3.1). 
 
The morphological changes of cells treated with 60 µM DHA (Figure 3.1 C and D) were 
suggestive of apoptosis. Nuclear condensation and shrinkage of the cytoplasm was observed 
most clearly at the 48 hour treatment point (Figure 3.1 D). Apoptotic bodies displaying 
membrane blebbing were also visible. Such apoptotic features were not observed in the 
control cells. These morphological features strongly suggested that DHA induced apoptosis 
in WHCO1 oesophageal cancer cells. 
 
Cells treated with 10 µM EXP57EA did not exhibit the same morphological features 
observed in cells treated with DHA (Figure 3.1 E and F). Instead, after 24 hours and 48 hours 
of treatment with EXP57EA numerous intracellular, perinuclear vacuoles were observed. The 
formation of the vacuoles occurred in a dose- (data not shown) and a time-dependent manner. 
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Also, unlike cells treated with DHA, the cells treated with EXP57EA appeared to maintain 
nuclear integrity even at the 48 hour treatment point. 
Figure 3.1: Morphology of WHCO1 cells exposed to DMSO only (A-B), DHA (C-D) and EXP57EA (E-F). 
Cells (300 000) were plated in 60 mm dishes and allowed to settle overnight followed by the addition of 60 µM 
DHA, 10 µM EXP57EA or DMSO (vehicle). After the indicated time periods, images of the cells were captured 
using an Olympus CKX41 microscope with an Olympus CMOS Colour Camera for Light Microscopy SC30 
and analysis® getIT! image software. DHA-treated cells exhibited features consistent with apoptosis whereas 
cells treated with EXP57EA did not. Instead, a striking accumulation of perinuclear vacuoles were observed in 
cells treated with EXP57EA.  
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3.2.2 Determining the cell death mechanisms engaged by DHA and EXP57EA in 
oesophageal squamous carcinoma cells 
The mechanisms by which cancer chemotherapeutic agents cause cell death is important 
since there is a common view that apoptosis is the preferred cell death pathway (Fulda and 
Debatin, 2006; Green and Kroemer, 2005; Lockshin and Zakeri, 2004; Reed, 2003) given that 
it does not induce an inflammatory response, and is probably most often activated by 
anticancer drugs (Fischer and Schulze-Osthoff, 2005; Hotchkiss et al., 2009; Kim et al., 
2002). 
 
In order to determine whether DHA and EXP57EA induced apoptosis in oesophageal cancer 
cells, a PARP cleavage assay was performed. PARP is a known caspase substrate and 
cleavage of PARP into two distinct fragments (116 kDa and 85 kDa) is frequently used as a 
marker of apoptosis (Boulares et al., 1999; Germain et al., 1999). PARP cleavage was 
investigated by western blot analysis using WHCO1 and WHCO6 cells treated with 5 µM 
doxorubicin (DOX) for 24 hours as a positive control and β-Tubulin as a loading control 
(Figure 3.2 A). WHCO1 cells treated with DHA showed a clear dose-dependent increase in 
PARP cleavage after 24 and 48 hours, whereas treatment with EXP57EA (57EA) induced 
very low levels of cleaved PARP after 24 hours which was not observed at the 48 hour 
treatment point. A similar result was observed in WHCO6 cells. These results were consistent 
with the morphological changes observed (Figure 3.1) where cells treated with DHA showed 




To confirm that EXP57EA does not induce apoptosis in WHCO1 and WHCO6 cells, an assay 
to measure levels of activated caspase-3 or caspase-7 was performed. The activation of 
executioner caspases, caspase 3 and 7, are biochemically important and the levels of activated 
caspase 3/7 are often used to measure apoptosis. This was done using the Caspase-Glo™ 3/7 
Assay kit by Promega (Cat#G8090) that detects luminescence after cleavage of a substrate 
specific for activated caspase-3 or caspase-7. Cells were treated (in triplicate) with varying 
concentrations of DHA and EXP57EA for 24 hours followed by the addition of the Caspase-
Glo reagent. Luminescence was read using a VeritasTM microplate luminometer (Promega) 
and the results were expressed relative to the caspase-3/7 activity observed in untreated cells, 
and the data was plotted as shown in Figures 3.2 (B) and 3.2 (C). As observed in the PARP 
cleavage assay, both cell lines treated with DHA displayed a significant dose-dependent 
increase in caspase-3/7 activity (Figure 3.2 B - C). The results obtained here further 
confirmed that EXP57EA does not induce apoptosis in WHCO1 and WHCO6 oesophageal 
cancer cells at both concentrations tested.  
 
A necrosis assay was performed using the CytoTox-ONE Homogeneous Membrane Integrity 
assay by Promega (Cat#G7891) to determine whether EXP57EA caused necrosis. As 
discussed in Chapter 1, necrosis is characterised by swelling of cells that eventually leads to 
cell lysis, followed by inflammation. The above-mentioned assay measured levels of LDH 
released by cells as an indication of necrosis. The kit included a reagent which fluoresced in 
response to cleavage by LDH. This fluorescence was measured using a fluorescence 
spectrophotometer (Cary Eclipse, Varian, Inc) and the readings represented the levels of 
necrosis that took place. Cells were plated in quadruplicate and treated with varying 
concentrations of DHA and EXP57EA. Considering that LDH has a short half-life (Promega, 
2009), the cells were treated for 6 hours after which the CytoTox-One reagent was added to 
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each well. A lysis buffer supplied with the kit served as a positive control, and the results are 
calculated as the percentage of the fluorescence signal measured for the control (Figures 3.3 
A and 3.3 B). 
Figure 3.2: Effect of compounds on PARP cleavage (A) and caspase-3/7 activity (B and C). (A), PARP 
cleavage was used as an indicator of apoptosis. Western blot analysis of WHCO1 and WHCO6 oesophageal 
cancer cells treated with varying concentrations of DHA and EXP57EA for 24 h and 48 h. Cells treated with 5 
µM doxorubicin (DOX) for 24 h were included as a positive control for PARP cleavage. Beta-Tubulin was used 
as a loading control. To confirm PARP cleavage results, Caspase-3/7 activity was measured in WHCO1 (B) and 
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WHCO6 (C) cells treated with the specified concentrations of DHA and EXP57EA for 24 h. Caspase-Glo 
reagent was added, and the luminescence measured on a VeritasTM microplate Luminometer (Promega). Results 
are shown relative to Caspase-3/7 activity in control (vehicle-treated) cells, and are represented as the mean ±SD 
of experiments performed in triplicate and repeated at least two times. *p < 0.05 
 
As shown in Figure 3.3 (A), WHCO1 cells treated with 15 µM and 30 µM DHA for 6 hours 
displayed no significant increase in LDH activity compared to untreated cells. A similar 
result was obtained for EXP57EA-treated cells (Figure 3.3 B). Therefore, the results obtained 
thus far indicate that DHA caused apoptosis and not necrosis in oesophageal cancer cells, 
whereas EXP57EA caused neither under the described treatment conditions. To characterise 
the processes associated with the decreased cell number subsequent to EXP57EA treatment, 
we followed up on the numerous perinuclear vacuoles observed in EXP57EA-treated cells. 
Figure 3.3: Effect of DHA and EXP57EA on LDH release in WHCO1 cells. The ability of DHA (A) and 
EXP57EA (B) to induce necrosis was evaluated using LDH release as a marker of necrosis. Cells were treated 
with the indicated concentrations of DHA or EXP57EA in quadruplicate for 6 h after which CytotoxONE 
reagent was added. Fluorescence was measured using a fluorescence spectrophotometer. Results are expressed 
as a percentage of the fluorescent signal obtained for the positive control (lysis buffer) and are represented as the 
mean ±SD of experiments performed in quadruplicate and repeated at least two times.*p<0.05 
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As mentioned, treatment of WHCO1 cells with EXP57EA resulted in a substantial increase in 
perinuclear vacuoles when compared to untreated cells (Figures 3.1 E and 3.1 F) and this was 
not observed in cells treated with DHA (Figures 3.1 C and 3.1 D). The formation of vacuoles 
within cells after treatment with chemical compounds could suggest the activation of 
autophagy (Klionsky et al., 2009). Autophagy is an alternate pathway that could result in cell 
death (Galluzzi et al., 2012; Kroemer et al., 2009) and a number of markers are available to 
test for the activation of this pathway. Beclin 1 and Atg5 are essential proteins involved in the 
formation of the autophagosome (autophagic vacuoles), and LC3-II is another important 
marker of autophagy. The elongation of the autophagosome requires the conversion of LC3-I 
to LC3-II which is membrane bound and the only known autophagy protein found on the 
completed autophagosome. To investigate whether EXP57EA induced autophagy in 
oesophageal cancer cells, the mRNA levels of Beclin 1 and Atg5 were analysed using 
quantitative real time RT-PCR. Western blot analysis and immunofluorescence analysis were 
employed to examine the changes in LC3-II expression levels after treatment with EXP57EA. 
 
Figure 3.4 shows the expression levels of Beclin 1 (Figure 3.4 A) and Atg5 (Figure 3.4 B) 
corrected to the housekeeping gene GusB (β-glucoronidase) after WHCO1 cells were treated 
with 5 µM and 10 µM EXP57EA for 24 hours. Cells treated with the vehicle only (0 µM) 
served as the control, and all the values were expressed relative to the control value. A 
significant increase in Beclin 1 expression levels was observed in cells treated with both 5 
µM and 10 µM EXP57EA (Figure 3.4 A) compared to vehicle-treated cells. A 1.8-fold 
increase in Atg5 expression levels was observed in cells treated with 10 µM EXP57EA 
(Figure 3.4 B). These results suggested that EXP57EA played a role in the induction of 
autophagy in oesophageal cancer cells but to confirm this, the expression levels of LC3-II 
was also evaluated.  
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Figure 3.4: Evaluation of mRNA levels of Beclin 1 (A) and Atg5 (B) using quantitative real time RT-PCR. 
Messenger RNA from cells treated with specified concentrations of EXP57EA for 24 h was analysed by 
quantitative real-time RT-PCR for the genes encoding Beclin 1 (A) and Atg5 (B). Results (corrected to GusB) 
are shown relative to control (vehicle-treated) cells, and are represented as the mean ±SD of experiments 
performed in triplicate and repeated at least two times. *p < 0.05 
 
Western blot analysis was performed to determine whether LC3-II and Beclin 1 expression 
levels were increased after WHCO1 cells were treated with varying concentrations of 
EXP57EA (Figure 3.5). Figure 3.5 (A) and (B) shows a dose-dependent increase in LC3-II 
expression and Beclin 1 expression, respectively, in response to EXP57EA treatment. 
Considering that LC3-II is only found on autophagosomes which are formed during the 
process of autophagy, these results clearly indicate that EXP57EA induces autophagy in 
WHCO1 cells. Furthermore, immunofluorescence microscopy was also used to determine the 
expression level and localisation of LC3-II in cells treated with EXP57EA (Figure 3.6 and 
3.7). Figure 3.6 (A) shows representative confocal microscopy (Zeiss LSM 510 Meta) images 
of WHCO1 cells treated with 10 µM EXP57EA compared to vehicle-treated (0 µM) cells. 
Consistent with the western blot results, a clear increase in punctate staining of LC3-II is 
observed in cells treated with EXP57EA compared to vehicle-treated cells. LC3-II expression 
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was mainly perinuclear which was not clear in Figure 3.6 (A) as it represents the merged 
image planes of a series of images (z-stacked) from different focal planes covering the entire 
structure of the cells; Figure 3.6 (B) represents one of the image planes.  
Figure 3.5: LC3-II (A) and Beclin 1 (B) expression in WHCO1 cells after treatment with EXP57EA. 
WHCO1 cells (300 000) were plated in 60 mm dishes and treated with varying concentrations of EXP57EA for 
24 h. Protein was harvested and quantified so that 40 µg could be separated by SDS-PAGE and transferred on to 
a nitrocellulose membrane. The membrane was probed with antibodies recognising LC3-I and LC3-II (A) and 
Beclin 1 (B). Beta-tubulin was used as a loading control and this figure is representative of two experiments. 
 
The perinuclear localisation of LC3-II was more clearly observed in Figure 3.7, where 
WHCO6 cells in the presence (10 µM) and absence of EXP57EA (0 µM) were examined 
under high power magnification using an Axiovert 200M fluorescent microscope (Zeiss).  
 
Taken together, these results confirm that EXP57EA increased the expression levels of LC3-
II, an important autophagy regulator involved in formation of the autophagosomes. Another 
method that is often used to assess autophagy in mammalian cells is transmission electron 
microscopy (TEM). This method is useful in demonstrating the inclusion of cytoplasmic 




Figure 3.6: Immunofluorescent localisation of LC3-II in WHCO1 cells by confocal microscopy. A total of 
80 000 WHCO1 cells were seeded in 6-well plates and treated with 10 µM EXP57EA for 24 h. Vehicle-treated 
cells (0 µM) were included as a negative control. Following treatment for 24 h, cells were fixed and prepared for 
immunofluorescence microscopy to determine LC3-II localisation using an anti-LC3 antibody. Cells were 
viewed under 100x magnification on a Zeiss LSM 510 Meta confocal microscope and images were captured, 
(A) represents z-stacked images and (B) represents one of the respective image planes at each treatment point. 





Figure 3.7: Immunofluorescent localisation of LC3-II in WHCO6 cells. A total of 80 000 WHCO1 cells 
were seeded in 6-well plates and treated with 10 µM EXP57EA for 24 h. Vehicle-treated cells (0 µM) were 
included as a negative control. Following treatment for 24 h, cells were fixed and prepared for 
immunofluorescence microscopy to determine LC3-II localisation using an anti-LC3 antibody. Cells were 
viewed under 100x magnification using a Zeiss Axiovert 200M fluorescent microscope and images were 
captured. DAPI staining for nuclei is shown. 
 
TEM was performed using WHCO1 cells treated with 5 µM and 10 µM EXP57EA. Control 
(vehicle-treated) cells were included and the results (Figure 3.8 A) show that these cells 
contained very few vacuoles. In addition, normal mitochondria (black arrowheads) were 
observed. In contrast, cells treated with 5 µM EXP57EA demonstrated a high number of 
vacuoles (Figure 3.8 B) that appeared to increase with dose (Figure 3.8 C).  
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Figure 3.8: Transmission electron photomicrographs of WHCO1 cells treated with EXP57EA. WHCO1 
cells (1 x 106) were plated in 100 mm dishes and treated with 5 µM (B) and 10 µM (C) EXP57EA for 24 h. 
Untreated cells (0 µM) were included as a negative control (A). After treatment samples were fixed in 2.5% 
glutaraldehyde and prepared for TEM. Representative transmission electron photomicrographs of WHCO1 cells 
treated with vehicle (A) or EXP57EA (B,C) indicate autophagosomes containing cytoplasmic material (short 
arrows); long arrows indicate typical autolysosomes; black arrowheads indicate mitochondria; grey arrowheads 
indicate ER and white arrowheads indicate multilamellar structures. 
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Autophagosomes (short arrows) are double-membraned structures containing cytoplasmic 
material. They can vary in size and shape, and sometimes due to sample preparation it is 
difficult to see the double-membrane clearly. However, an important criterion for the 
identification of autophagosomes is that cytoplasmic material (electron dense) is enclosed. 
Figure 3.8 (B) and (C) clearly shows autophagosomes (short arrows) containing cytoplasmic 
constituents. 
Figure 3.9: Effect of autophagy inhibitor, 3-MA, on WHCO1 and WHCO6 cells treated with EXP57EA. 
(A) WHCO1 and (B) WHCO6 cells were seeded in 96-well plates at a density of 3000 cells per well. Cells were 
pretreated 5 mM 3-MA for 1 h before treatment with 5 µM and 10 µM EXP57EA for 24 h. Vehicle-treated cells 
(0 µM) were included as a control. The MTT assay was performed and absorbance read on a BioTek plate 
reader. Results are shown relative to control (vehicle-treated) cells and are represented as the mean ±SD of 
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experiments performed in triplicate and repeated at least two times. *p < 0.05, (C) WHCO1 and (D) WHCO6 
cells were treated with and without 3-MA, in the absence or presence of EXP57EA, for 24 h. Protein was 
extracted and processed so that 40 µg lysate could be separated by SDS-PAGE and transferred on to a 
nitrocellulose membrane before probing with an anti-LC3 antibody. Beta-tubulin was used as a loading control, 
and densitometry bar graphs (obtained using ImageJ software) shown in (E) and (F) show LC3-II relative to β-
tubulin in WHCO1 and WHCO6 cells, respectively. This result is representative of two independent 
experiments. 
 
Autolysosomes (autophagosomes fused with lysosomes) containing organelles at various 
stages of degradation are visible in EXP57EA-treated cells and are indicated by the long 
black arrows. Consistent with the immunofluorescence analysis results, the autophagic 
vacuoles displayed perinuclear localisation. Electron-lucent vacuoles and multilamellar 
structures (white arrowheads) were also visible but these do not represent autophagic 
vacuoles (Eskelinen, 2008; Ylä-Anttila et al., 2009). 
 
The results represented here provide a clear indication that EXP57EA induced autophagy in 
oesophageal cancer cells under the treatment conditions described. This compound displayed 
a cytotoxic effect yet biochemical assays assessing for the presence of apoptosis and necrosis 
were negative. Thus, these results point to autophagy as the pathway that leads to cell death 
in cells treated with EXP57EA in oesophageal cancer cells. In order to understand this 
process a bit better, the autophagy inhibitor, 3-methyladenine (3-MA) was used. Cells were 
treated with EXP57EA in the presence and absence of 3-MA for 24 hours and the number of 
live cells was measured using the MTT assay. Figure 3.9 (A) and (B) show a significant 
increase in WHCO1 and WHCO6 cell number, respectively, when treated with 5 µM and 10 
µM EXP57EA in the presence of 3-MA. These results suggested that preventing autophagy 
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in EXP57EA-treated cells significantly reduced the cell loss associated with EXP57EA 
treatment. The results in panel C, D, E and F provided evidence that treatment with 3-MA (5 
mM) reduced autophagy, based on the decreased levels of LC3-II expression observed in 
cells treated with EXP57EA in the presence of 3-MA (Figure 3.9). A decrease in LC3-II 
expression levels was observed in EXP57EA-treated cells in the presence of 3-MA 
(densitometry demonstrated by Figure 3.9 E and F). 
Figure 3.10: Monitoring autophagic flux using ammonium chloride in WHCO1 and WHCO6 cells treated 
with EXP57EA. (A) WHCO1 and (B) WHCO6 cells were seeded in 60 mm dishes at a density of 300 000 cells 
per dish. Cells were pretreated with 15 mM NH4Cl for 1 h followed by treatment with 10 µM EXP57EA for 24 
h. Protein was extracted, processed and loaded (40 µg) for separation via SDS-PAGE. The protein was 
transferred onto a nitrocellulose membrane which was probed with an antibody specific for LC3-I and LC3-II. 
Beta-tubulin was used as loading control. ImageJ software was used to determine LC3-II expression levels 
relative to β-tubulin expression levels for WHCO1 (C) and WHCO6 (D) cells treated with EXP57EA in the 
presence and absence of 15 mM NH4Cl. This result is representative of two independent experiments. 
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Autophagy is a complex mechanism that is reliant on a variety of proteins and processes to 
reach completion, which includes fusion of autophagosomes to lysosomes, forming 
autolysosomes. Autolysosomes containing cytoplasmic material and organelles result in the 
degradation of the contents via lysosomal hydrolases. Excessive autophagy can result in cell 
death by continuous degradation of vital organelles (Maiuri et al., 2007). In order to ascertain 
whether EXP57EA-treated cells were undergoing the complete autophagic process, it was 
important that we monitored autophagy flux. An increase in LC3-II expression was 
insufficient to show that the complete process of autophagy, including formation of the 
autolysosome, was taking place. If the fusion of the autophagosome to the lysosome was 
inhibited or acidification of the lysosome is prevented there should be an accumulation of 
autophagosomes as they are degraded in the autolysosomes. Ammonium chloride (NH4Cl), a 
lysosomotropic agent, was used to monitor autophagy flux in this way. Cells were pretreated 
with 15 mM NH4Cl for 1 hour before treatment with EXP57EA for 24 hours. Figure 3.10 
shows that WHCO1 cells (Figures 3.10 A and C) and WHCO6 cells (Figures 3.10 B and D) 
treated with 10 µM EXP57EA in the presence of NH4Cl have increased levels of LC3-II 
compared to cells without NH4Cl, indicating that EXP57EA induces the complete autophagic 














DHA, the in vivo metabolite of some artemisinin derivatives, was investigated together with 
a novel artemisinin-isatin derivative, EXP57EA, to understand how these compounds exerted 
their anticancer activity against oesophageal cancer cells. Previous studies in the literature 
have shown that DHA induces apoptosis in a wide variety of cancer cell lines but since the 
hybrid compound, EXP57EA, is a novel compound, it is not known whether this compound 
induces apoptosis or not. The aim of this study was to investigate the cytotoxic effects of 
DHA and EXP57EA in the oesophageal cell culture model system used here.  
 
The initial part of this study involved the selection of treatment conditions for the WHCO1 
cell line (Chapter 2). In order to determine these, time- and dose-dependent experiments were 
performed. Having established the treatment conditions, the effects of these compounds on 
the morphology of WHCO1 cells were examined. The results showed that the morphology of 
DHA-treated cells was distinctly different from that of untreated cells (Figure 3.1). The 
morphological features observed such as cell shrinkage, nuclear condensation and plasma 
membrane blebbing are consistent with apoptosis (Lockshin and Zakeri, 2004). Based on the 
evidence generated in this study, particularly PARP cleavage and caspase-3/7 activation, it 
can be concluded that DHA induces apoptosis in OC cells. This is similar to reports by other 
authors, for example Hou et al. found that DHA and ART induced apoptosis in HepG2 liver 
cancer cell as measured by increased caspase 3 activity and cleaved PARP expression (Hou et 
al., 2008). In addition, they reported an increased Bax/Bcl-2 ratio in treated cells compared to 
untreated cells, however DHA and ART arrested HepG2 cells in the G0/G1 phase of the cell 
cycle (Hou et al., 2008), whereas we reported a G2/M block of the cell cycle induced by 
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DHA and ART in OC cells (Chapter 2). A similar result was obtained by Ji and colleagues, 
who demonstrated the ability of DHA to induce apoptosis (detected by flow cytometry using 
Annexin V-FITC and PI staining, increased Bax/Bcl-2 ratio as well as increased caspase-3 
activity) in osteosarcoma cells, which were arrested in the G2/M phase of the cell cycle after 
DHA treatment for 48 hours (Ji et al., 2011).  
 
Unlike DHA, EXP57EA did not induce apoptosis in WHCO1 and WHCO6 OC cells based 
on PARP cleavage and caspase-3/7 activation. Furthermore, EXP57EA also did not induce 
necrosis (Figure 3.3). However, using a wide variety of experimental approaches, we have 
shown that EXP57EA instead induced autophagy in OC cells. This includes Beclin 1, LC3-II 
and Atg5 induction in response to EXP57EA treatment, as well as the appearance of double 
membraned vesicles as visualised by TEM. A significant increase in the expression of critical 
proteins involved in the formation of the autophagosome, Beclin 1 and Atg5, was observed 
by quantitative real time RT-PCR. In addition, an increase in Beclin 1 expression after 
treatment with EXP57EA was shown by western blot analysis. A widely used method to 
show induction of autophagy is the expression of LC3-II by western blot analysis. When 
autophagy occurs, LC3 (or Atg8) is conjugated to PE, thus allowing LC3 to recruit the lipid 
molecules to lengthen the autophagosomal membranes during autophagosome formation. 
Lipid conjugation is achieved via an amide bond to a glycine residue, exposed by cleavage of 
LC3 by Atg4. During this process, the 18 kDa LC3-I is converted to 16 kDa LC3-II, which is 
directly associated with the autophagosomes (Kabeya et al., 2004). Thus, LC3-II expression 




In this study we showed, using two different experimental approaches, that treatment with 
EXP57EA increases the expression of LC3-II. Firstly the ability of EXP57EA to dose-
dependently increase LC3-II expression in oesophageal cancer cells was demonstrated by 
western blot analysis. This was followed by immunofluorescence microscopy illustrating an 
increase in punctate staining of LC3-II in cells treated with EXP57EA compared to vehicle-
only treated cells, confirming increased expression of LC3-II by EXP57EA. These 
experiments provided clear evidence that EXP57EA increased autophagy in oesophageal 
cancer cells; however according to guidelines published by Klionsky and colleagues 
(Klionsky et al., 2009), it is insufficient to demonstrate an increase in LC3-II (or 
autophagosome formation) when implicating the process of autophagy in cell death. The 
complete process of autophagy includes fusion of the autophagosome to the lysosome, 
forming the autolysosomes, resulting in degradation of its contents. Thus, in order to report 
that EXP57EA induces the complete autophagic process and not only an increase in 
autophagosome formation, an autophagic flux experiment was performed.  
 
When WHCO1 and WHCO6 cells were treated with EXP57EA in the presence of the 
lysosomotropic agent, ammonium chloride (NH4Cl), an increase LC3-II expression was 
observed when compared to cells treated with EXP57EA in the absence of NH4Cl. NH4Cl 
inhibits acidification within the autolysosome preventing degradation of its contents, 
including LC3-II, and can be used to measure autophagic flux (Mizushima et al., 2010). 
Other experimental approaches to show autophagic flux include pretreatment with the 
lysosomotropic agent bafilomycin A or lysosomal proteases such as E64d and leupeptin 
(Mizushima et al., 2010). The use of NH4Cl to inhibit the complete autophagic process has 
been demonstrated by other authors studying autophagy (Boland et al., 2008; Kaushik et al., 
2008; Singh et al., 2009), and the data obtained in this study showed an increase in LC3-II 
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expression in cells treated with EXP57EA in the presence of NH4Cl, compared to EXP57EA-
treated cells in the absence of NH4Cl, suggesting that the complete process of autophagy was 
induced by EXP57EA, and not merely an increase in autophagosome formation. Furthermore, 
the micrographs obtained following TEM correlated with these results as an increase in 
autolysosomes was seen in cells treated with EXP57EA compared to vehicle-only treated 
cells.  
 
In order to connect autophagy induced by EXP57EA with cell death, 3-methyladenine (3-
MA) was employed. The nucleotide derivative inhibits class III PI3K activity which is 
important for autophagy to take place (Wu et al., 2010). Essential class III PI3K complexes 
that include Beclin 1 are involved in the formation of the autophagosome (Chen and 
Klionsky, 2011). When PI3K activity is blocked using 3-MA, autophagy is inhibited and this 
has been demonstrated by a number of studies (Aoki et al., 2007; Bursch et al., 1996; Chen et 
al., 2010b, 2008; Cui et al., 2007; Donadelli et al., 2011; Eom et al., 2010; Kanzawa et al., 
2004; Li et al., 2009b, 2013; Ling et al., 2011; Seglen and Gordon, 1982; Shimizu et al., 
2010; Son et al., 2011). WHCO1 and WHCO6 cells treated with EXP57EA in the presence of 
3-MA displayed a significant increase in cell viability at both treatment concentrations tested, 
compared to EXP57EA-treated cells in the absence of 3-MA. Western blot analysis 
demonstrated a decrease in LC3-II expression when WHCO1 and WHCO6 cells were treated 
with EXP57EA in the presence of 3-MA compared to cells treated in the absence of 3-MA. 
Taken together, these results suggest that autophagy could be the cell death pathway 




Similarly, curcumin, a natural compound, was shown to be effective against U87-MG and 
U373-MG glioma cells with very little toxicity against normal cells (Aoki et al., 2007). 
Further investigation demonstrated that 3-MA inhibited autophagy and reversed the decrease 
in cell number induced by curcumin treatment, leading the authors to suggest that the natural 
compound induced autophagic cell death in glioma cells (Aoki et al., 2007). However, Levine 
and colleagues (Kroemer and Levine, 2008; Levine and Yuan, 2005) proposed that using 3-
MA alone to implicate autophagy as a cause of cell death may not be sufficient as 3-MA may 
have off-target effects, and suggested that using genetic means to inhibit autophagy, such as 
siRNA technology, should be employed. This was demonstrated by Puissant and colleagues, 
who suggested that the promising anticancer agent from natural sources, resveratrol, induced 
autophagic cell death in chronic myelogenous leukaemia cells (Puissant et al., 2010). 
Elaborate investigations using siRNA directed at Atg5, LC3 and p62 blocked autophagy and 
cell death, implicating autophagy as the death pathway induced by resveratrol (Puissant et al., 
2010). Due to time and budget constraints experienced during this project, experiments that 
involved silencing of essential autophagy genes in cells treated with EXP57EA could not be 
performed; though they would be included in future work.  
 
The role of autophagy in cell death is disputed, where some authors have suggested that 
autophagic cell death is mainly activated in cells where the apoptotic pathway is comprised 
(Gozuacik and Kimchi, 2004, 2007; Kroemer and Levine, 2008; Levine and Yuan, 2005; 
Lockshin and Zakeri, 2004). However, in this study we have clearly shown that DHA 
induced apoptosis in WHCO1 and WHCO6 oesophageal cancer cells lines, and that 
EXP57EA induced autophagy in the same cell lines. In addition, there was no increase in 
expression of apoptotic markers after EXP57EA treatment which correlated with 
morphological studies where no morphological features of apoptosis were observed in cells 
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treated with EXP57EA. Furthermore, cell number increased when cells were simultaneously 
treated with EXP57EA and 3-MA suggesting involvement of only autophagy and not 
apoptosis in cell death. Moreover, experiments conducted with DHA in the same cell lines as 
EXP57EA provided clear evidence that the apoptotic machinery in these cell lines were 
intact. 
 
The results presented here reinforces earlier evidence that DHA and EXP57EA exerts their 
cytotoxic activity against oesophageal cancer cells via different molecular mechanisms. The 
novel artemisinin-isatin hybrid was shown to kill cells at a lower concentration than DHA 
and to activate autophagy and not apoptosis. In contrast, cells treated with DHA displayed 
classical morphological features of apoptosis and strongly increased the expression of 
apoptotic markers used in this study. Considering that apoptosis is believed to be the 
preferred cell death pathway employed by cells, it is interesting that EXP57EA induced an 
alternative pathway in oesophageal cancer that resulted in more effective (lower IC50 value) 
cell death than the parental compound, DHA. Bearing this in mind, another study was 














THE SIGNALLING PATHWAYS ACTIVATED BY DHA AND EXP57EA IN 
OESOPHAGEAL CANCER CELLS 
 
4.1 Introduction 
In the previous two chapters we showed that DHA and the novel artemisinin-isatin hybrid, 
EXP57EA, induced cytotoxicity in oesophageal cancer cells, and that EXP57EA was more 
active than DHA in several cancer cell lines tested. Further investigations demonstrated that 
DHA strongly induced apoptosis in oesophageal cancer cell lines whereas EXP57EA induced 
autophagy, and not apoptosis. A number of studies have been performed to investigate the 
anticancer effects of artemisinin derivatives in a variety of cancer cell lines, however very 
little information is available regarding their effects in oesophageal cancer. In this chapter, 
we sought to elucidate the cellular processes activated by DHA and EXP57EA that 
contributed to their mechanism of action in oesophageal cancer cells. 
 
Artemisinin derivatives have been shown to exert their cytotoxic effects in several cancer cell 
lines via reactive oxygen species (ROS)-dependent pathways (Aghaei and Ashtiani, 2012; 
Berdelle et al., 2011; Du et al., 2010; Efferth et al., 2007; Handrick et al., 2010; Lu et al., 
2010; Michaelis et al., 2010; Zhang et al., 2010). Efferth and colleagues found that ART 
induced ROS-dependent apoptosis via the intrinsic pathway in four different leukaemic T cell 
lines, including one that was doxorubicin resistant (Efferth et al., 2007). DHA was shown to 
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induce ROS-dependent apoptosis in the A-431 skin cancer cell line (Aghaei and Ashtiani, 
2012) as well as in ASTC-a-1 lung cancer cells (Lu et al., 2010). These studies also showed 
that ROS played a causal role in the induction of apoptosis since treatment with ROS 
scavengers inhibited apoptosis. Furthermore, the generation of ROS is associated with DNA 
damage (Circu and Aw, 2010). In this study, we explored the generation of ROS in cells 
treated with DHA and the requirement of ROS to induce apoptosis.  
 
The evidence generated in Chapter 3 clearly showed that EXP57EA acts very differently 
from DHA, where EXP57EA induced autophagy. Considering that EXP57EA is an 
artemisinin hybrid compound, we wanted to determine the effects of EXP57EA on ROS 
production. Numerous studies have reported that increased ROS production can lead to the 
induction of autophagy (Chen et al., 2008; Donadelli et al., 2011; Khan et al., 2012; Ling et 
al., 2011; Son et al., 2011; Xie et al., 2011), providing a context for investigating ROS 
production in cells treated with EXP57EA and determining the effects thereof on autophagy. 
Furthermore, increased ROS production was shown to activate signalling pathways that led to 
the induction autophagy such as the JNK and ERK signalling pathway as well as the ER 
stress pathway (Wong et al., 2010; Xavier et al., 2013; Xie et al., 2011). This prompted an 
investigation of the effects of EXP57EA on ROS-induced pathways that led to the induction 
of autophagy using western blot analysis to measure protein expression in the presence and 
absence of EXP57EA. 
 
The results presented in this chapter attempted to characterise the signalling pathways 
involved in DHA- and EXP57EA-induced cytotoxicity in oesophageal cancer cells, and 
implicated ROS in the signalling pathways investigated. We have previously shown that 
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DHA and EXP57EA displayed different mechanisms of action in oesophageal cancer cells, 
and the results discussed below suggested that the compounds may activate different 





















4.2.1 Investigating the cellular processes activated by DHA in oesophageal squamous 
carcinoma cells 
4.2.1.1 The effect of DHA on ROS production 
To the best of our knowledge, the effect of DHA on ROS production in oesophageal cancer 
has not been investigated. Therefore we sought to determine the effect of DHA on ROS 
production in oesophageal cancer cells. The ROS sensitive probe, DCFDA, was used to 
measure ROS production in cells treated with DHA. DCFDA is a nonfluorescent cell 
permeable molecule. However, intracellular esterases cleave DCFDA into 2’-
7’dichlorodihydrofluorescein (DCFH2) which remains trapped within the cell and which can 
be oxidised to the fluorescent 2’-7’-dichlorofluorescein (DCF) in the presence of hydrogen 
peroxide. Although this method is widely used to measure hydrogen peroxide concentration 
in cells, other types of ROS can also be detected (Curtin et al., 2002). 
 
A number of protocols to measure ROS production using DCFDA were investigated, and 
after extensive optimisation a 96-well format assay was found to be optimal. A time course 
was initially performed to determine the optimal time point to measure ROS production in 
response to DHA treatment (Figure 4.1 A). Cells were seeded in opaque white 96-well plates 
and pretreated with DCFDA in Krebs-Ringer (KR) buffer for 15 minutes followed by 
treatment with DHA. Immediately after the treatment times, the fluorescence was measured 
using a Cary Eclipse fluorescence spectrophotometer (Varian, Inc.). As shown in Figure 4.1 
(A), the time course of ROS production in WHCO1 cells treated with DHA showed an 
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increase up to the 24 hour time point measured. Therefore, the 24 hour DHA treatment time 
was used for further experiments. Next, cells were treated with different concentrations of 
DHA for 24 hours (Figure 4.1 B), and a dose-dependent increase in ROS production was 
observed. 
Figure 4.1: ROS production in WHCO1 cells after treatment with DHA. (A.), To determine if WHCO1 
cells treated with DHA increased ROS production, a time course experiment was performed. Cells (1x104) were 
plated in 96-well white plates and pretreated with 50 µM DCFDA for 15 min followed by the addition of 60 µM 
DHA. Following the indicated treatment points, fluorescence was measured using a Cary Eclipse fluorescence 
spectrophotometer (484 nm excitation; 530 nm emission). (B.), A concentration course experiment was 
performed at 24 h. Cells (1x104) were plated in 96-well white plates and pretreated with 50 µM DCFDA for 15 
min followed by the addition of the indicated concentrations of DHA. After 24 h, fluorescence was measured 
using a Cary Eclipse fluorescence spectrophotometer (484 nm excitation; 530 nm emission). Results are shown 
relative to fluorescence readings in control (vehicle-treated) cells, and are represented as the mean ±SD of two 
experiments performed in triplicate. *p < 0.05 
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Previous studies performed to characterise artemisinin derivatives as anticancer agents have 
linked the increased ROS production observed after treatment with these compounds with 
DNA damage (Li et al., 2008). H2AX is a member of the histone family of proteins that 
functions in organising DNA in nucleosomes, the basic unit of chromatin, and is rapidly 
phosphorylated when DNA double-strand breaks occur (Fernandez-Capetillo et al., 2004). 
Phosphorylated H2AX (represented as γ-H2AX) is widely used as a sensitive marker of DNA 
damage, specifically double-strand breaks (Fernandez-Capetillo et al., 2004). Many 
endogenous and exogenous factors are known to cause double-strand breaks, including ROS 
which can be produced by intracellular processes such as the electron transport chain and by 
external causes such as exposure to ionizing radiation and chemical compounds (Podhorecka 
et al., 2010). We sought to determine the effect of DHA on the expression levels of γ-H2AX 
by western blot analysis (Figure 4.2). WHCO1 cells treated with DHA displayed a dose-
dependent increase in γ-H2AX levels after 24 hours and 48 hours (Figure 4.2), which 
correlated with the increase in ROS production observed previously (Figure 4.1). The results 
in Figure 4.2 also suggested that most of the H2AX phosphorylation had taken place after 24 
hours of treatment with DHA at 30 µM and 60 µM. However, there was still an increase in 
H2AX phosphorylation at the 48 hour time point compared to the 24 hour time point for cells 
treated with 15 µM DHA. 
 
Double-strand breaks resulting in phosphorylation of H2AX leads to the recruitment of 
important proteins involved in the DNA damage response (Barzilai and Yamamoto, 2004). 
Should efforts to repair the damaged DNA fail, cell cycle arrest and cell death may follow 
(Fragkos et al., 2009; Hartwell and Kastan, 1994). Figure 2.6 (Chapter 2) showed the ability 
of DHA to arrest cells in the G2/M phase of the cell cycle. Figure 4.3 confirmed these results, 
and included an analysis of the sub-G1 phase of the cell cycle. A dose-dependent increase of 
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cells arrested at the G2/M phase of the cell cycle was observed, illustrated by the dark grey 
bars in Figure 4.3. This experiment included the analysis of the sub-G1 population, shown by 
the black bars in Figure 4.3. A significant increase in the sub-G1 population was revealed 
indicating an increase in death in cells treated with increasing DHA concentrations. This 
correlated with the increase in the expression of cleaved PARP, a marker of apoptosis, in 
oesophageal cancer cells treated with DHA after 24 hours and 48 hours, shown in Figure 3.2 
(A) (Chapter 3). 
 
Figure 4.2: Effects of DHA on the expression levels of the DNA damage marker, γ-H2AX, in WHCO1 
cells after treatment for 24 h and 48 h. WHCO1 cells were seeded in 60 mm dishes (3 x 105 cells per dish) 
and treated with varying concentrations of DHA for 24 h and 48 h. Protein was extracted and quantified 
allowing 20 µg to be separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane 
was probed with antibodies against γ-H2AX and β-Tubulin, which was used as a loading control. This figure is 




Figure 4.3: Cell cycle profile, including sub-G1 analysis of WHCO1 oesophageal cancer cells treated with 
DHA for 24 h and 48 h. WHCO1 cells (5 x 105) were plated in 100 mm dishes and allowed to settle overnight. 
The next day cells were treated with the indicated concentrations of DHA (in triplicate) for 24 h (A) and 48 h 
(B). Cells were processed for flow cytometry, stained with propidium iodide and analysed on a FACSCalibur 
machine using CELLQuest Pro Software and Modfit LT version 3.2 for data analysis. The results are expressed 
as a mean of triplicates with ±SD indicated by the error bars, and experiments were repeated at least two times. 





4.2.1.2 The effects of the ROS scavenger, N-acetyl -L-cysteine (NAC), on ROS production 
and cytotoxicity caused by DHA 
To examine the role of ROS production in DHA-induced cytotoxicity in oesophageal cancer 
cells, we evaluated the effects of the antioxidant, N-acetyl-L-cysteine (NAC) on DHA 
treatment. NAC is an acetylated derivative of the amino acid L-cysteine that is a precursor of 
reduced glutathione, a tripeptide that protects cells from oxidative stress. NAC functions by 
supplying important precursors for the synthesis of glutathione, such as sulfhydryl groups, 
and is also able to scavenge ROS directly (Zhang et al., 2011). In order to investigate whether 
NAC had the ability to reduce DHA-induced cytotoxicity by decreasing induced-ROS levels, 
oesophageal cancer cells were treated with DHA in the presence and absence of NAC.  
 
WHCO1 cells treated with 15 µM, 30 µM and 60 µM DHA showed a significant increase in 
ROS production, as observed previously, however in the presence of NAC the levels of ROS 
generated in DHA-treated cells remained close to that of the vehicle-only treated cells (Figure 
4.4 A). A similar result was obtained with WHCO6 cells treated with 30 µM DHA (Figure 
4.4 B). A greater fold increase in ROS production was observed in WHCO6 cells treated with 
30 µM DHA (3-fold) than WHCO1 cells treated with the same concentration (1.2-fold), 
however when co-treated with NAC the ROS levels were reduced to that of vehicle-only 
treated cells. These results indicate that 10 mM NAC, a concentration widely used in the 
literature, successfully scavenged the ROS induced by treatment of oesophageal cancer cells 
with DHA. Therefore, we proceeded to investigate whether NAC was able to rescue cells 




Figure 4.4: Inhibition of DHA-induced ROS by a ROS scavenger, NAC, after 24 h in WHCO1 (A) and 
WHCO6 (B) cells. Cells (1x104) were plated in 96-well white plates and allowed to settle overnight. The next 
day cells were pretreated with 10 mM NAC (+NAC) or KR buffer only for 1 h, followed by pretreatment with 
50 µM DCFDA for 15 min. The indicated concentrations of DHA was added and incubated for 24 h. 
Fluorescence was measured using a Cary Eclipse fluorescence spectrophotometer (484 nm excitation; 530 nm 
emission). Results are shown relative to fluorescence readings in control (vehicle-treated) cells, and are 





Figure 4.5: Effect of NAC on WHCO1 (A and B) and WHCO6 (C and D) cell number (OD595nm) after 
treatment with DHA for 24 h (A and C) and 48 h (B and D). Cells were plated in 96-well plates at a density 
of 3000 cells per well and allowed to settle overnight. Cells were either pretreated with 10 mM NAC (+NAC) or 
media only for 1 h, followed by treatment with 30 µM DHA for 24 and 48 h. The media was removed and MTT 
reagent was added to fresh media and incubated for 4 h followed by the addition of solubilisation solution. The 
next day the absorbance was measured at 595 nm using a BioTek plate reader. Results are shown relative to 
absorbance readings in vehicle-only treated cells (0 µM) and are represented as the mean ±SD of experiments 
performed in triplicate and repeated at least two times. *p < 0.05, **p < 0.001 
 
Using the MTT assay the effect of NAC on WHCO1 and WHCO6 cell number after 
treatment with 30 µM DHA for 24 hours and 48 hours was evaluated (Figure 4.5). Cell 
number of both cell lines were significantly reduced after DHA treatment (white bars, Figure 
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4.5 A-D), but co-treatment with NAC resulted in an attenuation of the effect of DHA on cell 
number, as measured by absorbance readings at 595 nm. However, NAC did not completely 
block the effects of DHA since there was still a 20 - 30% reduction in cell number in DHA-
treated cells in the presence of NAC compared to untreated cells after 24 hours (Figure 4.5 A 
and C), and ~55% reduction in cell number after 48 hours (Figure 4.5 B and D). Considering 
that NAC interacted with the MTT reagent by increasing the absorbance readings on its own 
(data not shown), the protocol was adjusted to remove the media containing NAC and replace 
with fresh media containing the MTT reagent. The experiment shown in Figure 4.5 was 
carried out using the modified protocol. These results were confirmed using a different assay 
to measure the effects on cell number, the Neutral red uptake (NRU) assay, where similar 
results were obtained (data not shown). Visual inspection of the cells treated with DHA in the 
presence of NAC, using a phase-contrast microscope, further confirmed the ability of NAC to 
rescue DHA-treated cells from cell death as illustrated by Figure 4.6. Cells treated with DHA 
alone displayed a dose-dependent decrease in cell number and this effect was inhibited in the 
presence of NAC, where the number of cells in the DHA-treated samples resembled the 
vehicle-only treated sample.  
 
Having previously shown that DHA treatment increased the expression of the DNA damage 
marker, γ-H2AX, in oesophageal cancer cells (Figure 4.2), we next investigated the effects of 
NAC on the expression level of γ-H2AX when WHCO1 and WHCO6 cells were treated with 
DHA (Figure 4.7). A dose-dependent increase in γ-H2AX expression levels was observed in 
both WHCO1 and WHCO6 cells treated with DHA for 24 hours, and this was effectively 
attenuated in the presence of 10 mM NAC. A large decrease in γ-H2AX expression at the 30 
µM treatment point correlated with the increase in cell number observed in Figure 4.5, when 
WHCO1 and WHCO6 cells were co-treated with DHA and NAC. In addition, NAC caused a 
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minimal increase in γ-H2AX expression in the absence of DHA. However, in the presence of  
NAC and DHA the levels of γ-H2AX were lower than that of γ-H2AX levels in the presence 
of DHA alone. This data suggested that DHA-induced ROS was responsible for the DNA 
damage and cytotoxicity observed in WHCO1 and WHCO6 cells treated with DHA.  
Figure 4.6: Morphology of WHCO1 cells treated with DHA in the presence and absence of NAC for 48 h. 
Cells were plated in 60 mm dishes at a density of 3 x 105 cells per dish and allowed to settle overnight. Cells 
were either pretreated with 10 mM NAC (+NAC) or media only for 1 h, followed by treatment with the 
indicated concentrations of DHA for 48 h. Images of the cells were captured using a Olympus CKX42 phase 




Figure 4.7: Western blot analysis demonstrating the effects of NAC on γ-H2AX expression in WHCO1 
and WHCO6 cells treated with DHA. WHCO1 and WHCO6 cells (3 x 105) were plated in 60 mm dishes and 
incubated overnight. Cells were pretreated with 10 mM NAC (+) or media only (-) for 1 h followed by treatment 
with the indicated concentrations of DHA for 24 h. Protein was harvested and quantified so that 20 µg could be 
separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with 
antibodies recognising γ-H2AX. Beta-Tubulin and p38 were used as loading controls. This figure is 
representative of at least two experiments. 
 
In order to determine whether the ROS production and DNA damage induced by DHA had 
an effect on the cell cycle profile, cell cycle analysis was performed after WHCO1 and 
WHCO6 cells were treated with DHA in the presence and absence of NAC for 24 hours 
(Figure 4.8). As shown by the black bars, there was a significant decrease in the sub-G1 
population when cells were treated with 30 µM (~ 60%) and 60 µM (~30%) DHA in the 
presence of NAC concomitant with a significant decrease in the G2/M population (~55%), 
represented by the dark grey bars (Figure 4.8 A and B). In accordance with this data, it is 
evident that DHA-induced ROS played an important role in the G2/M cell cycle arrest 
observed in oesophageal cancer cells. Cell cycle arrest at the G2/M phase of the cell cycle 
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may be attributed to DNA damage, which if not repaired can lead to cell death (Hartwell and 
Kastan, 1994; Kastan et al., 1991; Taylor and Stark, 2001).  
 
We have demonstrated earlier that DHA induced apoptosis in oesophageal cancer cells, and 
in order to understand the role of DHA-induced ROS production in the activation of the 
apoptotic pathway we investigated the effect of DHA and NAC co-treatment on the 
expression of cleaved PARP (Figure 4.9). As seen previously, a clear increase in the 
expression of cleaved PARP was observed in WHCO1 and WHCO6 cells treated with DHA 
only, however this effect was abrogated in the presence of NAC at both 30 µM DHA (~ 80% 
in WHCO1 cells and ~95% in WHCO6 cells) and reduced at 60 µM DHA (~60% in WHCO1 
cells and ~30% in WHCO6 cells). These results correlated with the data shown above, and 
strongly suggested that the generation of ROS by DHA was responsible for the induction of 
apoptosis in WHCO1 and WHCO6 oesophageal cancer cells.  
 
Taken together, the results presented here provide strong evidence that DHA exerted its 
cytotoxic effects on oesophageal cancer cells via a ROS-dependent mechanism. The ROS 
scavenger, NAC, efficiently attenuated the effects of DHA in both WHCO1 and WHCO6 
cells and rescued cells from DHA-induced cytotoxicity. Having elucidated the mechanistic 
effects of DHA in our oesophageal cancer cell culture system, we next sought to explore the 
effects of the novel artemisinin-hybrid compound, EXP57EA, in the same system. 
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Figure 4.8: Cell cycle profile of WHCO1 (A) and WHCO6 (B) cells treated with DHA in the presence and 
absence of NAC. Cells were plated at a density of 5 x 105 cells per dish in 100 mm dish and incubated 
overnight. Cells were pretreated with 10 mM NAC (+NAC) or media only for 1 h followed by treatment with 
the indicated concentrations of DHA for 24 h. Cells were processed for flow cytometry, stained with propidium 
iodide and analysed on a FACSCalibur machine using CELLQuest Pro software and Modfit LT version 3.2 for 
data analysis. Results are represented as the mean ±SD of experiments performed in triplicate and repeated at 
least two times. *p < 0.05, **p < 0.001 
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Figure 4.9: The effect of NAC on DHA-induced PARP cleavage. WHCO1 and WHCO6 cells (3 x 105) were 
plated in 60 mm dishes and incubated overnight. Cells were pretreated with 10 mM NAC (+) or media only (-) 
for 1 h followed by treatment with the indicated concentrations of DHA for 24 h. Protein was harvested and 
quantified so that 20 µg could be separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The 
membrane was probed with antibodies recognising PARP and cleaved PARP. Beta-Tubulin was used as a 
loading control and this figure is representative of at least two experiments. 
 
4.2.2 The molecular mechanisms engaged by EXP57EA in oesophageal squamous 
carcinoma cells 
4.2.2.1 The effect of EXP57EA on ROS production 
WHCO1 cells were plated in 96-well white plates, pretreated with DCFDA and treated with 
EXP57EA for the indicated times. ROS was measured, as done previously, at 530 nm 
emission when the samples were excited at 484 nm using the Cary Eclipse fluorescence 
spectrophotometer (Varian, Inc.). A time course experiment measuring ROS production after 
treatment with EXP57EA up to 18 hours (data not shown) revealed that the optimal time to 
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measure ROS production was 5 hours therefore all subsequent ROS assays were performed 
after 5 hours treatment with EXP57EA (Figure 4.10). 
Figure 4.10: ROS production in WHCO1 cells after treatment with EXP57EA. WHCO1 cells (1x104) were 
pretreated with 50 µM DCFDA for 15 min followed by the addition of the indicated concentrations of 
EXP57EA in 96-well white plates for 5 h. Fluorescence was measured using a Cary Eclipse fluorescence 
spectrophotometer (484 nm excitation; 530 nm emission). Results are shown relative to fluorescence readings in 
control (vehicle-treated) cells, and are represented as the mean ±SD of experiments performed in triplicate, and 
repeated at least two times. **p < 0.001 
 
The effect of NAC on ROS generation after treatment with EXP57EA was examined, and 
WHCO1 (Figure 4.11 A) and WHCO6 cells (Figure 4.11 B) cells displayed a significant 
decrease in ROS generation after treatment with EXP57EA in the presence of 10 mM NAC. 
However, when the effect on cell number after co-treatment with EXP57EA and NAC was 
investigated, the results indicated that NAC did not rescue cells from EXP57EA-induced 
cytotoxicity (Figure 4.12), unlike the results observed in DHA-treated cells (Figure 4.5). 
Moreover, 5 µM EXP57EA in the presence of NAC appeared more cytotoxic than EXP57EA 




Figure 4.11: ROS production in WHCO1 (A) and WHCO6 (B) cells after treatment with EXP57EA in the 
presence and absence of NAC for 5 h. Cells (1x104) were plated in 96-well white plates and pretreated with 10 
mM NAC (+NAC) or KR buffer only for 1 h, followed by pretreatment with 50 µM DCFDA for 15 min. 
EXP57EA was added and incubated for 5 h. Fluorescence was measured using a Cary Eclipse fluorescence 
spectrophotometer (484 nm excitation; 530 nm emission). Results are shown relative to fluorescence readings in 
control (vehicle-treated) cells, and are represented as the mean ±SD of experiments performed in triplicate and 




Figure 4.12: Effect of NAC on WHCO1 (A and B) and WHCO6 (C and D) cell number (OD595nm) after 
treatment with EXP57EA for 24 h (A and C) and 48 h (B and D). Cells were plated in 96-well plates at a 
density of 3000 cells per well and allowed to settle overnight. Cells were either pretreated with 10 mM NAC 
(+NAC) or media only for 1 h, followed by treatment with 5 µM EXP57EA for 24 and 48 h. MTT reagent was 
added to fresh media and incubated for 4 h followed by the addition of solubilisation solution. The next day the 
absorbance was measured at 595 nm using a BioTek plate reader. Results are shown relative to absorbance 
readings in vehicle-only treated cells (0 µM) and are represented as the mean ±SD of experiments performed in 
triplicate and repeated at least two times. *p < 0.05 
 
The concentration of NAC used in the literature varies, and studies have used concentrations 
ranging from 1 mM to 20 mM NAC to inhibit ROS production (Alexandre et al., 2006; 
Donadelli et al., 2011; Park et al., 2011; Spagnuolo et al., 2006). We wanted to investigate 
whether lowering the NAC concentration may have an effect on rescuing oesophageal cancer 
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cells from EXP57EA-induced cytotoxicity (considering the apparent increase in toxicity 
observed in the presence of EXP57EA and NAC (Figure 4.12). Figure 4.13 (A) demonstrated 
that in addition to 10 mM NAC, 2.5 mM and 5 mM NAC were also effective in scavenging 
ROS generated in WHCO1 cells treated with EXP57EA for 5 hours. However, 10 mM NAC 
was the most effective, maintaining ROS levels close to the baseline levels or that of the 
vehicle-only treated cells. Cells treated with 5 µM EXP57EA for 24 hours in the absence of 
NAC caused a small but significant reduction in cell number (Figure 4.13 B). 
Figure 4.13: Effect of varying concentrations of NAC on ROS production (A) and cell number (OD595nm) 
(B) in WHCO1 cells were treated with EXP57EA. (A), Cells (1x104) were seeded in 96-well white plates and 
pretreated with 2.5 mM, 5mM and 10 mM NAC or KR buffer only for 1 h, followed by treatment with 50 µM 
DCFDA for 15 min. The indicated concentrations of EXP57EA was added and incubated for 5 h. Fluorescence 
was measured using a Cary Eclipse fluorescence spectrophotometer (484 nm excitation; 530 nm emission). 
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Results are shown relative to fluorescence readings in control (vehicle-treated) cells. (B), Cells (3000 per well) 
seeded in 96-well plates and were pretreated with 2.5 mM, 5mM and 10 mM NAC or media only for 1 h, 
followed by treatment with 5 µM EXP57EA for 24 h. MTT reagent was added to fresh media and incubated for 
4 h followed by the addition of solubilisation solution. The next day the absorbance was measured at 595 nm 
using a BioTek plate reader. Results are shown relative to absorbance readings in vehicle-only treated cells (0 
µM) and are represented as the mean ±SD of experiments performed in triplicate and repeated at least two 
times. *p < 0.05 compared to vehicle-only treated cells (0 µM). 
 
As observed before (in Figure 4.12), there was no effect on cell number when WHCO1 cells 
were treated with 5 µM EXP57EA in the presence of the 2.5 mM and 5 mM NAC for 24 
hours in comparison with cells treated with EXP57EA in the absence of NAC (Figure 4.13 
B). Nevertheless, an assay to measure cell number was performed using higher 
concentrations of NAC (15 mM and 20 mM – similar to concentrations used by other authors 
(Donadelli et al., 2011; Kim et al., 2012) together with 5 µM EXP57EA (Figure 4.14). The 
results revealed that 15 mM NAC was ineffective in rescuing WHCO1 cells from EXP57EA-
induced cytotoxicity and 20 mM NAC was very cytotoxic resulting in a 2.5 fold decrease in 
cell viability compared to vehicle-only treated cells. Subsequent experiments used 10 mM 




Figure 4.14: Effect of high NAC concentrations on WHCO1 cells after treatment with EXP57EA. Cells 
(3000 per well) seeded in 96-well plates and were pretreated with 15 mM, and 20 mM NAC or media only for 1 
h, followed by treatment with 5 µM EXP57EA for 24 h. MTT reagent was added to fresh media and incubated 
for 4 h followed by the addition of solubilisation solution. The next day the absorbance was measured at 595 nm 
using a BioTek plate reader. Results are shown relative to absorbance readings in vehicle-only treated cells (0 
µM) and are represented as the mean ±SD of experiments performed in triplicate and repeated at least two 
times. *p < 0.05 
 
Furthermore, western blot analysis was performed to assess the expression of LC3-II, a 
marker of autophagy, in WHCO1 cells treated with EXP57EA in the presence and absence of 
10 mM NAC. Illustrated in Figure 4.15 it was evident that the expression of LC3-II was 
unaffected in EXP57EA-treated WHCO1 cells in the presence of NAC. In addition, there was 
no change in the expression of cleaved PARP in cells treated with EXP57EA and NAC 
(Figure 4.16). In addition, to determine the effect of NAC on DNA damage in cells treated 
with EXP57EA, the expression levels of the DNA damage marker, γ-H2AX, was examined 
(Figure 4.17). In the absence of NAC, a dose-dependent increase in γ-H2AX expression was 
observed that was exacerbated by the presence of NAC, unlike the results observed for DHA-
treated cells in the presence of NAC where γ-H2AX expression was decreased compared to 
γ-H2AX expression in DHA-treated cells in the absence of NAC.  
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Figure 4.15: Western blot analysis illustrating the effect of NAC on the expression levels of LC3-II in 
WHCO1 cells treated with EXP57EA. WHCO1 cells (3 x 105) were plated in 60 mm dishes and incubated 
overnight. Cells were pretreated with 10 mM NAC (+) or media only (-) for 1 h followed by treatment with the 
indicated concentrations of EXP57EA for 24 h. Protein was harvested and quantified so that 40 µg could be 
separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with 
antibodies recognising LC3-I and LC3-II. Beta-Tubulin was used as a loading control and this figure is 
representative of at least two experiments. 
Figure 4.16: Western blot analysis illustrating the effect of NAC on expression levels of cleaved PARP in 
WHCO1 cells treated with EXP57EA for 24 h. WHCO1 cells (3 x 105) were plated in 60 mm dishes and 
incubated overnight. Cells were pretreated with 10 mM NAC (+) or media only (-) for 1 h followed by treatment 
with the indicated concentrations of EXP57EA for 24 h. Protein was harvested and quantified so that 20 µg 
could be separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was probed 
with antibodies recognising PARP and cleaved PARP. The last lane contained WHCO1 cells treated with 5 µM 
DOX for 24 has a positive control to show PARP cleavage. Beta-Tubulin was used as a loading control and this 
figure is representative of at least two experiments. 
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Given that NAC was ineffective in rescuing oesophageal cancer cells from cytotoxicity 
induced by EXP57EA, and considering that EXP57EA significantly increased ROS 
production it was worthwhile investigating whether using alternative ROS scavengers may be 
effective. Therefore, L-ascorbic acid (LAA) and 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox) were employed. LAA, more commonly known as vitamin C, and 
Trolox, a water-soluble analogue of vitamin E, are known to scavenge a wide array of ROS 
(Schlieve et al., 2006). 
Figure 4.17: The effect of NAC on γ-H2AX expression in cells treated with EXP57EA. WHCO1 cells (3 x 
105) were plated in 60 mm dishes and incubated overnight. Cells were pretreated with 10 mM NAC (+) or media 
only (-) for 1 h followed by treatment with the indicated concentrations of EXP57EA for 24 h. Protein was 
harvested and quantified so that 20 µg could be separated by SDS-PAGE and transferred onto a nitrocellulose 
membrane. The membrane was probed with antibodies recognising γ-H2AX. Beta-Tubulin was used as a 
loading control. This figure is representative of at least two experiments. 
 
The DCFDA ROS assay was suitable to use for these experiments because it detects a broad 
range of ROS. As shown in Figure 4.18 A, both LAA and Trolox significantly reduced ROS 
generated by WHCO1 cells treated with EXP57EA for 5 hours. However, both scavengers 
had minimal effect on cell number in cells treated with EXP57EA after 24 hours and 48 
hours. A report published by Chen and colleagues described superoxide as the main type of 
ROS that is associated with the induction of autophagy (Chen et al., 2009b). None of the 
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scavengers used above specifically quenched superoxide, thus TEMPOL (4-hydroxy-2,2,6,6- 
tetra-ethylpiperidine 1-oxyl), a superoxide-specific scavenger (Yamada et al., 2003), was 
used. 
 
WHCO1 and WHCO6 cells treated with EXP57EA in the presence of 0.25 mM TEMPOL 
displayed a significant reduction in ROS (grey bars) compared to cells treated with 
EXP57EA in the absence of TEMPOL (white bars) (Figure 4.19 A and B, respectively). 
Interestingly, a significant increase in cell number was observed in cells treated with 
EXP57EA in the presence of TEMPOL (grey bars) in WHCO1 (Figure 4.19 C) and WHCO6 
(Figure 4.19 D) cells for 24 hours when compared to EXP57EA-treated cells in the absence 
of TEMPOL (white bars). Thus, these results suggested that superoxide is the main type of 
ROS involved in EXP57EA-induced cytotoxicity.  
 
MnSOD, an endogenous scavenger of superoxide, functions by catalysing the reaction of 
superoxide to hydrogen peroxide and oxygen (Li et al., 2010). When cells are exposed to high 
concentrations of superoxide, SOD genes are transcribed in order to prevent oxidative stress. 
In order to substantiate the effect of EXP57EA on superoxide levels in oesophageal cancer 
cells, the expression of MnSOD (manganese superoxide dismutase) was investigated after 
treatment with EXP57EA after 8 hours and 24 hours (Figure 4.20). A dose-dependent 
increase in the expression of MnSOD was observed after the 8 hour treatment point that was 




Figure 4.18: Effect of LAA and Trolox on ROS production (A) and cell number after 24 h (B) and 48 h 
(C) in WHCO1 cells treated with EXP57EA (A), Cells (1x104) were seeded in 96-well white plates and 
pretreated with 100 µM LAA, 100 µM Trolox or Krebs Ringer’s buffer only for 1 h, followed by treatment with 
50 µM DCFDA for 15 min. The indicated concentrations of EXP57EA was added and incubated for 5 h. 
Fluorescence was measured using a Cary Eclipse fluorescence spectrophotometer (484 nm excitation; 530 nm 
emission). Results are shown relative to fluorescence readings in control (vehicle-treated) cells. (B, C), Cells 
(3000 per well) seeded in 96-well plates and were pretreated with 100 µM LAA, 100 µM Trolox or media only 
for 1 h, followed by treatment with 5 µM EXP57EA for 24 h (B) and 48 h (C). MTT reagent was added to fresh 
media and incubated for 4 h followed by the addition of solubilisation solution. The next day the absorbance 
was measured at 595 nm using a BioTek plate reader. Results are shown relative to absorbance readings in 
vehicle-only treated cells (0 µM) and are represented as the mean ±SD of experiments performed in triplicate 
and repeated at least two times. *p < 0.05 
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This result correlated with the ROS assay data where a significant increase in ROS 
production was observed after cells were treated with EXP57EA for 5 hours (Figure 4.10), 
suggesting that EXP57EA-induced cytotoxicity was mediated by early oxidative stress 
events. Furthermore, it is evident from these results that oesophageal cancer cells treated with 
EXP57EA responded to excessive superoxide levels by increasing the transcription of 
MnSOD. 
 
Having established that superoxide was the main type of ROS involved in EXP57EA-induced 
cytotoxicity, we next wanted to determine the effect of this type of ROS on EXP57EA-
induced autophagy. Thus, the effect of TEMPOL on EXP57EA-induced LC3-II expression 
was examined. WHCO1 cells treated with 10 µM EXP57EA in the presence of 0.25 mM 
TEMPOL displayed decreased expression of LC3-II compared to cells treated with 
EXP57EA in the absence of TEMPOL (Figure 4.21). The results presented here is consistent 





Figure 4.19: Effect of TEMPOL on ROS production (A and B) and cell number (OD490nm) (C and D) in 
WHCO1 and WHCO6 cells after treatment with EXP57EA. (A, B), Cells (1x104) were seeded in 96-well 
white plates and pretreated with 0.25 mM TEMPOL or KR buffer only for 1 h, followed by treatment with 50 
µM DCFDA for 15 min. The indicated concentrations of EXP57EA were added and incubated for 5 h. 
Fluorescence was measured using a Cary Eclipse fluorescence spectrophotometer (484 nm excitation; 530 nm 
emission). Results are shown relative to fluorescence readings in control (vehicle-treated) cells. (C, D), Cells 
(3000 per well) seeded in 96-well plates and were pretreated with 0.25 mM TEMPOL or media only for 1 h, 
followed by treatment with the indicated concentrations of EXP57EA for 24 h. NR (Neutral Red) reagent was 
added to fresh media and incubated for 3 h. Cells were washed with 1 x phosphate buffered saline (PBS) and 
incubated with NR desorb reagent for 45 min with rotation. Following 5 min incubation at RT (room 
temperature), absorbance was measured at 490 nm using a BioTek plate reader. Results are shown relative to 
absorbance readings in vehicle-only treated cells (0 µM) and are represented as the mean ±SD of experiments 




To further confirm the role of EXP57EA-generated superoxide in the induction of autophagy, 
the expression of phosphorylated p70S6 kinase (p-p70S6K) was assessed. The activation of 
this downstream target of mTOR, a negative regulator of autophagy, is known to be inhibited 
when autophagy occurs (Son et al., 2011; Sridharan et al., 2011). When WHCO1 and 
WHCO6 cells were treated with EXP57EA in the absence of TEMPOL, a decrease in p-
p70S6K expression was observed after the 8 hour treatment point (Figure 4.24 A) and the 24 
hour treatment point (Figure 4.24 B).  
Figure 4.20: Evaluation of mRNA levels of MnSOD in WHCO1 cells treated with EXP57EA for 8 h and 
24 h .WHCO1 cells were seeded at a density of 3 x105 per dish in 60 mm dishes. Cells were treated with 5 µM 
and 10 µM EXP57EA for 8 h and 24 h, after which RNA was extracted and processed. mRNA was analysed by 
quantitative real-time RT-PCR for the genes encoding MnSOD and GusB. Results (corrected using GusB 
expression levels) are shown relative to 0 µM (vehicle-treated) cells and are represented as the mean ±SD of 




This observation is consistent with the induction of autophagy. TEMPOL (0.25 mM) 
increased p-p70S6K expression levels by ~10% in WHCO1 cells and ~5% in WHCO6 cells 
at the 8 hour treatment point, and ~8% in WHCO6 cells at the 24 hour treatment point in the 
absence of EXP57EA. However, in the presence of EXP57EA and TEMPOL, elevated levels 
of p-p70S6K expression is detected in WHCO1 and WHCO6 cells after 8 hours (1.3 fold and 
3 fold, respectively) and 24 hours (8 fold and 11 fold, respectively), relative to p-p70S6K 
levels in EXP57EA-treated cells in the absence of TEMPOL (normalised to β-Tubulin) 
(Figure 4.22). These results implicated EXP57EA-induced superoxide in the inhibition of the 
mTOR pathway which correlates with the activation of the autophagic pathway. 
Figure 4.21: Western blot analysis demonstrating the effect of TEMPOL on expression levels of LC3-II in 
WHCO1 cells treated with EXP57EA. WHCO1 cells (3 x 105) were plated in 60 mm dishes and incubated 
overnight. Cells were pretreated with 0.25 mM TEMPOL or media only for 1 h followed by treatment with the 
10 µM EXP57EA for 24 h. Protein was harvested and quantified so that 40 µg could be separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with antibodies recognising 
LC3-I and LC3-II and β-Tubulin, the loading control. This figure is representative of at least two experiments 
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Figure 4.22: The effect of TEMPOL on expression of p-p70S6K in WHCO1 and WHCO6 cells treated 
with EXP57EA for 8 h (A) and 24 h (B). WHCO1 and WHCO6 cells (3 x 105) were plated in 60 mm dishes, 
and pretreated with 0.25 mM TEMPOL or media only for 1 h followed by treatment with the 10 µM EXP57EA 
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for 8 h (A) and 24 h (B). Protein was harvested and quantified so that 40 µg could be separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. The membrane was probed with antibodies recognising p-
p70S6K and β-Tubulin, the loading control. ImageJ software was used to determine p-p70S6K expression levels 
relative to β-Tubulin expression levels for WHCO1 (A.1) and WHCO6 (B.1) cells treated with EXP57EA in the 
presence and absence of 0.25 mM TEMPOL. This figure is representative of at least two experiments. 
 
4.2.2.2 The effect of EXP57EA-induced ROS on signalling pathways involved in the 
activation of autophagy  
Considering previous reports implicating mitogen activated protein kinases (MAPK) in the 
induction of autophagy via ROS-dependent mechanisms (Eom et al., 2010; Wong et al., 
2010; Xavier et al., 2013), we were curious to learn whether EXP57EA-induced ROS had an 
effect on the MAPK pathways involved in autophagy. Therefore, the next step was to 
elucidate the role of EXP57EA on the activation of c-Jun-N-terminal kinase (JNK), 
extracellular-signal-related kinase (ERK) and p38 MAPK using western blot analysis.  
 
Figure 4.23: The effect of EXP57EA after 24 h on the expression levels of phosphorylated JNK (pJNK) in 
WHCO1. WHCO1 cells (3 x 105) were plated in 60 mm dishes and incubated overnight. Cells were treated with 
the indicated concentrations of EXP57EA for 24 h. Cells treated with 20 nM TPA for 1 h served as a positive 
control. Protein was harvested and quantified so that 40 µg could be separated by SDS-PAGE and transferred 
onto a nitrocellulose membrane. The membrane was probed with antibodies recognising pJNK and total JNK. 
This figure is representative of at least two experiments 
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WHCO1 cells treated with EXP57EA for 24 hours induced a dose-dependent increase in JNK 
activation (pJNK) (Figure 4.23). Bearing in mind that the increase in ROS measured by the 
ROS assay and the increase in MnSOD expression was observed after cells were treated with 
EXP57EA for short time points (5 hours and 8 hours, respectively), the effect of EXP57EA 
on pJNK expression levels was monitored after 8 hours (Figure 4.24). The strong activation 
of JNK after the 8 hour treatment with EXP57EA was clearly evident in both WHCO1 and 
WHCO6 cell lines, and this effect was reduced (by ~50% in WHCO1 cells and ~30% in 
WHCO6 cells) by co-treatment with SP600125, an inhibitor of JNK activity. Interestingly, 
EXP57EA had minimal effects on the activation of ERK over a period of time (Figure 4.25) 
and p38 after 8 hours (Figure 4.26) in oesophageal cancer cells. 
Figure 4.24: The effect of EXP57EA after 8 h on the expression levels of pJNK in WHCO1 and WHCO6 
in the presence and absence of SP600125. WHCO1 and WHCO6 cells (3 x 105) were plated in 60 mm dishes 
and incubated overnight. Cells were pretreated with 25 µM SP600125 or media only for 1 h followed by 
treatment with 10 µM EXP57EA for 8 h. Protein was harvested and quantified so that 40 µg could be separated 
by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with antibodies 




Figure 4.25: The effect of EXP57EA on the expression levels of phosphorylated ERK (pERK) in WHCO1 
cells over time. WHCO1 cells (3 x 105) were plated in 60 mm dishes and incubated overnight. Cells were 
treated with 10 µM EXP57EA for the indicated time points. Cells treated with vehicle-only (0 µM) served as a 
control. Protein was harvested and quantified so that 40 µg could be separated by SDS-PAGE and transferred 
onto a nitrocellulose membrane. The membrane was probed with antibodies recognising pERK, total ERK and 
the loading control, β-Tubulin. This figure is representative of at least two experiments.  
 
It is possible that the production of superoxide by oesophageal cancer cells treated with 
EXP57EA could be attributed to the metabolism of the compound by p450 enzymes in the 
endoplasmic reticulum (ER), which is also one of the major producers of ROS. The ER can 
produce different types of ROS, particularly superoxide, during metabolism of exogenous 
compounds (Curtin et al., 2002; Kim et al., 2009), which is associated with ER stress 
concomitant with increased calcium release from the ER (Malhotra and Kaufman, 2007). 
Since ER stress is closely associated with calcium release, an assay to monitor calcium 
signalling was used. NFAT (nuclear factor of activated T cells) activity is directly linked to 
an increase in intracellular calcium. Briefly, a sustained increase in intracellular calcium 
activates calcineurin, which dephosphorylates cytoplasmic NFAT transcription factors 
allowing rapid translocation to the nucleus (Wilkins et al., 2004). NFAT luciferase reporter 
activity was assessed by transient transfection of WHCO1 cells with a NFAT luciferase 
reporter plasmid containing three tandem repeats of a 30 bp fragment of the IL-2 promoter 
known to bind NFAT.  
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Figure 4.26: The effect of EXP57EA after 8 h on the expression levels of phosphorylated p38 (p-p38) in 
WHCO1 and WHCO6 cells. WHCO1 and WHCO6 cells (3 x 105) were plated in 60 mm dishes, and treated 
with 10 µM EXP57EA for 8 h. Protein was harvested and quantified so that 40 µg could be separated by SDS-
PAGE and transferred onto a nitrocellulose membrane. The membrane was probed with antibodies recognising 
p-p38 and the loading control, β-Tubulin.  
 
NFAT transactivation was measured in the presence and absence of TEMPOL, and after 
treatment with 10 µM EXP57EA for 24 hours, WHCO1 and WHCO6 cells (Figure 4.27 A 
and B, respectively) displayed ~ 1.5-fold increase in NFAT luciferase activity in the absence 
of TEMPOL; this effect was attenuated in the presence of 0.25 mM TEMPOL. Given that the 
increase in ROS production and that activation of JNK was observed at earlier time points, 
the experiment was repeated after a 6-hour treatment with EXP57EA (Figure 4.27 C and D). 
Although a similar result was seen after 6 hours, a smaller fold-increase (~1.2-fold) was 
observed in the absence of TEMPOL. These results indicate the EXP57EA-induced 
superoxide may increase intracellular calcium, which could be a result of ER stress. A further 
experiment was performed to determine the expression levels of CHOP, a marker of ER 
stress, in EXP57EA-treated cells (data not shown). The results revealed a strong increase in 
CHOP expression in WHCO1 and WHCO6 cells treated with 10 µM EXP57EA, however 
this represented preliminary results that must be repeated.  
140 
 
Figure 4.27: NFAT luciferase activity in WHCO1 and WHCO6 cells treated with EXP57EA for 24 h (A 
and B) and 6 h (C and D) in the presence and absence of TEMPOL.WHCO1 cells (3 x 104 per well) were 
plated in 24-well plates, and transfected with 50 ng GFP-NFAT plasmid, 50 ng NFAT-luciferase and 5 ng pRL-
TK, using GenecellinTM Transfection Reagent. The following day cells were pretreated with 0.25 mM TEMPOL 
for 1 h then treated with 10 μM EXP57EA for 24 h (A, B) and 6 h (B, C). After the relevant time points passed, 
cells were stimulated with 100 nM TPA and 1.3 μM Ionomycin for 5 h, following which luciferase activity was 
measured using the VeritasTM microplate luminometer. Luciferase readings were normalised to Renilla 
luciferase in the same extract. Results are shown relative to readings in vehicle-only treated cells (0 µM) and are 









One of the objectives of this study was to characterise the effects of the artemisinin 
derivative, DHA, in our oesophageal cancer cell culture model together with the novel 
artemisinin-isatin hybrid, EXP57EA. The artemisinin derivatives, including DHA, have been 
investigated extensively in a large number of cancer cell lines as potential anticancer agents, 
but very little is known regarding the mechanistic effects of these compounds in oesophageal 
cancer. However, in the course of the finalisation of this thesis, a recent paper was published 
that reported the induction of apoptosis and autophagy by DHA in an OC cell culture model 
(Du et al., 2013). This paper is inconsistent with the observations made in this study, since we 
have never seen the induction of autophagy-associated vesicles in OC cells treated with 
DHA. 
 
Artemisinin derivatives have been shown to induce apoptosis in a wide variety of cancer cell 
lines, and increased ROS production has been implicated as one of the important events 
leading to cell death, as mentioned earlier. In this study, we have conclusively shown that 
DHA induced both ROS and apoptosis. Furthermore, a ROS scavenger effectively blocked 
ROS production and also blocked apoptosis, highlighting a causal link between ROS 
production and the induction of apoptosis.  
 
Different types of ROS (superoxide, hydroxyl radicals, hydrogen peroxide, singlet oxygen, 
nitric oxide and peroxynitrite) exist, of which most are produced at low concentrations in 
cells in order to participate in normal metabolic processes or are the byproducts thereof 
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(Barzilai and Yamamoto, 2004). Endogenous antioxidants such as superoxide dismutase, 
glutathione peroxidase, catalase, vitamins C and E are employed to maintain cellular 
homeostasis. Oxidative stress occurs when these scavenger mechanisms of the cell are 
overwhelmed by excessive ROS production, for example when cells are exposed to ionising 
radiation or exogenous compounds (Circu and Aw, 2010). Cancer cells have higher 
concentrations of ROS, compared to normal cells, due to increased metabolic activity as well 
as reduced levels of antioxidants due to tumourigenesis (Pelicano et al., 2004; Szatrowski and 
Nathan, 1991). This characteristic is often exploited by chemotherapeutic agents, which 
further increase the ROS concentration in cancer cells thus inducing cell death.  
 
ROS can cause cancer cell death by apoptosis by direct stimulation of the sensors in the death 
receptor pathway, by promoting MOMP resulting in cytochrome c release or by causing 
DNA damage resulting in a cell cycle arrest (Circu and Aw, 2010). In this study, we showed 
that DHA significantly increased ROS production in oesophageal cancer cells. Very high 
concentrations of ROS within cells are frequently associated with DNA damage. In fact, 
DNA damage induced by ROS contributes to most of the DNA damage events observed in 
cells of the human body and can activate signalling pathways that participate in the “DNA 
damage response” (Barzilai and Yamamoto, 2004). Double-strand breaks (DSB) inflicted by 
ROS are a type of DNA damage that can cause apoptosis (Rich et al., 2000).  
 
H2AX phosphorylation occurs on DSB during DNA damage and is often used as a marker 
for this process. The effect of DHA on the expression of phosphorylated H2AX (γ-H2AX) in 
WHCO1 and WHCO6 cells was determined. OC cells displayed a dose-dependent increase in 
γ-H2AX expression levels. The ROS scavenger, NAC, abrogated the effect of DHA on the 
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expression of γ-H2AX confirming that DHA-induced ROS production increased DNA 
damage in OC cells. A similar result was obtained by Berdelle and colleagues who reported 
the ROS-dependent DNA damaging effects of artesunate in LN-229 glioblastoma cells 
(Berdelle et al., 2011). Furthermore, ROS scavengers, including NAC, effectively inhibited 
the production of ROS and DNA damage and prevented cell death (Berdelle et al., 2011). 
Therefore, our study further substantiates reports in the literature of the ability of DHA to 
cause ROS-dependent DNA damage.  
 
DNA damage can arrest cells in the various phases of the cell cycle. DNA repair mechanisms 
are activated during the G1/S or G2/M checkpoints of the cell cycle and success of these 
mechanisms result in the release of the block on arrested cells and allow the progression to 
the next stage of the cell cycle (Hartwell and Kastan, 1994). However, if repair is not possible 
or DNA damage is too extensive, programmed cell death results (Fragkos et al., 2009; 
Hartwell and Kastan, 1994). We have previously shown that OC cells treated with DHA 
arrested cells in the G2/M phase of the cell cycle, which was effectively blocked by treatment 
with NAC, reflecting the role of ROS in the G2/M arrest observed. Lu and colleagues 
demonstrated a similar effect in lung adenocarcinoma using the ASTC-a-1 cell line. Cells 
treated with DHA for 24 hours and 48 hours caused a significant increase in cells arrested in 
the G2/M phase of the cell cycle and this effect was abrogated in the presence of NAC (Lu et 
al., 2010). In addition, NAC also prevented DHA induced ROS-dependent Bax translocation, 
cytochrome c release, caspase-9, caspase-8, and caspase-3 activation, confirming the 




In this study, WHCO1 and WHCO6 cells treated with DHA resulted in a dose-dependent 
increase in the sub-G1 phase of the cell cycle. This effect was significantly reduced when 
cells were treated with DHA in the presence of NAC. Further substantiating this observation, 
cells co-treated with NAC and DHA displayed a reduction in the expression of cleaved PARP 
compared to cells treated with DHA alone. Moreover, NAC effectively rescued cells from 
DHA-induced cytotoxicity, measured using the MTT assay. These results are consistent with 
previous reports in the literature demonstrating the ROS-dependent induction of cancer cell 
death by artemisinin derivatives.  
 
Interestingly, NAC was not able to rescue OC cells treated with the novel artemisinin-isatin 
hybrid compound, EXP57EA, despite being able to abrogate ROS production by EXP57EA-
treated cells, at different concentrations of NAC tested. Furthermore, cells treated with 
EXP57EA in the presence of NAC displayed no change in LC3-II or cleaved PARP 
expression. Two different types of ROS scavengers, LAA and Trolox, were also tested and 
found to be ineffective in rescuing cells from EXP57EA-induced cytotoxicity. Indeed, ROS 
produced by treatment of cells with EXP57EA was measured after 5 hours since that was the 
time point during which the largest increase in ROS production was observed. Therefore, the 
broad ROS scavengers were effective at reducing ROS at that time point, but could not rescue 
cells from EXP57EA-induced cytotoxicity after the 24-hour treatment point. This could have 
been as a result of the scavengers not effectively reducing all types of ROS induced by 
EXP57EA treatment, and this reasoning was validated by work published by Chen and 
colleagues, implicating superoxide as the main type of ROS involved in the induction of 
autophagy (Chen et al., 2009b). The effect of a superoxide specific-scavenger, TEMPOL, 
was tested in cells treated with EXP57EA, and it was found that TEMPOL abrogated the 
effect of EXP57EA on ROS production and was able to rescue cells from EXP57EA-induced 
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cytotoxicity, unlike NAC. Further corroborating the cytotoxic effects of EXP57EA-induced 
superoxide, OC cells treated with EXP57EA in the presence of TEMPOL displayed a 
reduction of LC3-II and an increase in p-p70S6K (downstream target of mTOR, a key 
negative regulator of autophagy) expression, compared to cells treated with EXP57EA alone. 
This observation verified the role of superoxide in the induction of the autophagic pathway. 
 
Superoxide can be produced by a variety of methods within the cells, and one method is via 
the microsomal monooxygenase (MMO) system of the ER. The MMO system is made up of 
cytochrome P450, NADPH-P450 reductase (NPR) and phospholipids. The cytochrome P450 
family, especially, P4502E1 plays an important role in the detoxification of exogenous 
compounds, producing large amounts of ROS, especially superoxide and hydrogen peroxide 
(Kim et al., 2009; Meunier et al., 2004). Large amounts of ROS production in the ER can 
lead to ER stress, and increased release of calcium into the cytoplasm is one of the hallmarks 
of ER stress (Malhotra and Kaufman, 2007). A substantial increase in cytoplasmic calcium is 
essential to maintain NFAT activity in the nucleus of cells (Wilkins et al., 2004), and such 
high concentrations of calcium release into the cytoplasm is usually attributed to ER stress. In 
cells treated with EXP57EA in the absence of TEMPOL a significant increase in NFAT 
activity was observed, and this effect was attenuated in the presence of TEMPOL, suggesting 
that superoxide is required for the increase in calcium concentrations and thus ER stress. 
Supporting the concept of ER-induced superoxide production by EXP57EA, OC cells treated 
with EXP57EA revealed a large increase in CHOP (ER stress marker) expression (data not 
shown); however the experiment was performed once in two cell lines and represents 




Superoxide can be quickly converted to hydrogen peroxide by SOD in the cell (Li et al., 
2010). It is interesting to note that hydrogen peroxide can be rapidly converted to the 
hydroxyl radical when in contact with iron, via the Fenton reaction (Curtin et al., 2002). 
Cancer cells are known to have high concentrations of iron due to increased metabolism. One 
possibility could be that EXP57EA-induced superoxide is rapidly converted to hydrogen 
peroxide within the cell, increasing hydroxyl radicals in the cells leading to cytotoxicity, 
considering that the ROS scavenger mechanisms cannot truly scavenge hydroxyl radicals 
(Palmieri and Sblendorio, 2006). In addition, superoxide can also produce other types of ROS 
such as peroxynitrile, hypochlorous acid and singlet oxygen, which may play a role in the 
signalling events within the cell. Therefore, EXP57EA-induced superoxide could result in 
autophagic cell death via signalling pathways mediated by different types of ROS compared 
to those produced by DHA, supporting the improved activity observed by EXP57EA in 
oesophageal cancer cells compared to DHA. Furthermore, our hypothesis that EXP57EA-
induced superoxide could be produced as a result of metabolism by cytochrome P450 
enzymes in the ER is supported by the fact that DHA is the in vivo active metabolite of 
artesunate, artemether and arteether, therefore requires no metabolism by the cytochrome 
P450 enzymes (Ilett et al., 2002; Sertel et al., 2010). Therefore, the type of ROS induced by 
DHA could be a direct result from the reaction of the characteristic artemisinin-endoperoxide 
bridge with intracellular iron, known to be increased in cancer cells compared to normal cells.  
 
The activation of JNK is frequently associated with increased ROS production (Circu and 
Aw, 2010), and cells treated with EXP57EA displayed increased phosphorylated JNK 
(pJNK) expression compared to vehicle-only treated cells. JNK activation is involved in the 
induction of autophagy by two ways: a.) pJNK can inhibit the Beclin 1-Bcl-2 complex 
freeing Beclin 1 to function in autophagosome formation, and b.) pJNK activates 
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transcription factors, cJun and AP-1, which are responsible for the transcription of Beclin 1 
(Li et al., 2009a; Park et al., 2009). Furthermore, JNK can be activated by different types of 
ROS, including superoxide (Bai et al., 2012). A number of studies have showed that 
compounds (such as bufalin , resveratrol and calyxin Y) were able to induce autophagy in 
cancer cells (including colorectal cancer, chronic myelogenous leukemia and lung cancer) via 
ROS-mediated JNK activation (Puissant et al., 2010; Wong et al., 2010; Xie et al., 2011; 
Zhang et al., 2013). Whilst we have shown that EXP57EA treatment results in the increased 
expression of pJNK, we have not been able to show the effects of TEMPOL on pJNK 
expression in cells treated with EXP57EA, due to time constraints.  
 
The results presented in this chapter provided strong evidence that DHA induced apoptosis in 
oesophageal cancer cells, mediated by ROS-induced DNA damage and cell cycle arrest. 
ROS-mediated apoptosis has been demonstrated in studies performed on various cancer cell 
lines treated with currently used anticancer drugs including paclitaxel (Alexandre et al., 
2006), etoposide (Oh et al., 2007), doxorubicin (Tsang et al., 2003) and cisplatin (Berndtsson 
et al., 2007; Miyajima et al., 1997). EXP57EA also increased ROS production in oesophageal 
cancer cells but our data suggested that superoxide produced by EXP57EA resulted in 
cytotoxicity. In accordance with our data, superoxide is the main type of ROS involved in 
EXP57EA-induced autophagy which maybe be mediated by ER stress and JNK signalling 










Oesophageal cancer represents a significant health challenge in South Africa, which is a high 
risk area for the disease. Considering that OC is usually asymptomatic and as a result, 
diagnosed at a very late stage, the prognosis for patients with OC is very poor. The morbidity 
and mortality associated with this disease could be reduced if improved chemotherapeutic 
options for these patients could be developed. Effective chemotherapy includes agents that 
are capable of targeting and killing cancer cells without affecting normal cells; and there is an 
ongoing search for such agents, especially from natural sources. Natural products have made 
a significant contribution to currently used chemotherapeutic agents, therefore the aim of this 
project was to investigate the effects of novel compounds derived from natural products 
against oesophageal cancer cells. 
 
This project focussed on artemisinins, compounds derived from a plant used in Traditional 
Chinese Medicine, and hybrids thereof. Novel hybrid compounds, which were synthesized by 
combining the artemisinin derivative, DHA, with the natural product scaffold, isatin, were 
investigated for their anticancer effects. In this study, it was demonstrated that the first 
generation artemisinin derivatives, ART and DHA, were active against oesophageal cancer 
cells, and that the novel hybrid compounds were more active than the first generation 
derivatives. Furthermore, this effect was demonstrated in a number of cancer cell lines, 
including cervical cancer and breast cancer cell lines. Both the first generation and the novel 
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compounds displayed selectivity to cancer cells versus normal cells; however the first 
generation derivatives were more selective for cancer cells over normal cells than the 
artemisinin-isatin hybrids. Importantly, lower concentrations of the novel compounds were 
required to kill cancer cells after the same treatment time as the first generation derivatives 
and the novel hybrid compounds were reproducibly more active than the first generation 
derivatives in all cancer cell lines tested. The observation that the novel compounds were 
more active than the parental compounds against cell lines that were considered 
chemoresistant, such as SiHa and MDA-MB-231, was very promising and warrants further 
investigation.  
 
This study examined the mechanistic effects of the artemisinin derivatives, focussing on 
DHA and the novel artemisinin-isatin hybrid, EXP57EA, which was the most active novel 
hybrid compound tested. The initial biological investigations suggested that the first 
generation derivatives may have a different molecular mechanism of action compared to the 
hybrid compounds (G2/M cell cycle arrest versus G0/G1 cell cycle arrest, respectively), and 
upon further investigations we demonstrated that the parent compound, DHA, strongly 
induced apoptosis in OC cell lines whereas the novel hybrid, EXP57EA, induced autophagy. 
The role of autophagy in tumourigenesis is quite controversial considering conflicting 
evidence for its role in cell survival and cell death. A number of reports have demonstrated 
the ability of potential anticancer compounds to induce autophagic cell death in a variety of 
cancer cell lines (Ling et al., 2011; Puissant et al., 2010; Xie et al., 2011; Zhang et al., 2013). 
In this study, our results suggested that EXP57EA induces autophagy as a cell death pathway 
since there was no evidence of either apoptosis or necrosis. Using 3-MA, a chemical inhibitor 
of autophagy that is widely used in the literature, in cells treated with EXP57EA we were 
able to show the inhibition of autophagy with a concomitant increase in cell number, 
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compared to cells treated in the absence of 3-MA. Furthermore, autophagic flux was 
demonstrated using ammonium chloride, indicating that the complete autophagic pathway 
was activated by EXP57EA. Together this suggests that EXP57EA induces autophagic cell 
death in treated cells. However, to fully implicate EXP57EA-induced autophagy as the cause 
of cell death, it would be important to determine the effects of genetically inhibiting essential 
autophagy regulators such as Beclin 1 and Atg5 on expression of essential autophagy markers 
such as LC3-II, and then to determine the effects on cell number in OC cells treated with 
EXP57EA. This is in line with the criteria recommended by the NCCD (Galluzzi et al., 2012) 
in order to implicate autophagy as the cell death pathway in EXP57EA-treated cells. 
Therefore the future work on this project will include genetically inhibiting two or more 
essential regulators of autophagy and determining the effect on LC3-II expression as well as 
the effect on cell number after treatment with EXP57EA. We have already met the other two 
criteria outlined: a.) showing that 3-MA suppresses cell death and decreases expression of 
LC3-II in EXP57EA-treated cells, and b.) demonstrating that EXP57EA does not activate 
apoptosis or necrosis in OC cells. 
 
The results obtained in this project demonstrated for the first time, to the best of our 
knowledge, that DHA induced ROS-dependent apoptosis in OC cells. DHA-treated OC cells 
displayed an increase in ROS production, γ-H2AX expression, G2/M cell cycle arrest, 
caspase3/7 activation and cleaved PARP expression. In the presence of the ROS scavenger, 
NAC, OC cells treated with DHA demonstrated a significant decrease in ROS production, γ-
H2AX expression, G2/M cell cycle arrest, cleaved PARP expression and cell number 
compared to DHA-treated cells in the absence of NAC, implicating DHA-induced ROS 
production as the main signalling event leading to apoptotic cell death. Whilst similar results 
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were obtained in other cancer cell lines (Berdelle et al., 2011; Lu et al., 2010), this has not 
been reported in oesophageal cancer.  
 
EXP57EA, on the other hand, was more active than DHA in our cell culture models and OC 
cells treated with EXP57EA in the presence of NAC did not respond in the same manner as 
OC cells treated with DHA in the presence of NAC. The results obtained in this study 
demonstrated a large increase in ROS production in cells treated with EXP57EA. Whilst 
NAC apparently scavenged the ROS generated by EXP57EA, it could not rescue the cells 
from the cytotoxicity associated with EXP57EA, unlike TEMPOL which scavenged the ROS 
and reduced the EXP57EA induced cytotoxicity. Consequently, we demonstrated that 
superoxide was the main type of ROS produced by OC cells treated with EXP57EA. The 
results obtained thereafter implicated EXP57EA-induced superoxide production in the 
activation of the autophagic pathway when TEMPOL, a superoxide-specific scavenger, 
abrogated the effects of EXP57EA on the expression of LC3-II and other markers of the 
autophagic pathway. Furthermore, we hypothesized that the superoxide produced after 
treatment with EXP57EA could be as a result of its metabolism by the cytochrome P450 
enzyme family in the ER. Our preliminary results suggested that ER stress pathway may be 
activated by EXP57EA in OC cells, and this requires further investigation. In addition, our 
results suggested that another important stress pathway, the JNK pathway, may have a role in 
EXP57EA-induced autophagy.  
 
Future work on this project will be done to confirm the effect of EXP57EA on ER stress by 
confirming the increased expression of CHOP as well as other proteins involved in the ER 
stress pathway such as GRP78. Furthermore, the expression levels of these proteins will be 
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evaluated in the presence and absence of TEMPOL to confirm that EXP57EA-induced 
superoxide is directly associated with ER stress. It will also be a valuable exercise to confirm 
the EXP57EA-ER stress-induced release of calcium, as calcium can exacerbate ROS 
production via interaction with the mitochondria (Malhotra and Kaufman, 2007). In addition, 
calcium can also activate autophagy through CaMKKβ activation leading to the activation of 
the AMPK pathway. Furthermore, apart from calcium signalling, the ER stress pathway is 
involved in the induction of autophagy via multiple mechanisms (discussed in 
Chapter1.2.3.4), including the JNK pathway. ER stress activates a variety of proteins 
including IRE1 that leads to the activation of JNK (Maholtra and Kaufman). Therefore, this 
investigation will also be included in the future work planned for this project. It will be 
important to characterise the effects of EXP57EA on the JNK pathway considering that JNK 
activation can induce autophagy and that the JNK pathway can be regulated by ROS and ER 
stress, both associated with EXP57EA treatment of oesophageal cancer cells. 
 
There is a need for new chemotherapeutic agents to treat oesophageal cancer. Artemisinins 
represent a new class of drugs that possess anticancer properties and in this study novel 
artemisinin hybrid compounds were investigated for their effects against oesophageal cancer. 
These compounds have not been studied, to the best of our knowledge, in oesophageal 
cancer. We have demonstrated that the novel compounds were more active than the first 
generation artemisinin derivatives and that DHA induced ROS-dependent apoptosis whereas 
the most active novel hybrid compound, EXP57EA, activated autophagy. Our results suggest 
that superoxide plays an important role in the cytotoxic effects observed in cells treated with 
EXP57EA. This certainly requires further investigation to answer important mechanistic 
questions pertaining to oesophageal cancer cells treated with EXP57EA, a promising drug 
lead for the treatment of cancer.  
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The hybrid compounds were synthesized with the intention of improving the activity of the 
parental compounds and this study provides evidence that this has been achieved. 
Furthermore, the EXP57EA displayed a molecular mechanism of action different to the 
parental compound. This has an important implication in the treatment of cancer where the 
development of resistance to anticancer drugs is a common occurrence. Therefore, 
characterising chemotherapeutic agents capable of activating alternate cell death and 
signalling pathways, compared those frequently induced by most currently used 



















MATERIALS AND METHODS 
 
6.1 Cell Culture 
 
6.1.1 Cell lines 
The three oesophageal cancer cell lines, WHCO1, WHCO5 and WHCO6, were derived from 
biopsies of primary oesophageal squamous cell carcinomas (Veale and Thornley, 1989) and 
kindly provided by Professor Rob Veale (University of Witwatersrand, South Africa). The 
KYSE oesophageal squamous cell carcinoma cell lines (KYSE30, KYSE150 and KYSE180) 
previously established by Shimada and co-workers (Shimada et al., 1992), were purchased 
from the German Resource Centre for Biological Material (http://www.dsmz.de). The CaSki, 
HeLa and SiHa cervical cancer cell lines, MCF7, MDA-MB-231 and T47D breast cancer cell 
lines, HepG2 liver cancer cell line and the SK-N-SH neuroblastoma cell line were purchased 
from the American Type Culture Collection (Rockville, MD, USA). Two primary fibroblast 
control cell cultures prepared from human skin, DMB and FG0, were used as a normal cell 






6.1.2 Cell culture 
All cell lines were maintained at 70 - 80% confluency in Gibco® Dulbecco’s Modified Eagle 
Medium (DMEM) (Invitrogen, USA) containing 10% heat-inactivated foetal bovine serum 
(FBS) (Gibco, Paisley, Scotland), penicillin (100 U/ml) and streptomycin (100 µg/ml). 
DMEM prepared in this way is referred to as complete DMEM. All cell lines used were 
cultured at 37°C in a humidified atmosphere which was supplied with 5% carbon dioxide.  
 
6.1.3 Sub-culturing cells 
Cells cultured in a 100 mm culture dish to a confluency of 70 – 80% were washed once with 
a 0.05% trypsin-EDTA (Difco, USA) solution (hereafter referred to as trypsin), followed by 
the addition of 3 ml fresh trypsin. The trypsinisation of cells was monitored with a light 
microscope (Telaval 31, Zeiss, Germany) for up to 5 min, or until 80 – 90% of cells had lifted 
off the culture dish. The trypsin was neutralised with 3 ml complete DMEM. The cell 
suspension was transferred to a 10 ml Falcon tube and centrifuged at 1000 rpm (revolutions 
per minute) for 5 min. The solution of media and trypsin was aspirated off and the pelleted 
cells were resuspended in 1 ml complete DMEM. A fresh 100 mm culture dish was prepared 
containing 10 ml fresh DMEM to which 500 µl of the cell suspension was inoculated. 
 
6.1.4 Freezing and thawing cells 
In order to prepare cell stocks, cells were grown to 80% confluency, sub-cultured with trypsin 
and neutralized with complete DMEM.  This was followed by centrifugation at 1000 rpm to 
pellet the cells. The cells were resuspended in cell freezing medium (70% complete DMEM, 
20% FBS and 10% DMSO) and 1 ml was aliquotted per cryotube. The cells were placed at -
156 
 
80°C for a maximum of one week before submergence in liquid nitrogen for long term 
storage.  
 
Cells removed from liquid nitrogen were swirled gently in a 37°C waterbath until a small ball 
of ice remained. The cells were transferred, drop-wise, to 5 ml pre-warmed complete DMEM 
and pelleted by centrifugation. The cells were resuspended in 1 ml complete DMEM and 
transferred to 60 mm dish containing 3 ml complete DMEM 
 
6.1.5 Test for mycoplasma 
Mycoplasma tests were routinely performed on all cell lines to rule out contamination. 
Mycoplasma are microbes that are invisible under normal tissue culture light microscopy. 
Cells were cultured in media free of penicillin and streptomycin for at least four days before 
plating onto coverslips. After a further incubation for up to 48 h, cells were fixed with fixing 
solution followed by staining with the fluorescent DNA-binding Hoechst 33258 
fluorochrome stain (Sigma-Aldrich® Co.). The coverslip was mounted after a brief wash with 
water and cells were visualised on the Zeiss Axiovert 200 Fluorescent microscope (Carl 
Zeiss, Germany). Stained nuclei appeared bright green and tiny green spots in the cytoplasm 
between nuclei were indicative of mycoplasma. The absence of the spots in the cytoplasm 






6.2 Compounds and inhibitors 
 
All compounds received from the Department of Chemistry (UCT) were dissolved in tissue 
culture grade DMSO (Sigma-Aldrich® Co), unless otherwise stated. Doxorubicin (DOX), 3-
methyladeninine (3-MA), ammonium chloride (NH4Cl), N-acetyl-L-cysteine (NAC), L-
ascorbic acid (LAA), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), 4-
hydroxy-2,2,6,6- tetra-ethylpiperidine 1-oxyl (TEMPOL), 12-o-tetradecanoylphorbol-13-
acetate (TPA), JNK inhibitor (SP600125) and Ionomycin (ION) were purchased from Sigma-
Aldrich® Co and dissolved in tissue culture grade DMSO with the exception of NAC, LAA , 
3-MA and NH4Cl, which were dissolved in sterile dH2O. 
 
6.3 Compound sensitivity testing 
 
The 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich® 
Co) assay was employed to test compound sensitivity. The IC50 values were determined using 
a range of concentrations (0, 0.1, 1, 5, 10, 50, 100 and 200 µM). Cells were plated at a 
density of 3000 cells per well in triplicate in 90 µl of media in 96-well plates and incubated 
O/N at 37°C. The cells were treated with 10 µl of compound diluted in media and DMSO to 
give a final DMSO concentration of 0.2%. The cells were incubated for 48 h after which 10 
µl MTT solution was added to each well and incubated for a further 4 h. MTT reagent 
consists of yellow tetrazolium salt that is reduced to purple formazan crystals in the 
mitochondria of living cells. After the 4 h incubation period the formazan crystals were 
solubilised by the addition of 100 µl solubilisation reagent (10% w/v SDS, 0.01 M HCl) 
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followed by an O/N incubation. The absorbance was subsequently measured at 595 nm on a 
BioTek EL800 (BioTek, Winooski, VT, USA) 96-well microplate reader. The absorbance of 
media plus compound was subtracted from the absorbance of the compound-treated cells in 
media to account for background absorbance. The IC50 values were calculated using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, USA, www.graphpad.com). 
The dose-response curves were generated by non-linear regression analysis (Non-linear 
regression (Sigmoidal dose response with variable slope)) to yield an IC50 value. The 
following formula was used: Y = bottom + (top-bottom)/ (1+10(log IC50 – x) (hill slope)). 
 
6.4 Cell proliferation and viability assays 
 
6.4.1 MTT assays 
6.4.1.1 Time-course experiments 
Time-course experiments were performed whereby cells were treated with the indicated 
concentrations of the compounds over a period of 4 days, and cell proliferation was 
measured. Cells were seeded at a density of 1500 cells in 90 µl media per well, in 
quadruplicate and allowed to settle O/N. This was followed by treatment (10 µl) with the 
various concentrations of each compound. After each time point elapsed, 10 µl MTT reagent 
was added and incubated for 4 h 37ºC followed by an O/N incubation with 100 µl 
solubilisation reagent at 37ºC. Absorbance was read at an OD of 595 nm using a BioTek 
microplate reader and a growth curve was generated using GraphPad Prism version 5.00 for 




6.4.1.2 Viability assays using chemical inhibitors 
The effect of the indicated concentrations of the compounds in the presence and absence of 
the respective chemical inhibitors on cell viability was determined using the MTT assay. 
Briefly, 3000 cells per well were seeded into 96-well plates, pretreated with the inhibitors for 
1 h, followed by treatment with the indicated compounds for 24 h and/or 48 h. MTT reagent 
was added and incubated for 4 h at 37ºC followed by an O/N incubation with 100 µl 
solubilisation reagent at 37ºC. Absorbance was read at an OD of 595 nm using a BioTek 
microplate reader. Microsoft Excel was used to analyse data and generate bar graphs.  
 
6.4.2 Neutral red uptake assays 
The neutral red uptake (NRU) assay was used when the MTT assay could not be employed 
due to reaction with certain inhibitors. This assay, based on the ability of viable cells to take 
up and bind neutral red, was also used to confirm the results of the MTT viability assays. In 
short, 3000 cells per well were seeded into 96-well plates, pretreated with the inhibitors for 1 
h, followed by treatment with the indicated compounds for 24 h and/or 48 h. Media was 
removed from each well, 200 µl neutral red (NR) media was added and incubated for 3 h. 
The NR media was removed and cells were washed once with 200 µl prewarmed 1 x PBS. 
One hundred microlitres NR desorb was added to each well. The plate was covered with foil 
and incubated at RT for 45 min with rotation. This was followed by a RT incubation with 
rotation for 5 min. Absorbance was read at 490 nm using BioTek microplate reader. 





6.5 Western blot analysis 
 
6.5.1 Extraction, processing and quantification of total cell protein 
Cells (3 x 105) were plated in 60 mm dishes and incubated for 24 h, after which cells were 
exposed to the indicated concentrations of each compound for the relevant time points. Media 
was removed and cells were washed twice with ice cold 1 x PBS. All rinses and media were 
collected in 12 ml tubes and subjected to centrifugation (1000 rpm for 5 min) to pellet cells 
that may have detached from the tissue culture dish during compound treatment. The 
adherent cells in the tissue culture dish were harvested (on ice) using a cell scraper (rubber 
policeman) and 60 µl of ice cold radioimmunoprecipitation assay (RIPA) buffer containing 1 
x protease inhibitor cocktail (Roche, Switzerland), 1 mM sodium orthovanadate and 20 mM 
sodium fluoride (to inhibit phosphatase activity). This lysis solution was used to resuspend 
the pelleted non-adherent cells, and the resulting lysates were subjected to sonication (on ice) 
for 10 s with a probe sonicator (Heat System-Ultrasonics). This was followed by 
centrifugation for 15 min at 11,000 x g (at 4°C), to remove cell debris. The supernatant 
containing the total protein was transferred to a fresh, chilled eppendorf tube and kept on ice. 
The protein concentration was determined using the Bicinchoninic Acid (BCA) Protein 
Assay Kit (Pierce, Thermo Scientific, USA) according to the manufacturer’s instructions, and 
either stored at -80°C or prepared for separation by sodium dodecyl sulphate polyacrylamide 






6.5.2 SDS-PAGE, immunoblotting and immunodetection 
The BioRad Mini-Protean II gel system (BioRad, USA) was used to separate proteins using 
either a 10% or 15% acrylamide (Sigma-Aldrich® Co) separating gel. A 4% acrylamide 
stacking gel was consistently used, and the SDS-polyacrylamide gels were cast in either 1 
mm or 1.5 mm glass plates. Protein samples (20 - 40 μg) were suspended in 1 x Laemmli 
buffer and denatured at 80°C for 5 min prior to loading into the wells of the SDS-
polyacrylamide gels. The protein molecular weight marker, Spectra Multicolour Broad Range 
Protein Ladder (Fermentas), was used to determine the size of the proteins. Proteins were 
subjected to electrophoresis at 100-150 volts for the appropriate time.  
 
Following electrophoresis, proteins were transferred to HybondTM-ECLTM nitrocellulose 
membranes (Amersham Biosciences, UK) using a buffered tank transfer system (BioRad), at 
100 volts for 1 h. Membranes were rinsed briefly using TBS with 0.1% Tween 20 (Sigma-
Aldrich® Co.) (TBS-T) and incubated for 1 h with 5% fat-free dry milk in TBS-T (blocking 
solution) to block nonspecific binding sites, then incubated with the primary antibody to the 
protein of interest at 4 °C O/N, with rotation. Antibody concentrations and incubation 
conditions were optimised for each individual antibody, and are shown in Table 6.1.The 
membrane was washed three times with TBS-T for 10 min each and incubated with 
secondary antibody for 1 h at RT, with rotation. The membrane was washed a further three 
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The immunoreactivity was detected by enhanced chemiluminescence and depending on the 
strength of the signal one of the following chemiluminescent substrates were used: 
SuperSignal West Pico or West Dura kits (Pierce, Thermo Scientific, USA) or Lumiglo or 
Lumiglo Reserve (KPL Inc., USA). Chemiluminescent light emission was detected manually 
using developer (AGFA G128) and fixative (AGFA G333C). Protein bands were visualised 
by developing AGFA X-ray film in developer, washing with water, and then fixing using the 
fixative, for the appropriate times according to manufacturer’s instructions. 
 
6.5.3 Stripping and reprobing membranes 
In order to reprobe membranes, the primary antibody was stripped off by incubation in 1M 
glycine at pH 2.5 for 7 min per side. This was followed by neutralisation with 1/10 volume 1 
M Tris-Cl, pH 8.0, after which the membranes were washed three times for 10 min each with 
TBS-T. Subsequently, the membranes were incubated in blocking solution for 30 - 45 min 
prior to O/N incubation with the primary antibody. 
 
6.6 RNA extraction, quantification and preparation for quantitative real-time RT-PCR 
 
6.6.1 RNA extraction from cultured cells 
Cells (80 000) were plated in 35 mm dishes in triplicate and incubated for 24 h, after which 
cells were exposed to  the indicated concentrations of each compound for the relevant times. 
RNA was harvested from treated cells with QIAzol (Qiagen, Germany) according to the 
manufacturer’s instructions. Briefly, cells were rinsed twice with ice cold 1 x PBS, after 
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which QIAzol was added to cells and incubated for 5 min at RT. With the aid of a rubber 
policeman the homogenate was scraped off the tissue culture dish and transferred to a chilled 
eppendorf tube. Subsequently, 0.2 ml chloroform per 1 ml of QIAzol was added to each 
sample, mixed vigorously for 15 s followed by a 2 min incubation at RT. The samples were 
centrifuged at 12 000 x g at 4°C for 15 min in order to separate the phases. The upper 
aqueous phase was transferred to a fresh eppendorf tube, and RNA was precipitated using 0.5 
ml isopropanol per 1 ml QIAzol. Following a thorough mix using a vortex and 10 min 
incubation at RT, samples were subjected to centrifugation at 12 000 x g at 4°C for 10 min. 
The supernatant was discarded and RNA pellets were washed with ice cold 75% ethanol 
(centrifugation at 7500 x g at 4°C for 5 min). RNA pellets were air-dried (for a maximum of 
10 min) and resuspended in 30 µl diethylpyrocarbonate (DEPC)-treated dH2O.  
 
RNA was quantified using the Nanodrop™ 2000c spectrophotometer (Thermo Scientific, 
USA) and 1 μg of RNA was mixed with RNA loading dye and electrophoresed on a 1.5% 
MOPS/formaldehyde agarose gel (containing 0.5 μg/μl ethidium bromide) to determine the 
integrity of the extracted RNA. 
 
6.6.2 Quantitative real time RT-PCR 
cDNA was prepared by reverse transcribing 2 µg of the total RNA by hybridization with 0.5 
µg oligo (dT)20 primer (Promega, USA) or 0.5 µg random hexamer primers (Oligonucleotides 
Synthesis Facility, UCT) in a final volume of 8 µl at 70°C for 10 min. Subsequently, 1 µl 
ImPromII Reverse Transcriptase II, 40 units of RNAsin RNase inhibitor, 2 mM MgCl2, 1 
mM dNTPs and 1 x ImPromII reaction buffer (all reagents from Promega, USA) were added 
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to each sample yielding a final volume of 20 µl. The samples were incubated at RT for 10 
min, 42°C for 30 min, 80°C for 2 min and the resultant cDNA were placed on ice until use or 
aliquotted and stored at -80°C for later use. 
 
Quantitative real time reverse transcription polymerase chain reaction (RT-PCR) was 
performed using the StepOne Real-time PCR System (Applied Biosystems, USA), and the 
comparative threshold cycle (CT) method was used for the calculation of expression fold 
change between samples. Real time RT-PCR was performed using triplicate samples with 2 
μl of cDNA (~200 ng), or dH2O as a negative control, using the KAPA SYBR qPCR Master 
Mix (KAPA Biosystems, South Africa), and 200 nM of the primer pairs listed in Table 6.2. 
The PCR cycling conditions were an enzyme activation step at 95°C for 3 min followed by 
40 cycles of denaturation at 95°C for 1 s and annealing at Ta for 20 s. CT values were 
calculated using StepOne Version 2.0 software (Applied Biosystems) and the ΔΔCT method 
was used to calculate the expression of target mRNA relative to that of a known 
housekeeping gene, β-glucuronidase (GusB). PCR products were electrophoresed on a 2% 
agarose gel containing ethidium bromide in order to ensure that a single, specific PCR 
product was amplified and that there was no contamination or primer dimer formation. 
Samples were prepared in 6 x loading dye (Fermentas) and electrophoresed at 65 V for 1 h. A 
DNA ladder (O’ GeneRuler DNA Ladder Mix, Thermo Scientific) was used to approximate 













Beclin1 Forward 5’AGGAACTCACAGCTCCATTAC 3’ 
 88 55 
Beclin1 Reverse 5’ AATGGCTCCTCTCCTGAGTT 3’ 
 




Atg5 Reverse 5’ TCGTCCAAACCACACATCTCG 3’ 
MnSOD Forward 5’ GCACTAGCAGCATGTTGAGC 3’ 
3’ 
142 60 
MnSOD Reverse 5’ GCGTTGATGTGAGGTTCCAG 3’ 
3’ GusB Forward 5’ CTCATTTGGAATTTTGCCGATT 3’ 
81 55 
GusB Reverse 5’ CCGAGTGAAGATCCCCTTTTTA 3’ 




Caspases are important mediators of the apoptotic pathway and their activity is often used to 
measure apoptosis by using a luminogenic substrate, where the luminescence produced is 
proportional to caspase activity. To assay for Caspase-3/7 activity, the Caspase-Glo® 3/7 
Assay (Promega Cat#G8090) was performed, according to the manufacturer’s instructions. 
Briefly, cells (3000 per well) were seeded in 96 well plates in a final volume of 90 μl, in 
triplicate. The next day cells were treated with the indicated concentration of the compounds 
bringing the final volume in the wells to 100 μl. An equal volume of Caspase-Glo® reagent 
was added to each well, mixed carefully by rotation at 300 rpm for 30 s and subsequently 
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incubated at RT for 1 h. Thereafter, 100 µl of the mixture in each well was tranferred to a 
white 96-well plate and luminescence was measured using the Glomax 96 Microplate 
Luminometer (Promega, USA). 
 
6.8 Necrosis Assay 
 
The CytoTox-ONE™ Homogeneous Membrane Integrity Assay (Promega Cat#G7891) was 
used to analyse the levels of necrosis by detection of lactate dehydrogenase (LDH) released 
from cells. Cells (3000 per well) were plated in 96 well plates in a final volume of 90 μl, in 
quadruplicate, and allowed to settle O/N. Thereafter, cells were treated with compounds (10 
μl) bringing the final volume in the wells to 100 μl. After the indicated time points elapsed, 
100 μl of CytoTox ONE reagent was added for 10 min followed by the addition of 50 μl of 
Stop solution. At each time point a lysis buffer, supplied with the kit, was added to a set of 
wells and served as the positive control. The fluorescence was measured using a Cary Eclipse 
fluorescent spectrophotometer, and the results were expressed as a percentage of the positive 
control.  
 
6.9 Phase-Contrast Microscopy 
 
Eighty thousand cells were plated on ethanol-flamed coverslips in 35 mm dishes and allowed 
settle O/N. The cells were then treated with different concentrations of the compounds and 
incubated for 24 h and 48 h at 37ºC. The cells were washed with 1 x PBS and fixed in 4% 
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paraformaldehyde in1 x PBS for 20 min at RT. Cells were washed once more with 1 x PBS 
and the coverslip was lifted carefully using tweezers and placed briefly in a beaker containing 
dH20. The excess dH20 was removed by touching the tip of the coverslip with paper towel 
and the cells were mounted onto slides in Mowiol 4-88 (Calbiochem #475904) and allowed 
to dry for at least 15 min before being visualised on the phase-contrast microscope (Axiovert 
200M microscope (Zeiss)). Images were captured using an AxioCamHR camera with 
Axiovision software, version 4.7 (Zeiss). 
 
6.10 Immunofluorescent analysis 
 
Cells were seeded at a density of 80 000 cells per well, on ethanol-flamed coverslips, in a 6-
well plate for immunofluorescent analysis of protein expression and localisation. The cells 
were treated with the indicated concentrations of the compounds for the relevant time points 
in a total volume of 1.5 ml media. Thereafter, 1 ml ice cold methanol was added to the cells 
and media and mixed briefly. The methanol/media mixture was discarded and 1 ml ice cold 
media was added to the cells and incubated at -20°C for 10 min. The methanol was discarded 
and the cells were rinsed 3 times with cold 1 x PBS. Cold 3% BSA prepared in 1 x PBS was 
added to the cells and incubated for 1 h, with rotation. Coverslips were incubated with 50 µl 
primary antibody (rabbit α-LC3, 1:500 in 3% BSA) in a humidified chamber for 1 h. 
Subsequently, the primary antibody was removed by three 5 min washes in 1 x PBS, and 50 
µl secondary antibody (Cy3-conjugated goat anti-rabbit, 1:1000 in 3% BSA) was placed on 
the coverslips. After a 1 h incubation in a darkened humidified chamber, coverslips were 
washed 3 times for 5 min in 1 x PBS. Nuclei of the cells were stained using 0.5 µg/ml 
Hoechst prepared in 1 x PBS for 30 s, and this was followed by 2 washes with 1 x PBS. The 
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coverslips were mounted on slides with Mowiol 4-88, and viewed under an Axiovert 200M 
microscope (Zeiss) and images were captured using AxioCamHR camera with Axiovision 
software, version 4.7 (Zeiss). Confocal images were taken using a Zeiss LSM 510 Meta 
confocal microscope with a Mai Tai two photon laser and ZEN 2009 software.  
 
6.11 Cell cycle profile analysis 
 
Cells were seeded in 100 mm dishes at a density of 0.5 x 106 cells per dish, in triplicate. The 
indicated concentrations of each compound was added and incubated for the relevant times. 
The media and washes (once with 2 ml trypsin) were collected on 50 ml Falcon tube and the 
cells were harvested using 3 ml 0.05% trypsin-EDTA. Complete DMEM (3 ml) was added to 
neutralise the trypsin, and the cell suspension was transferred to the tube containing the 
media and initial wash. This was followed by centrifugation at 1000 rpm for 5 min. The 
pelleted cells were resuspended in 1 ml 1 x PBS and cells were counted. Thereafter, 9 ml ice 
cold 95% ethanol was added to each sample which were stored at -20ºC for up to 2 weeks. 
The samples were centrifuged at 1000 rpm for 5 min, the pellets resuspended in 1 ml 1 x PBS 
and centrifuged at 1000 rpm for 5min, once more. The cell pellets were resuspended in 1 ml 1 
x PBS and transferred to a fresh eppendorf and subjected to a final centrifugation at 1000 rpm 
for 5 min. A total of 1 x 106 cells were incubated in 50 µg/ml RNAse A (in 1 x PBS) for 30 
min at RT. The cell cycle staining solution was added to each sample and incubated in the 
dark for 30 min. Cells were analysed on a Beckman Coulter FACScalibur flow cytometer 
(Becton Dickinson, USA) using CellQuest Pro Software (Becton Dickinson). The cell cycle 
profiles were analysed using ModFit 3.2 (Verity Software House, USA). 
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6.12 Reactive oxygen species (ROS) assay 
 
Cells were seeded in an opaque white 96-well plate at a density of 1 x 104 cells per well (in 
triplicate) in a final volume of 100 µl media. The next day media was removed and cells were 
rinsed once with pre-warmed KR buffer. This was followed by the addition of 100 µl 50 µM 
DCFDA in KR buffer, and a 15 min incubation at 37ºC in the dark. The cells were treated 
with the indicated concentrations of the compounds for the relevant time points, and the 
fluorescence was read at 484 nm excitation and 530 nm emission using a Cary Eclipse 
fluorescence spectrophotometer (Varian, Inc.). For the scavenging of ROS, the cells were 
pretreated with the scavengers (NAC, LAA, Trolox or TEMPOL) for 1 h before the DCFDA 
was added to the cells.  
 
6.13 Transmission electron microscopy (TEM) 
 
Ultrastructural analysis was performed to detect the induction of autophagy morphologically 
in compound-treated cells using transmission electron microscopy (TEM). Cells were seeded 
in 100 mm dishes at 1 x 106 cells per dish and incubated O/N. The cells were then treated 
with the indicated concentrations of the compound and incubated for 6 h and 24 h. Following 
treatment, cells (detached using 0.05% trypsin-EDTA) and media were collected and 
centrifuged at 1000 rpm for 5 min to pellet cells. Supernatant was discarded and the pelleted 
cells were washed with 1 ml ice cold 1 x PBS by centrifugation at 1000 rpm for 5 min at 4ºC. 
Cells were fixed with 2.5% glutaraldehyde in 0.1 M Sorenson’s phosphate buffer pH 7.4 for 
at least 1 h and then washed twice with the same buffer. The cells were post-fixed in 1% 
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OsO4 (Osmium tetroxide) in 0.1 M Sorenson’s phosphate buffer pH 7.4 for 1 h at RT 
followed by washing once with the same buffer and twice with dH2O. Cells were then pre-
stained with 1% uranyl acetate for 1 h at RT. This was followed by one dH2O wash before 
the dehydration process, which entailed multiple centrifugation (cell pelleting) and 
resuspension steps in increasing ethanol concentrations. Each centrifugation was 5 min long 
at 1000 rpm until 100% ethanol concentration was reached, in which cells were centrifuged 
twice for 10 min each at 1000 rpm (100% ethanol discarded and fresh 100% ethanol added 
after first 10 min elapsed). This was followed by two 10 min centrifugation steps in 100% 
acetone (following same procedure as with 100% ethanol), leading to the resin infiltration 
steps beginning with an O/N incubation at RT in a 1:1 ratio of resin:acetone. The next day the 
cells were pelleted by centrifugation (5 min at 1000 rpm), resuspended in a 3:1 ratio of resin: 
acetone and incubated for 6 h at RT. The cells were pelleted, resuspended in 100% resin and 
incubated O/N at RT. The next day the cells were pelleted, resuspended in 100% resin and 
incubated for 1 h. This was followed by the final embedding of the cells in resin by an O/N 
incubation at 60ºC in 100% resin. After the cells were embedded in the resin, ultrathin 
sections of 120 nm were cut using a Reichert Ultracut S ultramicrotome and collected in a 
boat of distilled water. Using a fine pair of tweezers, a copper grid was used to collect the 
ultrathin sections from the boat of water. The grids were placed on filter paper in a Petri dish 
which was inverted. The sections were then stained with 2% uranyl acetate for 10 min at RT 
followed by 5 washes with dH2O. The final 5 min staining with lead citrate culminated the 
sample preparation process allowing the sections to be analysed using a FEI Tecnai F20 





6.14 NFAT luciferase assay 
 
An assay to monitor NFAT luciferase activity was employed using a NFAT-luciferase report 
plasmid, containing three tandem repeats of a 30 bp fragment of the IL-2 promoter known to 
bind NFAT. Thirty thousand cells were plated per well in 24-well plates, and transfected with 
50 ng GFP-NFAT plasmid (Addgene plasmid # 24219, gift of Jerry Crabtree (Beals et al., 
1997), 50 ng NFAT-luciferase (Addgene plasmid # 10959, gift of Toren Finkel (Ichida and 
Finkel, 2001), and 5 ng pRL-TK, using 0.4 μl GenecellinTM Transfection Reagent (Celtic 
Molecular Diagnostics, South Africa). The following day cells were treated with the indicated 
concentrations of the compound and after an O/N incubation, stimulated with 100 nM TPA 
(Sigma-Aldrich® Co) and 1.3 μM Ionomycin (Sigma-Aldrich® Co) for 5 h, following which 
luciferase activity was measured using the VeritasTM microplate luminometer (Promega, 
USA). Luciferase readings were normalised to Renilla luciferase in the same extract. 
 
6.15 Statistical analysis 
 
Microsoft Excel or GraphPad Prism software was used for statistical analyses. Experiments 
were performed in triplicate or quadruplicate and represented as the mean ± standard 
deviation (SD), or the mean ± standard error of the mean (SEM), as indicated. Experiments 
were repeated at least two times. For data comparisons between untreated (vehicle-only 
treated) and treated (compound-treated) groups, the Student’s two-tailed paired t-tests were 





Cell culture solutions 
Complete DMEM 
450 ml DMEM 
50 ml FBS 
5 ml Penicillin (100 U/ml) and streptomycin (100 µg/ml) 
Stored at 4°C. 
 
10 x Phosphate buffered saline (PBS), pH 7.4 
40 g NaCl 
1 g KCl 
5.75 g Na2HPO4.7H2O 
1 g KH2PO4 
Made up to 500 ml with dH2O. 
 
1 x Phosphate buffered saline (PBS), pH 7.4 
100 ml 10 x PBS 
900 ml dH2O 
 
0.5 M EDTA, pH 8.0 
37.22 g EDTA 
140 ml dH2O 
Adjusted to pH 8.0 using 10 M NaOH. 




0.5 g Trypsin 
8 g NaCl 
1.45 g Na2HPO4.2H2O 
0.2 g KCl 
0.2 g KH2PO4 
10 mM EDTA pH 8.0 
Made up to 1000 ml with 1 X PBS, and stored at 4°C. 
 





Mycoplasma detection solutions  
Hank’s balanced salt solution, pH 7.4 
5.4 mM KCl 
0.3 mM Na2HPO4 
0.4 mM KH2PO4 
1.3 mM CaCl2 
0.5 mM MgCl2 
0.6 mM MgSO4 
137 mM NaCl 
5.6 mM D-glucose 
Made up to 1000 ml with dH2O, and stored at 4°C. 
175 
 
Mycoplasma fixing solution 
1 part glacial acetic acid to 3 parts methanol 
 
Hoechst stain (0.5μg/ml) 
5 mg Hoechst No. 33258 
100 ml Hank’s balanced salt solution 
Stored at -20°C. 
 
Mounting fluid 
1.05 g citric acid 
1.41 g Na2HPO4.2H2O 
50 ml glycerol 
pH 5.5 
Stored at 4°C. 
 
Drug sensitivity testing solutions 
MTT reagent (5 mg/ml) 
100 mg MTT 
20 ml 1 x PBS 
Vortexed briefly, incubated at 37°C for 15 min then filtered through a 0.2 µm filter. 
Wrapped in foil and stored at 4°C for up to one month. 
 
Solubilisation reagent  
25 g Sodium lauryl sulphate 
Made up to 250 ml with dH2O, then added 76.6μl concentrated HCl. 
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Neutral red (NR) stock solution (3.3 mg/ml) 
0.33 g Neutral Red H2O 
10 ml dH2O 
Filtered using a 0.2 µm filter, wrapped in foil and stored at RT for up to 2 months. 
 
NR media (33 µg/ml) 
1 ml Neutral red stock solution 
99 ml Complete media 
Made fresh, and maintained at 37°C before use. 
Used within 30 min of preparation. 
 
NR desorb 




Western Blot Analysis Solutions 
RIPA buffer 
150 mM Sodium chloride 
1 % Triton X-100 
1 % Sodium deoxycholate 
0.1 % SDS 





10% Acrylamide separating gel (10 ml) 
4 ml dH2O 
2.5 ml 1.5 M Tris-Cl, pH 8.8 
100 µl 10% SDS 
3.3 ml 30% Acrylamide 
100 µl 10% Ammonium persulphate 
10 µl TEMED 
 
15% Acrylamide separating gel (10 ml) 
2.3 ml dH2O 
2.5 ml 1.5 M Tris-Cl, pH 8.8 
100 µl 10% SDS 
5 ml 30% Acrylamide 
100 µl 10% Ammonium persulphate 
10 µl TEMED 
 
4% Acrylamide stacking gel (5 ml) 
3 ml dH2O 
1.25 ml 0.5 M Tris-Cl, pH 6.8 
50 µl 10% SDS 
670 µl 30% Acrylamide 
50 µl 10% Ammonium persulphate 





4 x Laemmli loading dye 
250 mM Tris-Cl, pH 6.8 
6 % SDS 
0.005 % Bromophenol Blue 
40 % Glycerol 
10 % β-mercaptoethanol 
 
10 x Running buffer 
30.2 g Tris  
144 g Glycine 
10 g SDS 
Made up to 1000 ml with dH2O. 
 
1 x Running buffer  
100 ml 10 x running buffer  
900 ml dH2O 
 
10 x Transfer buffer 
144 g Glycine 
30.3 g Tris 







1 x Transfer buffer (1000 ml) 
In this order: 
100 ml 10 x Transfer buffer  
700 ml dH2O 
200 ml methanol 
Made fresh before use, and kept ice cold until use.  
 
10 x Tris buffered saline (TBS), pH 7.5 
60.5 g Tris 
87.6 g NaCl 
Dissolved in 700 ml dH2O,  
Adjusted pH using 1 N HCL or 10 M NaOH, then made up to 1000 ml with dH2O.  
 
1 x TBS-T  
100 ml 10 x TBS  
900 ml dH2O  




0.5 g fat free milk powder (Elite) 






Rapid Coomassie staining solution 
0.024 % Coomassie Brilliant Blue 
10 % Acetic acid 
90 % dH2O 
 
Destain 
10 % Glacial Acetic Acid; 10% Methanol 
 
Real-time RT-PCR solutions 
DEPC-treated- dH2O 
0.1% DEPC in dH2O; autoclaved 
 
10 x MOPS 
41.86 g MOPS (0.2 M) 
16.6 ml 3 M NaAcetate (0.05 M) 
20 ml 0.5 M EDTA (0.01 M) 
Made up to 1000 ml with dH2O, and diluted to 1 x with dH2O as required. 
 
RNA Loading Buffer (1.5 ml) 
720 µl Formamide 
160 µl 10 x MOPS Buffer 
260 µl 37 % Formaldehyde  
80 µl dH2O 
100 µl 80 % Glycerol 
200 µl 0.25 % Bromophenol Blue  
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1.5 % MOPS/formaldehyde agarose gel 
0.75 g Agarose 
5 ml 10 x MOPS 
42 ml dH2O 
2.7 ml 37 % Formaldehyde 
2.5 µl (10 mg/ml) Ethidium Bromide 
Mixed agarose, 10 x MOPS and dH2O together; heated to dissolve, and then cooled to ~50°C. 
In fumehood, added formaldehyde and mixed well, then added ethidium bromide. 
 
10 x Tris borate EDTA (TBE) 
108 g Tris 
55 g Boric Acid 
7.4 g EDTA 
Made up to 1000 ml with dH2O 
 
2% agarose gel (100ml) 
2 g Agarose 
10 ml 10 x TBE 
90 ml dH2O 











80 ml dH2O 
Covered with foil and stirred for 1 h on a heated magnetic stirrer, with temperature kept 
below 60°C. Added 10M NaOH until solution appeared clear, then filtered using a 0.45 μM 
filter. Adjusted pH to pH 7 using HCl. For long term storage: 2.5 ml aliquots kept at -20°C. 
 
4% paraformaldehyde 
Thawed 16% paraformaldehyde, than added 7.5 ml 1 x PBS and mixed well 
 
Mowiol 4-88 
12 g Mowiol 4-88 
30 ml glycerol 
30 ml dH2O 
60 ml 0.2 M Tris-Cl pH 8.5 
Stirred at RT O/N, and then stirred at 50°C for 1 h. Centrifuged at 5000 x g for 15 min. 
Stored supernatant in 2ml aliquots at -20°C. Added 2.5 % anti-fading agent (N-propyl 









Cell cycle analysis solutions 
RNase A (50 μg/ml) 
300μl 1 mg/ml RNase A 
5.7 ml 1 x PBS 
 
0.1 M PIPES pH 6.8 
3.02 g PIPES 
100 ml dH2O 
 
Cell cycle staining solution 
0.1% Triton X-100 
2mM MgCl2 
100 mM NaCl 
10 mM PIPES pH 6.8 
10 µg/ml Propidium Iodide 
 
ROS assay solutions 
Krebs-Ringer (KR) Buffer pH 7.4 
110 mM NaCl 
2.6 mM KCl 
1.2 mM MgSO4 
1.2 mM KH2PO4 
25 mM NaHCO3 
11 mM glucose 
Made up to final volume using sterile dH2O, filter sterilised and stored at 4°C. 
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DCFDA stock (50 mM) 
0.0074 g DCFDA 
303.7 µl DMSO 
Prepared 15 µl aliquots 
Covered with foil and stored at -20°C 
 
TEM solutions 
In order to prepare 0.2 M Sorenson’s Phosphate buffer and 0.1 M Sorenson’s buffer, Solution 
A and Solution B (shown in Table 6.3) were initially prepared: 
 
Table 6.3: Preparation of Solution A and Solution B 
 Solution Reagent MW Mass dH2O 
A 0.2 M dibasic sodium phosphate Na2HPO4●2H2O 178.05 g/mol 35.61 g 1000 ml 
B 0.2 M monobasic sodium phosphate NaH2PO4●H2O 138.01 g/mol 27.6 g 1000 ml 
 
 
The volumes of Solution A and B were added, as shown in the Table 6.4 and 6.5, to achieve  
0.2 M Sorenson’s Phosphate buffer and 0.1 M Sorenson’s buffer, respectively. 
 
Table 6.4: 0.2 M Sorenson’s Phosphate buffer pH7.4: 
Solution A Solution B Total 
40.5 ml 9.5 ml 50 ml 





Table 6.5: 0.1M Sorenson’s Phosphate buffer, pH7.4 
Solution A Solution B dH2O Total 
40.5 ml 9.5 ml 50 ml 100 ml 
81 ml 19 ml 100 ml 200 ml 
 
0.2 M Sorenson’s phosphate buffer, pH 7.4 was used to prepare 2.5% Glutaraldehyde 
fixative, as shown in Table 6.6. 
 
Table 6.6: 2.5% Glutaraldehyde fixative   
Solution Volume 
0.2 M Sorenson’s Phosphate buffer pH7.4 (stock) 25 ml 
25% Glutaraldehyde 5 ml 











Figure A.1: Western blot analysis demonstrating the increased expression levels of γ-H2AX and cleaved 
PARP in WHCO1 treated with doxorubicin (DOX) over time. WHCO1 (3 x 105) were seeded in 60 mm 
dishes and incubated overnight. Cells were treated with vehicle only (0 µM) and 5 µM DOX for 0.5, 1, 3 and 6 
h (A) and 24 and 48 h (B). Protein was harvested and quantified so that 20 µg could be separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. The membrane was probed with antibodies recognising γ-






Figure A.2: MOPS/formaldehyde agarose gel electrophoresis of RNA samples prepared using Qiazol. 
RNA prepared from WHCO1 cells treated with the indicated concentrations of EXP57EA for 24 h and subjected 

















Figure A.3: Phase-contrast microscopy images of WHCO1 cells treated with EXP57EA for 24 h. 
Eighty thousand cells were seeded on ethanol-flamed coverslips in 35 mm dishes. The next day cells were 
treated 5 µM and 10 µM EXP57EA and incubated for 24 h. Cells treated with vehicle-only (0 µM) served as the 
untreated control group. Subsequently, cells were fixed with 4% paraformaldehyde and mounted onto slides in 
Mowiol 4-88 prior to viewing using an Axiovert 200M microscope (Zeiss). Images were captured using an 
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